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SUMMARY 
 
 
 
Gene therapy is the delivery of genetic material to cells to produce a therapeutic 
effect.  Retroviruses are one of the most common viral vectors used for gene therapy, 
especially lung gene therapy.  However the lung has many physical and immunological 
barriers to gene transfer vectors, and currently, too few cells are genetically modified for 
the effective treatment of lung diseases such as cystic fibrosis.  One of the main reasons 
for low cell transduction is the lack of commonly-used receptors for gene therapy vectors 
on the apical surface of polarized epithelial cells.  The objective of this project was to 
determine how to incorporate proteins into the lentiviral lipid bilayer in order to develop a 
recombinant retrovirus that can efficiently deliver genes to polarized cells via their apical 
membranes.   
 We created a lentivirus pseudotyped with envelope proteins from human 
parainfluenza type 3 (HPIV3), which has a natural tropism for the apical surface of 
polarized lung epithelial cells.  Lentivirus particles were able to incorporate HPIV3 
glycoproteins, hemagglutinin-neuraminidase (HN) and fusion (F), and viruses were able 
to transduce polarized cells via the apical surface in a manner consistent with lentiviral-
mediated transduction via sialated receptors for HPIV3.  However titers were too low for 
clinical use. 
We also determined whether lentiviruses could incorporate non-viral proteins into 
its lipid bilayer and examined the factors necessary for protein incorporation.  We 
investigated the ability of two glycosylphosphatidylinositol (GPI) anchored proteins, 
folate receptor (FR-WT) and Tac-CD16 (CD25 or the interleukin-2 receptor alpha chain 
which has been modified with the GPI anchor motif from CD16) to incorporate into 
viruses.  We found that Tac-CD16 and FR-WT exhibited the classic GPI anchored 
protein property of associating with lipid rafts, however Tac-CD16 colocalized with Gag 
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and incorporated into lentiviral particles, while FR-WT did not colocalize with Gag and 
was not incorporated into virus particles.  We found that FR-WT colocalized to less 
dense rafts and Tac-CD16, Gag, and amphotropic Env were localized to more dense 
rafts.  Treatment of cells with fumonisin B1 (FB1) or methyl-beta-cyclodextrin (MβCD) 
increased colocalization of FR-WT with Gag in lipid rafts such that FR-WT was 
incorporated into virus particles.  Taken together, these results demonstrated lipid rafts 
segregate raft proteins, and for a protein to be incorporated into virus particles, it must 
be colocalized with lentivirus-associated rafts. 
  We then investigated the cause of low HPIV3 pseudotyped lentivirus titers.  We 
determined transfected cells contained fewer cell-surface HN and F than wild-type 
infected cells.  We codon-optimized HN to increase HN expression and used it to 
transfect lentivirus producer cells.  Cell surface expression of HN, as well as the amount 
of HN incorporated into virus particles, increased.  Virus transduction of cells, including 
to the apical surface of polarized cells, also increased.  Interestingly, even though codon 
optimization improved the expression levels of HN and virus titers, we found that HPIV3 
pseudotyped viruses still contained about 14-fold fewer envelope proteins than 
lentiviruses pseudotyped with the amphotropic envelope protein.  We then hypothesized 
HN and F incorporation was low because interactions between HN and F with lentiviral 
Gag were low.  We found that HN and F were not as colocalized with Gag or lipid rafts 
as amphotropic Env and tried to increase passive and active interactions with Gag to 
increase incorporation levels.  To increase active interactions with Gag, we created HN 
and HIV Env fusion proteins that would actively interact with Gag.  We found that 
colocalization and incorporation increased with the fusion proteins, however titers 
decreased.  To increase passive interactions with Gag, we disrupted the barriers that 
prevented HN and F from passively interacting with Gag.  When producer cells of 
lentiviruses pseudotyped with HPIV3 (HPIV3 LV) or amphotropic Env (Ampho LV) were 
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treated with 0.5 mM MβCD for 54 hours after transfection to disturb lipid rafts,  titers of 
HPIV3 LV increased while titers of Ampho LV decreased.  When we analyzed the 
amount of envelope incorporation from MβCD treated producer cells, we found the 
amount of amphotropic Env in virus particles decreased 3.0-fold while the amount of HN 
increased 1.4-fold.  This data suggested that increasing interactions of HPIV3 envelope 
proteins with Gag through active and passive interactions enhanced HN and F 
incorporation into lentiviral particles. 
 In summary, we analyzed the process of incorporating heterologous viral and 
non-viral proteins into lentiviruses and determined key factors that allowed for successful 
and functional protein incorporation into the lentiviral lipid bilayer.  We found that 
proteins can be incorporated into virus particles if they colocalized with lentivirus-
associated rafts, and that heterologous viral proteins from HPIV3 can pseudotype 
lentiviruses for infection of polarized cells.  This research is significant because it 
provides insight into viral assembly and protein incorporation for the generation of 
pseudotyped lentiviruses for human gene transfer.   
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CHAPTER 1 
 
BACKGROUND AND OBJECTIVES 
 
  
 
1.1  Gene Therapy for Diseases of the Lung 
Gene therapy is the delivery of genetic material to cells to produce a therapeutic 
effect.  An excellent example of a pulmonary disease in which gene therapy may prove 
therapeutic is cystic fibrosis (CF).  Affecting over 30,000 individuals in the United States 
annually, CF is the most common lethal autosomal recessive disease in the Caucasian 
population [1].  Although many organs in the body are affected, it is in the lung where 
disease manifestation, such as thick mucus, inflammation, and bacterial infections, is the 
major cause of morbidity and mortality.  The most common cause of cystic fibrosis was 
identified as mutations in the cystic fibrosis transmembrane conductance regulator 
(CFTR) gene, which encodes a chloride ion channel [2].  Mutations in CFTR lead to 
imbalanced ion and water movement across the airway epithelium.   
Gene therapy is an attractive option for CF because it is a monogenic disorder 
and there are currently no satisfactory treatments for it.  From the cloning of the CFTR 
gene [3] to present day, much progress has been made towards effective gene therapy 
for CF.  Proof-of-principle has been demonstrated for CFTR gene transfer in vitro and in 
animal models [4, 5].  Clinical trials in CF patients were first carried out in 1993 [6], 
however of the 29 trials since then, only one of them has gone on to Phase II [7].  The 
main conclusions from the clinical trials were that while relatively safe and feasible, too 
few cells were genetically modified and the effects of gene transfer were only temporary 
[2].  It was believed that CF gene therapy was an easily attainable goal because the 
gene was identified and the target could be reached noninvasively.  However it is still 
unsuccessful in effectively treating cystic fibrosis patients because of many barriers to 
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gene therapy vectors, which results in too few cells being genetically modified 
permanently with the normal CFTR gene to have a significant effect on the manifestation 
of the disease. 
Besides CF, the use of gene therapy to attempt to treat other pulmonary 
diseases is increasing.  Examples include other monogenic disorders such as α1-
antitrypsin deficiency, and also more complicated diseases such as chronic obstructive 
pulmonary disease (COPD), asthma, interstitial lung diseases, and even lung cancer [8].  
However similar to CF, gene therapy is only a promising treatment for these diseases 
because of the numerous barriers facing gene therapy vectors [8]. 
  
1.2  Barriers of Lung Gene Therapy 
As accessible as it may seem for delivery of gene therapy vectors, the lung has 
many physical and immunological barriers that inhibit effective transduction of the target 
cells.  Since extensive research has been performed on gene delivery for the treatment 
of CF, the following paragraphs will highlight the difficulties faced during gene delivery to 
the CF lung as an example.  These barriers, namely identifying and delivering the 
genetic material to the target cell type, apply not only to CF gene delivery, but generally 
also to gene delivery in other pulmonary diseases.   
The lung is lined with a pseudo-stratified epithelial monolayer composed of many 
cell types including basal, mucus, serous, ciliated, and intermediate cells [9].  Identifying 
the target cell type for CF gene therapy has proved difficult due to the heterogeneous 
and complicated distribution pattern of CFTR in the lungs.  While most of the pathology 
of CF manifests in the distal small airways, it is in ciliated cells located in the superficial 
epithelium and the difficult-to-access submucosal glands of the proximal airways that 
has the highest CFTR expression levels [10, 11].  Also, putative progenitor cells should 
be ideally targeted instead of the epithelial cells, which are terminally differentiated with 
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a lifespan of 21-120 days [9, 12].  However many distinct populations of lung progenitor 
cells have been identified [13], and besides residing in difficult-to-access areas, it is 
unclear which progenitor population to target.  There is however encouraging evidence 
that only 5-10% of the epithelial cells in the lung need to be genetically modified with the 
normal CFTR for correction of the chloride transport abnormalities [14, 15]. 
The first obstacle the gene transfer vector will encounter in any lung is the mucus 
layer (Figure 1.1).  In the normal airway, a thin layer of mucus is a natural innate immune 
barrier designed to trap viruses and bacteria.  The act of mucociliary clearance will then 
clear these foreign objects from the lung.  Because of the defective ion channel, the 
mucus of CF patients is characterized by viscous secretions, which has been shown to 
severely limit the transport ability of gene transfer vectors to the cells [16].  Pretreatment 
of the mucus with mucolytic drugs improves transduction efficiencies, however there is 
still the natural defense of mucociliary clearance to overcome [17].  CF patients also 
produce sticky sputum, which consists of inflammatory cells, cell debris, mucus, and 
DNA, all of which has been shown to limit access of viral and nonviral vectors to 
epithelial cells [18].  Beneath the mucus layer, is the airway surface liquid (ALS), which 
contains electrolytes, immunoglobulins, cytokines, antimicrobial peptides and proteins, 
surfactant proteins, proteinase inhibitors, and other epithelial secretions [19].  In the 
lungs of CF patients, the inflammatory debris in the ALS is markedly increased and has 
been shown to inhibit gene transfer to the lung [20-23], however it does not seem to 
have affected retroviral-mediated gene transfer [24].  In addition, the lung has innate 
immune responses to foreign particles, including alveolar macrophages and neutrophils 
which act to phagocytose and inactivate viral particles [24, 25], and humoral responses 
which may affect the choice of gene transfer vector used [26].  Also, gene transfer 
vectors will have to locally pass through the glycocalyx and extracellular matrix, whose  
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Figure 1.1.  Barriers of lung gene therapy.  Gene transfer vectors encounter many 
barriers in the lung such as the mucus layer, airway surface liquid layer, cellular debris, 
immune cells, bacteria, sputum, and cilia.  Once past those barriers, the gene transfer 
vector must circumvent the glycocalyx, thick actin layer, tight junctions preventing 
access to common receptors for gene therapy vectors, and lysosmes to reach the target 
nucleus. 
 
 
treatment with proteinases in vitro has been shown to increase the low viral-mediated 
gene transfer [27-29].   
The epithelial cells themselves present a greater barrier for successful CF gene 
therapy.  The lung is lined with a highly polarized layer of epithelial cells, which have an 
asymmetric distribution of cell surface proteins.  It has been extremely difficult to transfer 
genes to the apical membrane of polarized epithelial cells even in vitro because tight 
junctions between cells limit the access of commonly-used gene transfer vectors to their 
cellular receptors, which are preferentially located on the basolateral side [30-32].  
Additionally, the low rate of endocytosis from the exposed apical membrane further 
reduces uptake of gene transfer vectors [31, 32].  Strategies to enhance transduction 
from the apical surface with viral and nonviral vectors include tight-junction disruption 
[33-36], UV irradiation [32], and calcium phosphate co-precipitation [37], however their 
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use in CF therapy is questioned since they damage the lung epithelium.  Once past the 
cell membrane, gene transfer vectors will also have to circumvent the complex 
architecture of the polarized epithelial cell to deliver the gene to the nucleus, navigating 
around the thick actin layer and evading endosomal breakdown [38]. 
CF clinical trials have been mainly marked by the low number of cells 
transduced.  In order for effective treatment to occur in any lung gene therapy, the gene 
therapy vector must be able to get past the body’s various physical and immune defense 
mechanisms.  However, overcoming these numerous physical and immune barriers will 
still leave a major issue required for successful treatment:  apical binding and 
internalization of the vector into the cells for gene delivery. 
 
1.3  Retroviral-mediated Gene Delivery 
Retroviruses are one of the most common viral vectors used for gene therapy 
especially lung gene therapy [7].  Often derived from Moloney murine leukemia virus 
(MLV), they comprise of two copies of genomic RNA containing the psi or packaging 
sequence and reverse transcriptase (encoded by the Pol gene).  These proteins are 
surrounded by structural core proteins (encoded by the Gag gene), followed by a lipid 
bilayer acquired from the producer cell, and envelope glycoproteins (encoded by the Env 
gene) which protrude out from the lipid bilayer (Figure 1.2).  Generally retroviruses 
attach to the cell surface through nonspecific interactions between proteins on the 
surface of the cell and on the virus, and not through receptor/Env-dependent binding [39, 
40].  However once at the cell surface, the envelope protein of retroviruses can 
specifically bind to its receptor if present and induce fusion of the lipid bilayers for 
efficient viral entry.  After fusion, the genome of the virus and virus proteins are released 
into the cell, reverse transcription of the RNA into DNA occurs, and the viral DNA is  
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Figure 1.2.  Transduction of target cells by recombinant retroviruses.  Cells are transduced by 
incubation with stocks of retroviruses.  Retroviruses diffuse to the surface of the cell and bind via 
nonspecific interactions.  The envelope proteins then bind to cell receptors and initiate fusion 
between the lipid bilayer of the virus and the cell which releases the internal components of the virus 
into the cytosol.  In the cytoplasm, the RNA genome of the virus is reverse transcribed to DNA, the 
DNA is transported to the nucleus and integrated into the chromosomal DNA of the cell.  The 
therapeutic gene is then expressed. 
 
Figure 1.3.  Production of recombinant retroviruses.  Recombinant retroviruses are produced by 
transfecting the producer cell with vectors containing the therapeutic gene and the viral gene.  The 
therapeutic gene contains the packaging sequence that allows for efficient incorporation into virus 
particles.  The viral vector encodes for viral proteins such as capsid proteins and envelope proteins.  
The capsid proteins self-assemble around the RNA genome with the packaging sequence, and bud 
from the surface of the cell into the cell culture medium.  During budding, the virus particle 
incorporates a lipid bilayer from the cell.  This lipid bilayer contains the virus envelope proteins and 
other cell membrane proteins. 
Producer Cell
Virus Particle
A.  Transfection
B2.  Expression of 
viral proteins
C.  Assembly
D.  Budding
Cell membrane 
proteins
B1.  Transcription 
of vector
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directed to the nucleus where it integrates into the chromosomal DNA of the host cell.  
During and after integration, the viral DNA is stably expressed and inherited by daughter 
cells.  Recombinant retroviruses are identical to that of wild-type viruses but engineered 
such that they encode for a therapeutic gene of interest or a reporter gene, and do not 
contain the viral genes necessary for replication [41]. 
For the production of recombinant retroviruses, generally cells are transfected 
with plasmids encoding for the viral genes (Gag, Pol, Env) and the therapeutic vector 
(Figure 1.3).  The producer cells express the viral proteins and transcribe the therapeutic 
vector, after which the viral proteins recognize the psi-sequence in the therapeutic vector 
and package it.  The viral proteins subsequently assemble into a virus particle which 
buds from the cell membrane.  The media, which contain putative virus particles, is then 
collected and used to deliver genes to the target cells. 
The ability of retroviral vectors to efficiently integrate the gene has led to much 
interest in their use for lung gene therapy [42].  Besides eliminating the need for re-
administration, retroviral vectors also have an adequate packaging capacity for RNA, 
and envelope proteins which may be less immunogenic than that of other viral gene 
delivery systems such as adenoviral or AAV vectors [43].  Some limitations however 
include producing enough particles for clinical trials, the need for target cells to be 
actively dividing, unlike cells of the lung [42], and also limited receptor number on the 
apical side of polarized airway epithelial cells [44].  Lentiviral vectors, such as those 
based on human immunodeficiency virus (HIV), are a subclass of retroviruses that can 
overcome the need for dividing target cells as they can infect and integrate their genome 
into non-dividing cells.  They also have been shown to transcytose through a polarized 
monolayer of cells [45], which may be useful for infecting progenitor cells.  In addition, 
lentiviral vectors can also incorporate the envelope proteins of other viruses into their 
viral lipid bilayer, thereby changing its targeting, in a process known as pseudotyping.   
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1.4  Viral and Non-Viral Protein Incorporation into Lentiviruses 
 Pseudotyping.  Pseudotyping lentiviruses is an attractive feature since the 
envelope proteins are strongly associated with the virus, and viruses can be targeted to 
abundant receptors on the apical surface of airway cells without modifications of the 
envelope protein that can reduce virus-cell fusion [46].  Lentiviruses pseudotyped with 
the envelope protein from Ebola virus were able to infect 30% of mice trachea, including 
submucosal glands, with long-term and high gene expression [47].  However, safety is a 
concern and work is being performed to redesign the envelope protein for improved 
safety characteristics [48].  A more recent study has been performed with a lentivirus 
pseudotyped with influenza D glycoprotein which resulted in persistent in vivo gene 
expression of polarized airway epithelial mouse cells for over one year, perhaps 
indicating infection of progenitor cells [49]. 
The envelope proteins from human parainfluenza virus type 3 (HPIV3) may be a 
good choice for the pseudotyping of lentiviruses.  HPIV3 has been shown to have a 
natural tropism for airway epithelial cells, efficiently infecting cells via sialic acid-
containing receptors that are abundantly expressed on the apical membrane of lung 
cells [50, 51].  HPIV3 is an enveloped, negative-strand RNA virus which replicates in the 
cytoplasm of cells.  The binding and fusing abilities of HPIV3 have been separated into 
two envelope proteins, hemagluttinin-neuraminidase (HN) which binds to sialic acid, and 
fusion (F).  The simian immunodeficiency virus has been shown to be pseudotyped with 
the F and HN envelope proteins from another member of the paramyxovirus family, 
Sendai virus [52].  This vector was able to transduce cells in vitro, however it has not yet 
been tested in vivo.   
Non-Viral Proteins.  Studies with HIV have shown that viruses can carry many 
host cell proteins internally and externally on its lipid bilayer.  While much is still 
unknown on how these proteins are incorporated and why, there is growing evidence 
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that viruses may use host cell proteins for enhanced infection [53].  For example, virus-
associated cellular adhesion molecule ICAM-1 has been shown to increase HIV 
infectivity in target T-cells by 5 to 10-fold [54].  Natural insertion of the costimulatory 
molecules CD80 and CD86 onto the viral lipid bilayer not only increases virus infectivity 
by facilitating attachment, they can stimulate the NF-κB transcription factor [55].  Besides 
natural insertion, retroviruses can be engineered to incorporate nonviral proteins for 
enhanced targeting by overexpression of the protein, however the effects have not been 
quantified [56].  It has also been shown that it is important to choose targeted receptors 
on the cell that can efficiently support a productive cell infection pathway [57]. 
One class of host proteins that lentiviruses can incorporate into their lipid bilayer 
are glycosylphosphatidylinositol (GPI)-anchored proteins [58, 59].  These proteins are 
post-translationally modified at the C-terminal with the lipid-anchoring GPI moiety [60].  
GPI-anchored proteins are localized to lipid rafts on the cell surface [61], and attachment 
of a GPI-anchor to a protein can retarget the protein to lipid rafts on the outer plasma 
membrane [62].  Lipid rafts are regions on the cell surface enriched in cholesterol and 
sphingomyelin, which allow for tighter packing and resistance to solubilization in 
detergents at low temperatures [63].  Lentiviruses have been shown to use lipid rafts as 
a scaffold from which to assemble and bud [64, 65].  Besides host GPI-anchored 
proteins, lentiviruses have also been shown to incorporate GPI-anchored viral proteins in 
their viral lipid bilayer [66, 67].  It may be advantageous to incorporate a targeted yet 
non-fusogenic protein into the viral lipid bilayer with GPI-anchoring for enhanced binding 
or signaling to target cells. 
 
1.5  Thesis Objectives 
The objective of this project is to determine how to incorporate proteins into the 
lentiviral lipid bilayer in order to develop a recombinant retrovirus that can efficiently 
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deliver genes to polarized epithelial cells via their apical membranes.  To accomplish 
these objectives, we pursued the following aims: 
1. Create and characterize lentiviruses pseudotyped with the human 
parainfluenza type 3 (HPIV3) envelope proteins, hemagglutinin-neuraminidase (HN) and 
fusion (F), for infection of polarized cells via the apical surface.   
2.  Identify the factors necessary for incorporation of proteins into the lentiviral 
lipid bilayer. 
3.  Engineer the human parainfluenza envelope proteins, HN and F, such that 
they are functionally incorporated into lentiviral particles for improved transduction 
efficiency to polarized cells via the apical surface.   
 
1.6  Organization of the Thesis 
 In chapter one, we will briefly introduce gene therapy for diseases of the lung and 
retroviral-mediated gene transfer.  A major emphasis will be placed on barriers of lung 
gene transfer and incorporation of viral and non-viral proteins into lentivirus particles. 
 In chapter two, we create lentiviruses pseudotyped with the human parainfluenza 
type 3 envelope proteins, HN and F for infection of polarized cells.  We characterize the 
level of envelope incorporation, determine if the viruses can transduce cells, and also 
determine whether transduction is consistent with HN and F pseudotyped lentivirus 
infection. 
 In chapter three, we investigate the cause of low HPIV3 pseudotyped lentivirus 
titers.  We compare expression levels in transfected cells to wild-type HPIV3 infected 
cells, and determine whether an increase in HN expression will increase incorporation 
levels and titer. 
 In chapter four, we determine whether two GPI anchored proteins are 
incorporated into lentiviral particles.  We also determine whether incorporation is due to 
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colocalization with lentiviral Gag in lipid rafts and the effect of lipid raft disturbance on 
virus incorporation. 
 In chapter five, we investigate whether increasing active or passive interactions 
of HN with lentiviral Gag increases the amount of envelope incorporation.  We also 
determine whether this leads to an increase in titer. 
 In chapter six, we summarize our major conclusions and present some 
suggestions for future work. 
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CHAPTER 2 
 
LENTIVIRAL VECTORS PSEUDOTYPED WITH ENVELOPE GLYCOPROTEINS 
DERIVED FROM HUMAN PARAINFLUENZA VIRUS TYPE 31 
 
  
 
2.1  Abstract 
We describe the generation of lentiviruses pseudotyped with human 
parainfluenza type 3 envelope (HPIV3) glycoproteins.  Lentivirus particles, expressed in 
293T/17 cells, incorporate HPIV3 hemagglutinin-neuraminidase (HN) and fusion (F) 
proteins into their lipid bilayers and are able to transduce human kidney epithelial cells 
and polarized MDCK, HBE, and A549 cells.  Neuraminidase, AZT, and anti-HPIV3 
antisera block transduction, which is consistent with lentiviral-mediated transduction via 
sialated receptors for HPIV3.   Our findings show that HPIV3 pseudotyped lentiviruses 
can be formed and may have a number of useful properties for human gene transfer. 
 
2.2  Introduction 
Lentiviruses have been increasingly considered as a potential gene transfer 
vector for human gene therapy, primarily because they are able to stably modify cells 
that are not dividing [1].  Stable modification is important for the treatment of chronic and 
inherited disease [2].  The ability to modify cells that are not dividing is also 
advantageous for in vivo gene transfer since most cells in the body are quiescent or 
replicate slowly [3].  The type of cell that a lentivirus is able to genetically modify is 
largely dictated by the interaction between the envelope protein of the virus and its 
cellular receptor [4].  Lentiviruses that harbor the envelope protein of the wild-type virus 
are only able to transfer genes to cells that express CD4 and are therefore of limited use 
                                                 
1 Modified from Biotechnol Prog 2004 Nov-Dec;20(6):1810-6. 
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for human gene therapy.  To overcome this limitation, lentiviruses have been 
pseudotyped with a number of different viral envelope proteins to enable them to 
transduce a wider range of cell types [5-8].  The most commonly used lentiviruses are 
pseudotyped with the rhabdoviral G protein of the vesicular stomatitis virus (VSV-G) [9-
11].  VSV-G pseudotyped lentiviruses can be produced with high titers, concentrated 
several hundred-fold by ultracentrifugation with minimal loss of virus activity, and are 
able to transfer genes to a wide range of cells types. 
Unfortunately, VSV-G pseudotyped viruses are not able to transfer genes to all 
cell types of interest for human gene therapy.  For example, they are unable to efficiently 
transduce airway epithelial cells via their apical surface, the target of interest for many 
gene therapies of the lung, including cystic fibrosis [12].  Moreover, the cytotoxicity of 
VSV-G complicates the development of stable VSV-G pseudotyped virus producer cell 
lines and may limit the total dose of virus that can be applied to cells to transduce them 
[11].  VSV-G pseudotyped viruses are also not suitable for therapies that need gene 
delivery to be restricted to one cell type (i.e., for targeted gene delivery). 
One strategy to overcome some of these shortcomings is to determine if other 
envelope proteins are able to form pseudotypes with lentiviruses.  Human parainfluenza 
type 3 (HPIV3), a paramyxovirus, is of interest because it is able to infect polarized lung 
epithelial cells via their apical surface, a property that would be valuable for gene 
transfer to the lung [13].  In addition, HPIV3 segregates the two main functions of viral 
envelope proteins, binding and fusion, into two glycoproteins, the hemagglutinin-
neuraminidase (HN) and fusion (F) proteins, a characteristic that could be useful for the 
development of targeted viruses.  The HN protein provides HPIV3 with the ability to bind 
to a cell surface sialated receptor for the virus.  The F glycoprotein, in conjunction with 
HN, induces the lipid bilayer of the virus to fuse with the plasma membrane of the host 
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cell.  In this study, we determined if human parainfluenza type 3 (HPIV3) proteins could 
be used to pseudotype lentiviruses. 
 
2.3  Materials and Methods 
Chemicals and antibodies. Poly-L-Lysine and 3′-Azido-3′-deoxythymidine 
(AZT) were purchased from Sigma (St. Louis, MO).  Complete mini protease inhibitor 
cocktail tablets and neuraminidase (Clostridium perfringens) were purchased from 
Roche Diagnostics (Indianapolis, IN).  Dulbecco’s phosphate-buffered saline (DPBS) 
with and without calcium and magnesium were purchased from Mediatech (Herndon, 
VA).  5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) was purchased from 
Denville Scientific (Metuchen, NJ).  Mouse ascites monoclonal antibody c110 against 
HPIV3-F was generously provided by B.R. Murphy, Respiratory Viruses Section, NIAID, 
NIH (Bethesda, MD).  Guinea pig anti-serum against HPIV3 (strain 47885) was obtained 
through the NIAID Reference Reagent Repository (Bethesda, MD).  Monoclonal rabbit 
antibodies specific for HPIV3-HN were described previously [14].  Cy3-conjugated 
donkey anti-mouse IgG (H+L), Cy2-conjugated donkey anti-guinea pig IgG (H+L), and 
normal donkey serum were purchased from Jackson Immunoresearch Laboratories, Inc. 
(West Grove, PA).   
Plasmids.  For construction of a HPIV3-F and HPIV3-HN expression plasmid, 
the entire coding sequence of HPIV3-F (GenBank accession no. M14892) and HPIV3-
HN (GenBank accession no. 403376) were PCR amplified and cloned into the Cla I and 
Sph I sites of pCAGGS.MCS [15].  The ligation sites of the plasmid were verified by DNA 
sequencing.   
Cell culture.  293T/17 cells (human embryonic kidney epithelial), MDCK cells 
(Madin-Darby canine kidney epithelial; ATCC CCL-34), and HeLa cells (human cervical 
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kidney) were maintained in Dulbecco’s modified essential medium (DMEM)  
supplemented with 10% heat-inactivated fetal bovine serum, 100 U/mL of penicillin, and 
100 μg/mL streptomycin (HyClone Laboratories; Logan, UT).   
Immunofluorescence microscopy.   293T/17 cells, seeded the previous day in 
12-well plates coated with poly-L-lysine (2 x 106 cells per well), were infected with wild 
type HPIV3 at a multiplicity of infection (MOI) of 10 or transfected with 2 ug each of both 
HPIV3-F and HN glycoproteins using Lipofectamine 2000 (Invitrogen; Carlsbad, CA) 
according to the manufacturer’s instructions.  The cells were incubated for 24 hours at 
37°C before plating 5 x 105 cells on coverslips (#1.5 12 mm, Fisher Scientific; Suwanee, 
GA).  Twenty-four hours later, cells were fixed for 10 minutes in 2% paraformaldehyde in 
phosphate buffered saline (PBS) at 25°C, washed in PBS and 5% donkey sera 
(PBS/serum), and incubated in primary antibody in PBS/serum for one hour at 25°C.  
After washing three times (PBS), cells were incubated with labeled secondary antibody 
in PBS/serum for one hour at 25°C before washing three times in PBS and once in 
double distilled water.  Cells were mounted onto glass slides with gelvatol [16] and 
samples examined under a microscope (Olympus IX50; Melville, NY) through a 10x lens. 
Virus Production.  Human parainfluenza virus type 3 (strain Wash/57/47885) 
was obtained from the National Institute of Allergy and Infectious Disease (Bethesda, 
MD) and propagated on monolayers of HeLa cells.  Lentiviruses pseudotyped with the 
amphotropic or human parainfluenza virus type 3 envelope proteins were produced by 
using Lipofectamine 2000 to co-transfect 293T cells with 8 μg of the packaging construct 
pCMVΔR8.91 (kind gift of Scott S. Case), 8 μg of lentivirus vector pTY-EFnlacZ or pTY-
eGFP (AIDS Research and Reference Reagent Program, Bethesda, MD), and 8 μg of 
the amphotropic envelope protein expression plasmid pFB4070ASALF (a kind gift of 
Stephen Russell) or 8 μg each of pCAGGS-hPIV3-F and pCAGGS-hPIV3-HN.  Viral 
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supernatants were collected every 12 hours from 36-60 hours after transfection, filtered 
sterilized (0.45 µm), and frozen (-800C) for later use.  
   Transduction.  Target cells were seeded in poly-L-lysine coated 12-well plates 
(1 x 105 per well) and incubated at 37°C.  The next day, viral supernatant dilutions were 
incubated with cells for 48 hours, and then the cells fixed and stained for β-galactosidase 
activity with X-Gal and the number of lacZ+ colony forming units (CFU) per ml counted 
[17].  To determine the effect of neuraminidase or AZT on transduction, cells were 
pretreated for 90 minutes with neuraminidase (0 to 2 U/mL) or AZT (2.5 μM), incubated 
with virus brought to the same concentration of these reagents, then fixed and stained 
for β-galactosidase activity.  To examine the ability of the viruses to transduce polarized 
cells, MDCK cells were seeded 4 days prior to transduction in 0.4 µm tissue culture 
treated Transwell polyester supports (1 x 105 cells per insert) (Costar-Corning; Corning, 
NY), and then incubated at 37°C until polarized as evidenced by a step jump in their 
transepithelial resistance (>200 Ω*cm2) [18] as measured with a voltohmmeter (World 
Precision Instruments; Sarasota, FL).  Viral supernatants, concentrated 10-fold by 
ultrafiltration with Macrosep centrifugal concentrators (300-kDa molecular mass cutoff; 
Pall Gelman Laboratory;  Ann Arbor, MI) with 8 μg/mL of Polybrene, were applied to the 
apical (100 μL) or basolateral (50 μL) surfaces of the polarized cells for one hour.  Two 
days later, the cells were fixed and stained for β-galactosidase activity.  As a control, 
cells were depolarized by incubation with EDTA (6 mM) in Hepes (10 mM) buffer, and 
then transduced with concentrated viral supernatants to determine the effect of 
depolarization on infection. 
Metabolic labeling and immunoprecipitation.  Thirty-six hours after 
transfection, cells were incubated with methionine and cysteine-free DMEM for 15 min at 
37°C.    Cells were then labeled for 18 hours at 37°C with 500 μCi of [35S]methionine-
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cysteine protein labeling mix (Perkin Elmer Life Sciences;  Wellesley, MA).  Cells were 
lysed at 4°C for 10 minutes with RIPA buffer (50 mM Tris-HCl [pH 7.6], 150 mM NaCl, 
0.5% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, and protease inhibitors), 
centrifuged for 10 min at 20,800 × g to pellet the nuclei, HPIV envelope proteins isolated 
from the supernatants with guinea pig anti-serum against HPIV3 pre-bound to protein-A 
sepharose beads, and then analyzed by SDS-PAGE as described below.  Virus samples 
were obtained by ultracentrifugation of viral supernatants (4 mL) in a SW55Ti Beckman 
rotor (110,000 × g, 2 h, 4°C) through a 20% sucrose cushion.  For separation and 
purification of viral vector by continuous density gradient centrifugation, viral supernatant 
(2 mL) were centrifuged in a Beckman SW41Ti rotor (150,000 × g, 16 h, 4°C) through a 
20%-60% continuous sucrose density gradient prepared with a SG series gradient 
maker (Hoefer Scientific Instruments;  San Francisco, CA).  Eight fractions (1.25 mL) 
were collected and the density of each fraction determined as mass/volume and 
reported in g/mL.  Fractions were diluted with 10.75 mL Dulbecco’s PBS without calcium 
and magnesium, and then the viruses centrifuged a second time in a Beckman SW41Ti 
Rotor (150,000 × g, 2 h and 4°C).  Virus pellets were resuspended in RIPA buffer (50 μL) 
for 30 minutes at 25°C.  Samples were separated by size by SDS-PAGE (4-15%), and 
then the gel dried (72°C for 45 minutes) and visualized by autoradiography (BioMax MR 
film; Amersham; Piscataway, NJ).  
Data analysis.  Data are summarized as the mean +/- the standard deviation for 
at least triplicate samples.  Statistical analysis was performed using one-way analysis of 
variance for repeated measurements of the same variable.  The Tukey multiple 
comparison test was used to conduct pairwise comparisons between means.  
Differences at P < 0.05 were considered statistically significant. 
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2.4  Results 
We constructed expression plasmids for human parainfluenza virus type 3 
hemagglutinin-neuraminidase (pCAGGS-HPIV3-HN) and fusion (pCAGGS-HPIV3-F) 
proteins.  To investigate the expression of these envelope glycoproteins, we transfected 
293T/17 cells with the plasmids, radiolabeled the cells with [35S]methionine-cysteine 
protein labeling mix, then immunoprecipitated lysates of the cells with a mouse 
monoclonal antibody against HPIV3-F and rabbit monoclonal antibody against HPIV3-
HN.  The samples were separated by size by SDS-PAGE and visualized by 
autoradiography.  The envelope glycoproteins HPIV3-F (about 50 kDa) and HPIV3-HN 
(about 70 kDa) glycoproteins were easily detected, confirming their expression in 
transfected 293T/17 cells (Figure 2.1).  Expression of these proteins on the surfaces of 
the cells, expected to be a prerequisite for their incorporation into the lentiviral vectors, 
was confirmed by immunostaining (Figure 2.2). 
To determine if lentivirus vectors are able to form transduction competent 
pseudotypes with HPIV3-HN and F glycoproteins, we transfected 293T/17 cells with 
expression vectors that encoded HPIV3-F (pCAGGS-HPIV3-F), HPIV3-HN (pCAGGS-
HPIV3-HN), HIV-1 gag, pol, rev, and tat (pCMVΔR8.91), and a lentiviral vector that 
encoded lacZ (pTYEFnlacZ).  Twenty-four hours later the medium was replaced and the 
cells cultured an additional 12 hours.  Some syncitium formation was observed, 
indicating that the envelope proteins were biologically active and capable of inducing 
cell-cell fusion (data not shown).  The medium, which contained putative lentivirus-
HPIV3 (HPIV3/LV) pseudotyped viruses, was used to transduce 293T/17 and MDCK  
cells.  Low but measurable titers were observed (Table 2.1).  Significantly higher titers 
were observed when the cells were transduced with lentiviruses pseudotyped with the 
amphotropic envelope protein Ampho/LV (Table 2.1), which confirmed that the cell lines  
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Figure 2.1.  Expression of HPIV3-HN and F in 293T/17 cells.  Lysates of metabolically 
labeled 293T/17 cells transfected with pCAGGS-HPIV3-HN and pCAGGS-HPIV3-F were 
immunoprecipitated with a mouse monoclonal antibody against HPIV3-F and a rabbit 
monoclonal antibody against HPIV3-HN.  The expected bands for HPIV3-HN and 
HPIV3-F are indicated by the arrows.  Lane 1, molecular weight markers; lane 2, lysates 
of 293T/17 cells transfected with pCAGGS-HPIV3-HN and pCAGGS-HPIV3-F; lane 3, 
lysates of mock transfected 293T/17 cells. 
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Figure 2.2.  HPIV3-HN and F surface expression in 293T/17 cells.  Cells were 
transfected with both pCAGGS-HPIV3-F and pCAGGS-HPIV3-HN, then 48h later fixed, 
but not permeabilized, and immunostained with HPIV3-specific guinea pig polyclonal 
antibody and anti-guinea pig Cy2-conjugated donkey secondary antibody (A) or mouse 
ascites against HPIV3-F and anti-mouse Cy3-conjugated donkey secondary antibody 
(B).  As a positive control, wild-type HPIV3 infected cells were fixed and immunostained 
for HPIV3 (C) and HPIV3-F (D) using the same antibodies.  Cells were viewed by 
epifluorescence microscopy (10X).   
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we tested were not refractory to lentivirus transduction and that our virus production 
methods were sufficient to yield high titer virus stocks. 
We conducted additional experiments to determine if the titers we measured 
were the result of bonafide lentiviral-mediated transduction events.  We found that 
lentiviruses pseudotyped with only one (HN or F) or none (bald) of the HPIV3 envelope 
proteins were unable to transduce cells, and that transduction was almost completely 
blocked by treatment of cells with AZT (2.5 μM) thirty minutes prior to and during 
infection (Table 2.1).  Elimination of sialic acid from the surfaces of the cells by treating 
them with neuraminidase before and during infection reduced virus titers in a dose-
dependent manner (Figure 2.3).  Titers were reduced more than 98% when cell-surface 
sialic acids were cleaved by incubating the cells with C. perfringens neuraminidase (2 
U/mL, 37°C) ninety minutes prior to, and during, transduction (Table 2.1).  As expected, 
the titers of amphotropic pseudotyped lentiviruses, which do not need to interact with 
cell-surface sialic acids to infect cells, were not reduced by neuraminidase treatment of 
the cells.  In addition, incubation of cells with antisera against HPIV inhibited 
transduction by HPIV3 pseudotyped lentiviruses but, as expected, had no effect on 
transduction by amphotrophic pseudotyped lentiviruses (Figure 2.4).  These data 
confirmed that the titers we observed were the result of lentivirus transduction, and were 
not caused by pseudotransduction or other non-viral mediated events.  Our data also 
showed that the lentiviruses were pseudotyped with HPIV3 envelope proteins (i.e., 
HPIV3/LV viruses) transduced cells through interactions between the HPIV3-HN and F 
proteins and a sialated cell-surface receptor. 
 Given the low titers of the HPIV3/LV virus stocks, we considered it a possibility 
that the virus particles were not physically associated with the HPIV3 envelope proteins,  
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Figure 2.3.  Dose-response curve of pseudotype transduction in the presence of 
neuraminidase.  293T cells were incubated with varying amounts of neuraminidase at 37 
0C ninety minutes prior to and during the virus titer experiment.  Transduced cells were 
incubated for 2 days at 37 0C until confluent, fixed and stained for lacZ activity with X-
gal, colonies of lacZ+ cells counted, and the titer (CFU/mL) calculated. 
  
 
 
  
 
Figure 2.4.  The effect of HPIV3 specific antisera on transduction.  293T cells were 
incubated at 37 0C without (-) or with (+) a 1:300 dilution of anti-HPIV3 guinea pig 
polyclonal antibody during transduction.  Transduced cells were incubated for 2 days at 
37 0C until confluent, fixed and stained for lacZ activity with X-gal, colonies of lacZ+ cells 
counted, and the titer (CFU/mL) calculated as previously described.  * significantly 
different from control (p < 0.05) by Tukey multiple comparison test.    
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and that the transduction events we had observed were the result of the 
complementation of envelope negative viruses with membrane vesicles (i.e., not 
associated with a lentivirus core) containing HPIV3 envelope proteins.  As a first step 
towards determining if HPIV3-HN proteins were associated with the lentivirus particles, 
we measured the hemagglutination (HA) titer of a stock of HPIV3/LV pseudotyped 
viruses by incubating serial dilutions of the viruses with equal volumes of guinea pig red 
blood cells for 1 hour at 4°C.  The HA titer of the HPIV3/LV pseudotyped virus stocks 
was 16 HA units/mL.  As controls we measured the HA titer of a stock of wild type HPIV3 
virus (512 HA units/mL), of envelope-negative lentiviruses (<4 HA units/mL), and of 
culture media from cells that expressed the HPIV3 envelope proteins HN and F but no 
lentivirus proteins (<4 HA units/mL).  Agglutination was reversed and HA titers reduced 
to undetectable levels when the hemagglutination microtiter plates were warmed to 37°C 
for one hour, which confirmed that that the pseudotyped lentiviruses contained 
neuraminidase activity.  These data support the conclusion that lentivirus vectors are 
able to incorporate enzymatically active HPIV3-HN proteins. 
To determine if lentivirus vectors are able to incorporate both HPIV3-HN and 
HPIV3-F proteins, we transfected 293T/17 cells with pCAGGS-HPIV3-F, pCAGGS-
HPIV3-HN, pCMVΔR8.91, and pTYEFnlacZ, then thirty-six hours later metabolically 
labeled the cells with [35S]methionine-cysteine protein labeling mix.  Cell culture 
supernatant was harvested and the radiolabeled virus particles partially purified by 
ultracentrifugation through a 20% sucrose cushion, resuspended in lysis buffer, 
separated by size by SDS-PAGE, then the gel dried and visualized by autoradiography.  
As controls, supernatant was harvested from 293T/17 cells that had not been 
transfected, or had been transfected to express lentivirus proteins only (i.e., envelope 
negative viruses), lentivirus proteins and HPIV3-F only, or lentivirus proteins and HPIV3-
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HN only, or had been infected with wild-type HPIV3 virus.  We found that both HPIV3-
HN and HPIV3-F were present in lysates of HPIV3/LV pseudotypes (Figure 2.5A), but to 
a lesser extent than wild-type HPIV3.  In cells that expressed only HPIV3-F (Figure 2.5A, 
lane 4), both the inactive precursor (F0) and its activated proteolytic cleavage product 
(F1) were visible, demonstrating that the protein is properly processed in 293T/17 cells.  
Interestingly, more envelope protein was detected in virus lysates when only HPIV3-HN 
or HPIV3-F was expressed in the virus producer cells than when both proteins were 
expressed. 
 We considered it a possibility, although unlikely, that the HPIV3 envelope 
proteins that we had detected in the previous experiment were present in the 
supernatants of virus producer cells, not as integral components of intact pseudotyped 
lentiviruses, but instead as part of non-viral lipid complexes that co-purified with the 
lentiviruses.  To verify that the HPIV3-HN and F proteins were in fact physically 
associated with lentivirus particles and not part of non-viral lipid complexes that co-purify 
with lentiviruses, we purified radiolabeled virus supernatants by ultracentrifugation 
through a 20%-60% sucrose density gradient.  Fractions were collected, pelleted by 
ultracentrifugation, resuspended in lysis buffer, separated by size by SDS-PAGE, then 
the gel dried and visualized by autoradiography.  We found that HPIV3-HN and HPIV3-F 
proteins migrated to the same fractions as the lentivirus capsid (CA) and matrix (MA) 
proteins (Figure 2.5B).  Taken together, our results indicate that HPIV3 envelope 
proteins are released into the medium when expressed in cells that are producing 
lentivirus particles, and that the released lentiviruses are able to incorporate HPIV3-HN 
and F envelope proteins within their lipid bilayers to form pseudotyped viruses that are 
capable of transducing cells. 
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Figure 2.5.  HPIV3-HN and F incorporation into lentivirus particles.  (A) Supernatants 
from metabolically labeled 293T/17 producer cells were partially purified by 
ultracentrifugation through a 20% sucrose cushion, resuspended in lysis buffer, 
separated by size by SDS-PAGE electrophoresis, then the gel dried and visualized by 
autoradiography. Supernatants from 293T/17 cells producing lentiviruses pseudotyped 
with both HPIV3 envelope proteins (lane 3), with HPIV3-F only (lane 4) or with HPIV3-
HN only (lane 5), are shown.  The expected bands for HPIV3-HN, F1, and lentivirus 
capsid (CA) proteins are indicated by the arrows.  Supernatants from mock transfected 
293T/17 cells (lane 1) served as a negative control for HPIV3-HN and F protein 
expression.  Supernatants from 293T/17 cells infected with wild type HPIV3 (lane 6) 
served as a positive control for HPIV3-HN and F protein expression.  293T/17 cells 
producing non-enveloped lentiviruses (lane 2) served as a positive control for lentivirus 
protein expression.  Molecular weight markers are in lane M.  (B) Supernatants from 
metabolically labeled 293T/17 cells producing lentiviruses pseudotyped with both HPIV3 
envelope proteins were purified by ultracentrifugation through a continuous sucrose 
gradient (20% to 60%), eight fractions collected, and the density of each fraction 
measured.  Each fraction was pelleted by ultracentrifugation, resuspended in lysis buffer, 
separated by size by SDS-PAGE electrophoresis, then the gel dried and visualized by 
autoradiography.  The expected bands for HPIV3 envelope proteins (HN and F1) were 
detected in the same fractions (4 and 5) that contained lentiviral capsid (CA) and matrix 
(MA) proteins.  Molecular weight markers are in lane M.  The density of fractions 1 
through 8 were 1.109, 1.133, 1.154, 1.172, 1.191, 1.220, 1.237 and 1.241 g/mL.   
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Concentration of the parainfluenza pseudotyped viruses would be advantageous 
for increasing titer.  We tested the ability of HPIV3/LV to be concentrated either with a 
centrifugal concentrator or with cationic and anionic polymers [17].  We found that 
HPIV3/LV viruses can be concentrated 10-fold with a 7-fold increase in viral titer (Figure 
2.6).  We also investigated the possibility that virus titers could be increased by 
incubation of the producer cells with 0.05 U/mL of neuraminidase to inhibit interactions 
between sialidated glycoproteins and HPIV3 glycoproteins that could hinder the release 
of HPIV3 pseudotyped lentiviral particles [19].  After pelleting viruses with the cationic 
and anionic polymers and resuspending to the original amount with media, we found that 
the addition of neuraminidase to virus producer cells has no effect on titer (Figure 2.7A).  
We also attempted to increase titers by incubation of producer cells with 10 mM sodium 
butyrate which has been shown to activate expression of the packaging construct [20], 
however treatment had no effect on titers (Figure 2.7B). 
To assess whether the HPIV3 pseudotyped lentivirus exhibited the tropism of 
parainfluenza on polarized cells, 10-fold concentrated HPIV3/LV was applied to the 
apical or basolateral surface of polarized MDCK cells in the presence of polybrene.  
Amphotrophic pseudotyped lentiviruses, which preferentially transduce polarized cells 
via their basolateral membranes, were also applied as a control.  We confirmed that the 
cells were polarized and that tight junctions were intact during transduction by verifying 
that the transepithelial resistance was high (> 200 Ω*cm2) before and after transduction.   
Lentiviruses pseudotyped with the HPIV3 glycoproteins were able to transduce 
polarized cells with equal efficiency from the apical and basolateral surface (Figure 2.8).  
As expected, lentiviruses pseudotyped with amphotrophic envelope protein preferentially 
infected cells when applied to the basolateral side of polarized cells.  When polarization 
was disrupted by treatment of cells with a calcium chelator (EDTA), amphotropic 
lentivirus-mediated gene transfer increased several-fold to double the level seen during 
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Figure 2.6.  Concentration of HPIV3 lentiviral pseudotypes increases titer.  HPIV3/LV 
virus was concentrated either with a centrifugal concentrator (open bars) or cationic and 
anionic polymers (closed bars) and diluted in fresh media.  293T cells were then 
transduced and incubated for 2 days at 37 0C until confluent, fixed and stained for lacZ 
activity with X-gal, colonies of lacZ+ cells counted, and the titer (CFU/mL) calculated.   
 
 
 
 
 
Figure 2.7.  Treatment of HPIV3/LV producer cells does not enhance titers.  HPIV3/LV 
producer cells were incubated with 0.05 U/mL neuraminidase or 10 mM sodium butyrate 
24 hours after transfection for 24 hours before viruses were harvested.  HPIV3/LV virus 
was then pelleted with cationic and anionic polymers and diluted in fresh media.  293T 
cells were then transduced and incubated for 2 days at 37 0C until confluent, fixed and 
stained for lacZ activity with X-gal, colonies of lacZ+ cells counted, and the titer 
(CFU/mL) calculated.   
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Figure 2.8.  Transduction of polarized MDCK cells by HPIV3/LV and Ampho/LV.  
Polarized MDCK cells as measured by a transepithelial resistance > 200 Ω were 
transduced apically (closed bars) with 100 μL of 10X HPIV3/LV or 1X Ampho/LV, or 50 
μL basolaterally (open bars) by inversion of the Transwell.  Cells were transduced for 1 h 
in the presence of 8 μg/mL polybrene.  As a control, cells were depolarized with 6 mM 
EDTA in HEPES (10 mM) for 30 min prior to and during apical transduction (grey bars), 
or incubated with 2.5 μM AZT thirty minutes prior to and during the experiment (hatched 
bars).  Cells were incubated for 2 d at 37 0C until confluent, fixed and stained for lacZ 
activity with X-gal, and the number of lacZ+ colonies counted.       
  
 
 
 
 
basolateral infection of polarized cells [21].  As a control, when 2.5 µM AZT was added 
during the transduction of polarized and unpolarized cells, the titers of both HPIV3/LV 
and Ampho/LV were abolished. 
 Though titers of HPIV3 pseudotyped lentiviruses are several orders of magnitude 
less than amphotropic pseudotyped lentiviruses, HPIV3 pseudotyped eGFP-containing 
lentiviruses were able to transduce polarized lung cells with similar efficiency as 
amphotropic pseudotyped lentiviruses from the apical side (Figure 2.9).  
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Figure 2.9.  Transduction of polarized HBE or A549 cells by HPIV3/LV and Ampho/LV.  
Polarized HBE cells as measured by a transepithelial resistance > 600 Ω were 
transduced apically with 100 μL of polymer-pelleted 2X HPIV3/LV or 2X Ampho/LV 
carrying the eGFP gene.  Cells were transduced for 2 d and viewed by epifluorescent 
microscopy at 10X.  Polarized A549 as measured by a transepithelial resistance > 120 Ω 
were transduced apically with 100 μL of HPIV3/LV or Ampho/LV carrying the eGFP gene 
for 1.5 h and cultured for 2 d before viewed by epifluorescent microscopy at 10X. 
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2.5  Discussion 
We have demonstrated that HPIV3 HN and F proteins are incorporated into 
lentivirus particles to form infectious viruses.  The titers of the HPIV3 pseudotyped 
lentiviruses are low, possibly because the viruses contain too few envelope proteins to 
efficiently infect cells [22].  A number of approaches can be envisioned to increase the 
level of envelope protein incorporation.  One approach might be to increase the number 
of transiently transfected cells that express all of the genes necessary to produce a 
transduction competent virus by reducing the number of plasmids needed to transfect 
the virus producer cells, such as by developing a cell line that stably expresses HPIV3-F 
and the retroviral vector.  Another approach might be to genetically modify the envelope 
proteins to increase their level of incorporation.  This approach has been successfully 
used to increase the level of incorporation of heterologous envelope proteins by 
truncation of their cytoplasmic domains, fusion with the cytoplasmic domains of retroviral 
or lentiviral envelope proteins, or through the use of more sophisticated modifications 
designed to relieve steric hindrance or alter envelope protein folding [23-26]. 
Alternatively, it is possible that HPIV3/LV viruses inefficiently infect cells because 
of a defect in the interactions between HN and F when they are within the context of a 
pseudotyped lentivirus particle.  Although the exact mechanism is not known, membrane 
fusion mediated by HPIV3-F glycoproteins, which are in the form of a trimer, strictly 
requires the presence of homotypic HN glycoproteins, which are in the form of a 
tetramer [13, 27].  Presumably, upon binding to its cell surface receptor, the HN 
glycoproteins undergo a conformational change that allows them to interact with 
neighboring F glycoproteins, inducing them to initiate fusion between the virus and cell 
[28-30].  Perturbations in the structure or stoichiometry of the HN-F complexes, perhaps 
due to their association with heterologous lentivirus capsid proteins, might reduce the 
efficiency with which virus fusion is induced after receptor binding. 
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Previous successes with improving the infectivity of other pseudotyped viruses 
suggest that it may be possible to substantially improve the titers of HPIV3/LV 
pseudotyped viruses.  For example, the titer of an African green monkey simian 
immunodeficiency virus (SIVagm) pseudotyped with Sendai virus envelope proteins was 
increased several-fold by truncation of the cytoplasmic domain of the Sendai virus F 
protein, and by addition of the cytoplasmic tail of the SIVagm envelope protein to the N-
terminus of the Sendai virus HN protein [23].  Similar approaches have increased the 
titers of a number of other pseudotyped retroviruses and lentiviruses [24, 31-34]. 
High titer HPIV3/LV viruses may have a number of useful properties as gene 
transfer vectors.  As we have shown, lentiviruses pseudotyped with HPIV3 envelope 
proteins adopt the tropism of wild-type HPIV3 viruses, which may enable them to 
transduce a number of different cell types that express the sialated HPIV3 receptor, 
including polarized lung epithelial cells via their apical membrane.  HPIV3/LV viruses are 
also likely to be more resistant to inactivation during purification and concentration steps 
then are viruses pseudotyped with retroviral envelope proteins.  Unlike retrovirus 
envelope proteins that are weakly associated with the virus particle via non-covalent 
bonds, HPIV3-HN and F are both transmembrane proteins.  We also speculate that 
because HPIV3/LV pseudotyped viruses have two envelope proteins, one that mediates 
binding (HN), and one that mediates fusion (F), it may be possible to genetically 
engineer the virus to bind to a specific, targeted cell type without adversely affecting its 
fusogenicity. 
In summary, we have shown that lentiviruses can be pseudotyped with HPIV3 
envelope proteins to exhibit the tropism of HPIV3.  HPIV3/LV viruses may have a 
number of advantages as gene transfer vectors, including the ability to transfer genes to 
cells that are susceptible to infection by wild-type HPIV3, and could prove useful as a 
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model experimental system for studying the factors that control the incorporation and 
function of heterologous envelope proteins in lentivirus particles.  
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CHAPTER 3 
 
LENTIVIRUSES INEFFICIENTLY INCORPORATE HUMAN PARAINFLUENZA TYPE 3 
ENVELOPE PROTEINS2 
 
  
 
3.1  Abstract 
We have previously shown that the envelope glycoproteins of human 
parainfluenza type 3 (HPIV3), F and HN, are able to pseudotype lentiviruses, but the 
titers of these viruses are too low for use in clinical gene transfer.  In this study we 
investigated the cause of these low titers.  We compared the mRNA and protein 
expression levels of HN and F in transfected cells and in cells infected with wild-type 
HPIV3.  Transfected cells contained similar levels of HN and F cytosolic mRNA, but 
fewer cell-surface HN and F proteins (3.8 and 1.3-fold less, respectively), than cells 
infected with wild-type HPIV3.  To increase expression of HN in transfected cells, we 
codon-optimized HN and used it to transfect lentivirus producer cells.  Cell surface 
expression of HN, as well as the amount of HN incorporated into virus particles, 
increased 2 to 3-fold.  Virus titers increased 1.2 to 6.4-fold, and the transduction 
efficiency of polarized MDCK cells via their apical surfaces increased 1.4-fold.  
Interestingly, even though codon optimization improved the expression levels of HN and 
virus titers, we found that HPIV3 pseudotyped viruses contained about 14-fold fewer 
envelope proteins than lentiviruses pseudotyped with the amphotropic envelope protein.  
Taken together, our findings suggest that titers are low, not because virus producer cells 
express levels of HPIV3 envelope proteins that are too low, but because too few of these 
proteins are incorporated by the lentiviruses for them to be able to efficiently transduce 
cells. 
                                                 
2 Modified from Biotechnol Bioeng accepted July 31, 2007 
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3.2  Introduction 
 
Recombinant retroviruses are used in gene therapy clinical trials because they 
can permanently integrate a therapeutic gene into the DNA of target cells, resulting, in 
principle, in a long-term cure [1, 2].  Lentiviral vectors, such as those based on human 
immunodeficiency virus (HIV), are a subclass of retroviruses that can infect and integrate 
their genome into non-dividing cells [3].  Retroviral-mediated gene transfer can be used 
to treat inherited genetic disorders, complex genetic disorders, and infectious diseases, 
and has numerous applications in tissue engineering.  Unfortunately, the current 
generation of recombinant retroviruses have some limitations that restrict their 
usefulness for in vivo applications [4, 5].  For example, it is difficult to control the tropism 
of retroviruses; that is, the types of cells that retroviruses can, and cannot, transduce.   
Retroviral tropism is largely determined by the interaction between envelope 
proteins that protrude from the surface of the virus and receptors for the virus on the 
surface of the cell [6, 7].  Frequently, retroviruses that are being studied for use in 
human gene therapy have had their wild-type envelope protein replaced with one from 
another virus to form a pseudotyped virus (i.e., a virus composed of proteins from more 
than one virus).  The most commonly-used envelope proteins for pseudotyping 
retroviruses are the amphotropic and VSVG envelope proteins [7, 8].  These proteins are 
favored primarily because they enable the viruses to transduce a wide range of human 
cell types. 
Unfortunately this lack of cell-type specificity may reduce the usefulness of VSVG 
or amphotropic envelope proteins for viral-mediated gene therapy in vivo, where it is 
often important to transduce a specific targeted cell type and no others.  In addition, 
VSVG and amphotropic pseudotyped retroviruses do not efficiently transduce some 
clinically relevant cell types such as polarized epithelial cells of the lung via their apical 
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surfaces, which are important targets for cystic fibrosis and other lung gene therapies [9-
11].  To overcome this problem, researchers have attempted to pseudotype lentiviruses 
with envelope proteins derived from a number of lung-tropic viruses, including influenza, 
respiratory syncytial virus, influenza D, Ross River virus, and Jaagsiekte sheep 
retrovirus [12-16].  Unfortunately, lentiviruses pseudotyped with these proteins either do 
not transduce polarized airway cells via their apical surfaces, or do so with efficiencies 
that are too low to be useful for clinical gene transfer.   
Some promising envelope proteins have been genetically modified to improve 
their ability to pseudotype lentiviruses.   Kobayashi et al. successfully genetically 
modified both Sendai virus envelope proteins F and HN to pseudotype SIV-derived 
lentiviruses (SIVagm) [17].  These viruses transduced polarized rat tracheal epithelial 
cells in vitro, but their ability to efficiently transduce cells in vivo has not yet been tested.  
Medina et al. modified the Zaire strain of the Ebola virus glycoprotein (EboZ) to improve 
its safety and gene transfer efficiency by deleting toxic sequences [18].  Lentiviruses 
pseudotyped with these engineered Zaire EboZ envelope proteins transduced up to 52% 
of polarized mouse airway epithelial cells in vivo after direct tracheal injection [18].   
As part of this important continuing effort to identify and develop alternative 
lentivirus pseudotypes for the purposes of human gene therapy, we have begun to 
investigate the ability of human parainfluenza virus type 3 (HPIV3) envelope proteins to 
pseudotype lentiviruses.  We expect HPIV3 pseudotyped lentiviruses to be useful for 
gene delivery to the lung because wild-type HPIV3 infection begins with interactions 
between the envelope proteins (hemagluttinin-neuraminidase (HN) and fusion (F)) of the 
virus and cell-surface sialic-acid containing receptors that are abundantly expressed on 
the apical membranes of lung cells [19, 20].  Importantly, HPIV3 infections do not 
generate long-term immunity in infected patients.  This suggests that it may be possible 
to administer HPIV3 pseudotyped viruses to a patient as often as necessary to achieve 
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the desired therapeutic outcome, which would be a distinct advantage over most other 
viral vectors [21, 22].  
We have previously shown that human parainfluenza virus type 3 envelope 
proteins F and HN are able to pseudotype lentiviruses, and that these viruses infect 
polarized cells via their apical surfaces, albeit with titers too low to be useful for clinical 
gene transfer [23].  In this study, we tested the hypothesis that titers are low because too 
few particles are released by the virus producer cells, cellular expression of the HPIV3 
envelope proteins (HN and F) is low, or too few HPIV3 envelope proteins are 
incorporated by the lentiviruses.  The implications of our findings for the generation of 
pseudotyped lentiviruses that are useful for clinical gene transfer are discussed. 
 
 
3.2  Materials and Methods 
 
Chemicals and antibodies.  Poly-L-lysine, 1,5-Dimethyl-1,5-
diazaundecamethylene polymethobromide (Polybrene), o-phenylenediamine 
dihydrochloride (OPD), and 5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) 
were purchased from Sigma Chemical (St. Louis, MO).  Complete mini protease inhibitor 
cocktail tablets were purchased from Roche Diagnostics (Indianapolis, IN).  Coomassie 
Plus-200 protein assay reagent was purchased from Pierce (Rockford, IL).  Mouse 
ascites monoclonal antibody 215 against HPIV3-F and mouse ascites monoclonal 
antibody 66/4 against HPIV3-HN were generously provided by Judy Beeler (WHO 
Programme for Vaccine Development Reagent Bank for Respiratory Syncytial Virus and 
Parainfluenza Type 3).  HIV-1 p24 gag mouse ascites monoclonal antibody #24-3 was 
obtained through the AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH: HIV-1 p24 gag monoclonal from Dr. Michael H. Malim.  Mouse 
ascites monoclonal antibody c110 against HPIV3-F was generously provided by B.R. 
Murphy, Respiratory Viruses Section, NIAID, NIH (Bethesda, MD).  Guinea pig 
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antiserum against HPIV3 (strain 47885) was obtained through the NIAID Reference 
Reagent Repository (Bethesda, MD).  Mouse anti-gp70 antibodies were purified from the 
supernatant of the 83A25 hybridoma cell line [24] following standard procedures [25].  
Cy2-conjugated donkey anti-guinea pig IgG (H+L), Cy2-conjugated donkey anti-mouse 
IgG (H+L), horseradish peroxidase (HRP)-conjugated donkey anti-mouse IgG (H+L), 
and normal donkey serum were purchased from Jackson Immunoresearch Laboratories, 
Inc. (West Grove, PA). 
Cell culture.  293T/17 cells and HeLa cells were maintained in Dulbecco’s 
modified essential medium (DMEM) supplemented with 10% heat inactivated fetal 
bovine serum (FBS), 100 U/mL of penicillin, and 100 μg/mL streptomycin (HyClone 
Laboratories; Logan, UT).  Vero cells and MDCK cells were maintained in Minimum 
essential medium (Eagle) supplemented with 10% fetal bovine serum, 100 U/mL of 
penicillin, and 100 μg/mL streptomycin.  Plates coated with poly-L-lysine were incubated 
for 5 min in the 0.01% solution (150-300 kDa), washed once with deionized water, and 
dried. 
Virus production.   Human parainfluenza virus type 3 (strain Wash/57/47885), 
obtained from the National Institute of Allergy and Infectious Disease (Bethesda, MD), 
was propagated on monolayers of HeLa cells.  Lentiviruses pseudotyped with the 
amphotropic or human parainfluenza virus type 3 envelope proteins were produced by 
transfecting 293T/17 cells, seeded (1x107 per well) the previous day on poly-L-lysine 
coated plates with Lipofectamine 2000 (Invitrogen; Carlsbad, CA) and 6 μg of the 
packaging construct pCMVΔR8.91 [26], 6 μg of the lentivirus vector pTYEFnlacZ or 
pTYEFeGFP (AIDS Research and Reference Reagent Program; Bethesda, MD), and 6 
μg of the amphotropic envelope protein expression plasmid pFB4070ASALF [27] or 6 μg 
each of the HPIV3 F and HN envelope expression plasmids (i.e., pCAGGS-hPIV3-F and 
pCAGGS-hPIV3-HN, respectively).  Viral supernatants were collected every 12 h from 
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48 to 60 h after transfection, filter sterilized (0.45 μm), and frozen (-80°C) for later use.  
For some experiments, an expression vector encoding codon-optimized HPIV3-HN was 
used to generate pseudotyped lentiviruses.  Codon-optimization of HPIV3-HN was 
performed by GENEART, Inc (Toronto, Canada).  The cDNA was subcloned into the Cla 
I and Sph I sites of the pCAGGS.MCS expression vector [28] and the structure of the 
ligation sites was verified by DNA sequencing.   
Metabolic labeling and immunoprecipitation.  To detect proteins in virus 
stocks and producer cells, cells were transfected as above, or infected with wild-type 
HPIV3 at an MOI of 1 for twenty-four hours, and then incubated with methionine and 
cysteine-free DMEM for 15 min at 37°C. Cells were then radiolabeled for 16 h at 37°C 
with 450 μCi of [35S]methionine-cysteine protein labeling mix (GE Healthcare; 
Piscataway, NJ).  Cells were lysed at 4°C for 10 min with RIPA buffer (50 mM Tris- HCl 
[pH 7.6], 150 mM NaCl, 0.5% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, and 
protease inhibitors) and centrifuged for 10 min at 20,800 x g to pellet the nuclei.  Virus 
samples were obtained by ultracentrifugation of the viral supernatants in a SW41Ti 
Beckman rotor (150,000 x g, 2 h, 4°C) through a 20% sucrose cushion after which the 
pellets were resuspended in RIPA buffer for 30 min at 25°C.  Cell lysates or virus 
samples were immunoprecipitated with guinea pig anti-serum against HPIV3, mouse 
monoclonal antibody against gp70 (83A25), mouse monoclonal antibody against F 
(c110), or mouse monoclonal antibody against HN (66/4) prebound to protein-A 
sepharose beads (Pierce).  Equal amounts per sample of p24 (Retro-Tek HIV-1 p24 
Antigen ELISA Kit; ZeptoMetrix; Buffalo, NY) or total protein were loaded, the proteins 
were separated by size by SDS-PAGE (4-15%), and then the gel dried (72°C for 45 min) 
and visualized by autoradiography (Bio-Max MR film; Amersham; Piscataway, NJ).  To 
quantitatively compare the amount of protein that was visualized as bands on the film, 
we used ImageJ to measure the band area and intensity and compared the product of 
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the two values (we assumed the amphotropic and HPIV3 envelope proteins were 
labeled to a similar extent since the fraction of their residues that are cysteines or 
methionines are about the same (20 residues out of 548 in F, 25 residues out of 572 in 
HN, and 33 residues out of 654 in amphotropic env)).  We also compared the amount of 
radioactivity that was in the bands.  We cut out the bands from the gels as slices, 
brought their volume to 3 mL with Ecoscint A scintillation cocktail (National Diagnostics), 
and used a scintillation counter (Tricarb 2900TR; Perkin Elmer) to quantify the amount of 
35S in the samples. 
Immunoblotting.  To detect p24 in virus samples, equal amounts of protein from 
each sample were combined 1:2 (v/v) with sample buffer containing 5% β-
mercaptoethanol (both from Bio-Rad; Hercules, CA), vortexed, boiled for 5 min, 
separated by size by SDS-PAGE (4-20% Tris-HCl gel, Bio-Rad), and transferred to a 
PVDF membrane (0.2 μm, Bio-Rad).  To probe for p24 in the membrane, mouse anti-
p24 (24-3) was diluted 1:5000 in blocking buffer (5% nonfat milk in PBS with 0.1% 
Tween 20) and bound IgG was detected by incubation with HRP-conjugated donkey 
anti-mouse (diluted 1:100,000 in blocking buffer), and detected with a chemiluminescent 
detection system (Super Signal West Femto kit; Pierce). 
Cell-based ELISA.  We used cell-based ELISAs to quantitatively compare the 
amount of F and HN expressed on the surfaces of the HeLa cells.  We plated 20,000 
HeLa cells per well and transfected them with Polyfect (Qiagen; Valencia, CA) and either 
0.2 μg of pCAGGS-hPIV3-HN alone, 0.2 μg of pCAGGS-hPIV3-HN and 0.2 μg 
pCAGGS-hPIV3-F, 0.2 μg codon optimized HN (pCAGGS-CO-HPIV3-HN) alone, 0.2 μg 
pCAGGS-CO-HPIV3-HN and 0.2 μg pCAGGS-hPIV3-F, or infected them with wild-type 
HPIV3 at an MOI of 1.  The next day the cells were washed once with PBS (100 
μL/well), fixed for 10 min with 4% paraformaldehye (100 μL/well), and blocked for 15 min 
with PBS/sera (100 μL/well).  Next, the cells were incubated with anti-F (215) or anti-HN 
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(66/4) antibodies (diluted 1:800 in PBS/sera, 100 μL per well) for 1 h at room 
temperature. Cells were then washed four times with PBS (100 μL/well) and incubated 
with HRP-conjugated donkey anti-mouse secondary antibody (diluted 1:500 in 
PBS/sera) for 1 h at room temperature.  Following four additional washes with PBS the 
wells were developed for 10 min with OPD solution (100 μL/well) (10 mg OPD, 10μL 
H2O2 in 25 mL of substrate buffer (24 mM citric acid·monohydrate, 51 mM 
Na2HPO4·7H2O, pH 5.0)).  The reaction was stopped with 8 N sulfuric acid (50 μL/well), 
the optical density at 490 nm (OD490) was measured using an absorbance plate reader 
(Versamax; Molecular Devices; Sunnyvale, CA), and the nonspecific background at 650 
nm (OD650) was subtracted. Values for each point are the average of at least triplicate 
wells. 
Flow cytometry.  To quantitatively measure F and HN surface expression on 
293T cells, approximately 2x106 cells were seeded on poly-L-lysine coated 6-well plates 
and transfected with Lipofectamine 2000 using 1 μg of each plasmid (F only, HN only, or 
HPIV3/LV which included plasmids for HN, F, Gag-Pol, and lacZ) or infected with wild-
type HPIV3 at an MOI of 1.  The next day, cells were washed with PBS, released with 
versene (PBS, 5 mM EDTA), and incubated with a 1:500 dilution of anti-F (c110) or anti-
HN (guinea pig antisera) in DMEM at 4°C for 1 hour.  Next, the cells were washed three 
times with DMEM and once with PBS and then incubated with donkey anti-mouse or 
guinea pig Cy2-conjugated secondary antibody diluted 1:500 in PBS at 4°C for 1 hour 
and then the cells were washed as before in PBS and resuspended in 500 μL of 
PBS/10% FBS.  An average of 50,000 cells were counted per sample with the LSR II 
flow cytometer (Becton Dickinson) and the data analyzed with a FACS DiVa (BD 
Biosciences; Palo Alto, CA). 
RNA isolation and quantitative real-time PCR.  Total, cytoplasmic, and nuclear 
RNA was extracted from cells using an RNeasy Mini Kit and Qiashredder (Qiagen) and 
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the concentration of nucleic acid in the samples was determined by measuring their 
absorbance at 260 nm.  We transfected 293T/17 cells (2x106) with 4 μg HPIV3-HN, 1 μg 
each of HPIV3-F, HN, β-galactosidase, and Gag-Pol, or infected them with wild-type 
HPIV3 at an MOI of 1.  Two days later, total RNA or cytoplasmic and nuclear RNA 
fractions were isolated from cell lysates and 1 μg of RNA was reverse transcribed using 
OligoDT primers with the Superscript First-Strand Synthesis for RT-PCR kit (Invitrogen).  
The resulting DNA (1 μL) was then amplified by polymerase chain reaction (PCR) using 
Platinum Pfx DNA polymerase and reagents (Invitrogen) and HN or F-specific primers, 
after which the amplicons were separated by size by agarose gel electrophresis on a 1% 
agarose gel.  The sequences of the HN primers were PCR-HN-Forward (5’ 
TACCAATCACGGGAAAGATGC 3’) and PCR-HN-Reverse (5’ 
TGGAATCTCTGTTTTGAACAACATAGG 3’).  The sequences of the F primers were 
PCR-F-Forward (5’ TGCTAATTATTACAACCATGATTATGGC 3’) and PCR-F-Reverse  
(5’ ACATATGGTTTATCATTTTGATCCACTCG 3’).  For quantitative real-time PCR, 1 µl 
of each cDNA reaction was analyzed in triplicate for the amplification of HPIV3-HN and 
GAPDH.  Amplification conditions were performed with an ABI Prism sequence detection 
system in the presence of SYBR green (ABI) and relative standard curve analysis was 
performed on the samples as outlined in ABI user bulletin 2 (Relative quantitation of 
gene expression: ABI PRISM 7700 sequence detection system: user bulletin 2: Rev B).  
The pairs of primers we used were qPCR-HN-forward (5’ 
CAAAAATAAGGTTAATGCCGGG 3’) and qPCR-HN-reverse (5’ 
AGGACGGAGTTCTAACACAGCC 3’), or the intron-spanning qPCR-GAPDH-forward (5’ 
TGAAGGTCGGAGTCAACGG 3’) and q-PCR-GAPDH-reverse (5’ 
AGAGTTAAAAGCAGCCCTGGTG 3’).   
Transduction.  Target cells were seeded in poly-L-lysine coated 12-well plates 
(1x105 cells per well) and incubated at 37°C. The next day, viral supernatant dilutions 
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were incubated with cells for 48 h, after which the cells were fixed and stained for β-
galactosidase activity with X-Gal, and the number of lacZ+ colony-forming units (CFU) 
per milliliter was counted.  To examine the ability of the viruses to transduce polarized 
cells, MDCK cells were seeded on tissue culture treated Transwell polyester supports (4 
x 104 cells per insert) (Costar-Corning; Corning, NY) and then incubated at 37°C until 
polarized as evidenced by a step jump in their transepithelial resistance (>600 Ω*cm2) as 
measured with a voltohmmeter (World Precision Instruments; Sarasota, FL).  
Supernatants of viruses that encoded green fluorescent protein (GFP) (100 μL) were 
mixed with 8 μg/mL of Polybrene and then applied to the apical or basolateral surfaces 
of the polarized cells for 2 h.  The cells were washed twice with DMEM, cultured for two 
days, and then analyzed by flow cytometry for GFP expression.  As a control, cells were 
incubated with EDTA (6mM) in Hepes (10 mM) for 30 min to depolarize them, and then 
transduced with viral supernatants to determine the effect of depolarization on infection.  
To measure the titer of wild-type HPIV3, a standard plaque assay was performed.  
Briefly, serial dilutions of the viruses were prepared and incubated on confluent 
monolayers of cells for 1 h at 37°C.  The cells were then overlaid with a solution of 1% 
agar (Fisher Scientific; Fairlawn, NJ) in DMEM supplemented with 4% FBS.  The cells 
were incubated at 37°C for 3 days, and then stained with 1 mL of 0.05% neutral red 
(Fisher) in PBS for 1 hour and washed twice in PBS, after which the number of visible 
plaque-forming units (PFU) per milliliter were counted.   
Statistics.  Data are summarized as the mean ± the standard deviation for at 
least triplicate samples.  Statistical analysis was performed using one-way analysis of 
variance for repeated measurements of the same variable.  The Tukey multiple 
comparison test was used to conduct pairwise comparisons between means.  
Differences at p < 0.05 were considered statistically significant. 
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3.4  Results 
 
We have previously shown that lentiviruses form low titer pseudotypes with 
HPIV3-F and HPIV3-HN [23].  We reasoned that titers were low because the virus 
producer cells released too few particles, cellular expression of the HPIV3 envelope 
proteins (HN and F) was low, or too few HPIV3 envelope proteins were incorporated by 
the lentiviruses.  To determine if fewer particles were released by HPIV3-lentivirus 
producer cells, we compared the amount of virus capsid protein present in high titer 
stocks of amphotropic lentivirus to the amount present in stocks of HPIV3 pseudotyped 
lentivirus.  We transfected 1x107 293T/17 cells in a 10cm dish with plasmids encoding 
for β-galactosidase, lentiviral Gag-Pol, and either HPIV3-F and HPIV3-HN, or the MuLV 
amphotropic envelope (Env) protein.  Two days later the virus-laden supernatants were 
harvested, filter sterilized, pelleted by ultracentrifugation through a 20% sucrose cushion, 
and then analyzed by Western blot for the presence of lentiviral p24 (Figure 3.1).  Similar 
amounts of p24 were detected in both amphotropic pseudotyped lentiviruses and HPIV3 
pseudotyped lentiviruses, which suggests that insufficient release of the particles from 
the virus producer cells is not the cause for the low titer of HPIV3 pseudotyped 
lentiviruses. 
We also wondered if titers could be low because the HPIV3-lentivirus particles 
decayed at a faster rate than amphotropic lentivirus particles.  We produced HPIV3 or 
amphotropic pseudotyped lentivirus as above, harvested, filter sterilized, and then 
incubated the viral supernatant for 0, 8, 19, or 27 hours at 370C before transducing cells 
in a diluted titer assay (Figure 3.2).  HPIV3-lentivirus particles decay at a similar rate to 
amphotropic-lentivirus particles (t1/2 = 15.7 ± 1.6 hours compared to t1/2 = 15.2 ± 1.0 
hours, respectively). 
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Figure 3.1.  HPIV3-pseudotyped lentiviral stocks contain similar numbers of virus 
particles as amphotropic Env-pseudotyped lentiviral stocks.  293T/17 cells (1x107) were 
transfected with 6 μg each of plasmids encoding β-galactosidase, lentiviral Gag-Pol, and 
either HPIV3-F and HPIV3-HN, or MuLV amphotropic envelope (Env) protein.  
Supernatants containing amphotropic lentiviruses (Lane 2) or HPIV3-pseudotyped 
lentiviruses (Lane 3) were concentrated 18-fold by ultracentrifugation through a 20% 
sucrose cushion.  The pellet was analyzed by Western blot using p24 mouse ascites 
monoclonal antibody (#24-3) and HRP-conjugated anti-mouse secondary antibody.  The 
data is representative of three separate experiments.  
  
 
 
 
 
Figure 3.2.  HPIV3-pseudotyped lentiviral stocks decay at a similar rate to amphotropic 
Env-pseudotyped lentiviral stocks.  293T/17 cells (1x107) were transfected with 6 μg 
each of plasmids encoding β-galactosidase, lentiviral Gag-Pol, and either HPIV3-F and 
HPIV3-HN, or MuLV amphotropic envelope (Env) protein.  Supernatants containing 
amphotropic lentiviruses (A) or HPIV3-pseudotyped lentiviruses (B) were decayed for 0, 
8, 19, or 27 hours at 370C and used to transduce cells.  Transduced cells were 
incubated for 2 days at 37 0C until confluent, fixed and stained for lacZ activity with X-
gal, colonies of lacZ+ cells counted, and the titer (CFU/mL) calculated. 
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Next, we examined the possibility that titers were low due to inadequate 
expression of F and HN in producer cells.  First we compared HPIV3 F and HN 
expression levels in cells transfected to produce HPIV3 pseudotyped lentivirus to 
expression levels in cells infected with wild-type HPIV3.  We plated HeLa cells in a 96-
well dish and the following day, transfected cells with plasmids for either F or HN, both F  
and HN, or infected cells with wild-type HPIV3 at an MOI of 1.  Two days later, we used 
a cell-based ELISA to quantify the expression levels of F and HN.  Cells were 
immunostained with a mouse monoclonal antibody against HPIV3-F (215) or HN (66/4), 
and a HRP-conjugated secondary antibody, after which the cells were developed with a 
solution of o-phenylenediamine dihydrochloride (OPD) and the optical density of each 
well measured (Figure 3.3).  Expression of F in transfected cells was 1.6-fold lower than 
in wild-type infected cells when the cells were transfected to express F only, and slightly 
higher – 1.3-fold lower than in wild-type infected cells – when the cells were co-
transfected to express both F and HN.  HN expression in transfected cells was 3.8-fold 
lower than in wild-type infected cells, whether or not the cells expressed HN only or both 
HN and F.  We also used flow cytometry to compare F and HN expression in transfected 
and infected cells.  Cells were plated in a 6-well dish, transfected or infected as 
described above, immunostained with a mouse monoclonal antibody against HPIV3-F 
(c110) or a guinea pig polyclonal antibody against HN, and then the percentage of cells 
that expressed the envelope proteins quantified (Table 3.1).  The percentage of 
transfected cells that expressed F and HN was 1.4 and 1.7-fold lower, respectively, than 
that of wild-type infected cells.  These results show that the expression of F to some 
extent, and HN to a greater extent, is lower in virus producer cells than in cells infected 
with wild-type HPIV3.   
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Figure 3.3.  The expression levels of cell-surface HPIV3-F and HN is lower in 
transfected cells than in cells infected with wild-type HPIV3.  Hela cells (20,000) were 
transfected with expression plasmids for HPIV3-F (0.2 μg) and/or HPIV3-HN (0.2 μg), or 
infected with wild-type (WT) HPIV3 at an MOI of 1.  Two days later, cells were washed, 
fixed (2% paraformaldehyde), blocked (PBS/sera), and then sequentially stained with 
mouse monoclonal specific for HPIV3-F (215) or HN (66/4) and an HRP-conjugated anti-
mouse secondary antibody.  Stained cells were developed with a solution of OPD, the 
optical density at 490 nm was measured using an absorbance plate reader, and the 
nonspecific background at 650nm was subtracted.  Values for each point are the 
average of at least triplicate wells.  Statistically significant differences (p<0.05) from the 
expression levels of F and HN in cells infected with wild-type HPIV3 are denoted with Δ 
and *, respectively. 
  
 
 
 
Table 3.1.  The percentage of cells that express HPIV3-F and HN in transfected and 
wild-type infected cells. 
   
Treatment HPIV3-F (%)a,b HPIV3-HN (%)a,c 
   
   
Untreated 0.37 ± 0.15 0.50 ± 0.21 
Transfected with F 61 ± 11 N/A 
Transfected with HN N/A 51 ± 15 
Transfected with F, HN, Gag-Pol, 
LacZ 
67 ± 10 30 ± 1.5 
Infected with wild-type HPIV3 88 ± 13 85 ± 11 
   
Flow cytometric analysis was used to determine the percentage of 293T cells that 
expressed HPIV3 F or HN when transfected with expression plasmids for F alone, HN 
alone, F, HN, Gag-Pol, and LacZ, or infected with wild-type HPIV3.  aPercentages 
represent the mean of experimental values +/- one standard deviation.  bHPIV3-F (%); 
percentage of cells expressing HPIV3-F.  cHPIV3-HN (%); percentage of cells 
expressing HPIV3-HN.  N/A=not applicable. 
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Since HN expression was the most limiting, we decided to examine more closely 
the causes for its low level of expression in transfected cells.  First we wondered if HN 
mRNA was inappropriately spliced in transfected cells due to the presence of cryptic 
splice sites within its sequence.  We considered this a possibility since transfection of 
virus producer cells with an expression plasmid for HN alters the lifecycle of the HN 
mRNA from one that has evolved to operate entirely within the cytoplasm in infected 
cells to one in which it is formed and processed within the nucleus in transfected cells.    
To test for this possibility, total RNA was isolated from 293T/17 cells that had been 
transfected with the HPIV3-HN expression vector or from cells infected with wild-type 
HPIV3, reverse-transcribed, amplified by PCR using primers that span the entire HN 
sequence, and then the amplicons separated by size by gel electrophoresis (Figure 
3.4A).  The molecular weights of the amplicons were the same which indicated that the 
HN mRNA had not been aberrantly spliced.  Similarly, Figure 3.4A also shows F is not 
aberrantly spliced. 
We also assessed whether HN mRNA in transfected cells was efficiently 
exported from the nucleus.  Cytoplasmic and nuclear RNA were isolated from 
fractionated cells, reverse transcribed, and then amplified by real-time PCR (Figure 
3.4B).  No significant differences (p<0.05) in HN mRNA levels were detected, regardless 
of whether the cells were infected with wild-type HPIV3, transfected with only the 
expression plasmid for HN, or multiply transfected to express HN, Gag-Pol, and the 
lentiviral transgene β-galactosidase.  A small amount of HN RNA was detected in the 
nuclear fraction of wild-type HPIV3 infected cells due to limitations with the experimental 
procedure which did not completely prevent contamination of the nuclear fraction with 
cytoplasmic mRNA.  These results suggest that HN mRNA is efficiently exported from 
the nucleus to the cytoplasm in transfected cells.   
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Figure 3.4.  HN and F RNA is not aberrantly spliced and HN is efficiently exported from 
the nucleus to the cytoplasm.  (A)  293T/17 cells (2x106) were transfected with an 
expression plasmid for HPIV3-HN (4 μg) (lanes 1 and 4), HPIV3-F (4 μg) (lanes 10 and 
13), or infected with wild-type HPIV3 at an MOI of 1 (lanes 3, 6, 12, 15).  Two days later, 
total RNA was isolated from lysates of the cells and 1 μg was reverse-transcribed using 
OligodT primers.  The resulting DNA was then amplified by polymerase chain reaction 
(PCR) using HN-specific primers (Lanes 1-7) or F-specific primers (Lanes 9-15), after 
which the amplicons were separated by size by agarose gel electrophresis on a 1% 
agarose gel.  The positive control was the HPIV3-HN or F plasmid DNA that was used to 
transfect the cells (Lane 7 for HN and 9 for F), and the negative controls were samples 
from untreated cells (lanes 2 and 5 for HN and lanes 11 and 14 for F) and samples that 
were PCR-amplified without first being reverse transcribed (lanes 4-6, 13-15).  (B)  
293T/17 cells (2x106) were transfected with 1 μg of an expression plasmid for HPIV3-HN 
(HN), 1 μg each of expression plasmids for HPIV3-F, HPIV3-HN, β-galactosidase, and 
lentiviral Gag-Pol (LV), or infected with wild-type HPIV3 (WT) at an MOI of 1.  Two days 
later, RNA from the cytoplasmic and nuclear fractions were isolated using the RNeasy kit 
per the manufacturer’s instructions.  Portions (1 μg) of the cytoplasmic and nuclear RNA 
fractions were reverse-transcribed using OligodT primers and then quantified by real-
time PCR using HN-specific or GAPDH-specific primers.  Bars show the mean level ± 
standard deviation of HN RNA normalized to GAPDH control from triplicates of three 
experiments. 
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Since our data suggested that HN expression was not low due to aberrant mRNA 
splicing or export to the cytoplasm, we next considered the possibility that translation 
was impaired due to suboptimal codon usage or the presence of mRNA structures or 
negative regulatory sequences that inhibit translation.  We codon optimized the HN 
sequence to improve codon usage and to eliminate any inhibitory structures or 
sequences that might have been present, and then constructed an expression plasmid 
for the codon-optimized HN.  To examine the effect of codon-optimization on HN 
expression, we transfected HeLa cells with the just the expression plasmid for the 
codon-optimized HPIV3-HN, or we co-transfected the cells with expression plasmids for 
both the codon optimized HN and wild-type F.  In parallel, cells were transfected with an 
expression plasmid for wild-type HN, or co-transfected with expression plasmids for both 
wild-type HN and F.  Two days later, we quantified the expression levels of HN and F by 
cell-based ELISA.  We found that HN expression was more than two-fold higher when 
codon-optimized HN was used to transfect cells, but, interestingly, these increases were 
only observed in cells that were co-transfected with codon-optimized HN and wild-type F 
(Figure 3.5A).  Cells that were singly transfected with codon-optimized HN did not 
express significantly higher levels of cell-surface HN than cells transfected with wild-type 
HPIV3-HN or co-transfected with wild-type HPIV3 HN and F.  Surprisingly, F expression, 
which also increases in the presence of HN (1.6-fold), more than doubled (2.1-fold) in 
the presence of codon-optimized HN (Figure 3.5B).  
To determine if codon optimization increased envelope incorporation into 
lentiviral particles, we transfected 293T/17 cells with expression plasmids that encoded 
HPIV3-F, lentiviral Gag-Pol, the lentiviral vector encoding the β-galactosidase transgene, 
and codon optimized or non-codon optimized HPIV3-HN.  The next day we metabolically 
labeled the cells with [35S] methionine-cysteine protein labeling mix for 16 hours, 
immunoprecipitated HPIV3-HN from lysates of the cells and from the virus supernatant  
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Figure 3.5.  Cells transfected with codon-optimized HPIV3-HN express higher levels of 
HPIV3 envelope proteins.  (A)  Hela cells (20,000) were singly transfected (0.2 μg each) 
with an expression plasmid for wild-type HPIV3-HN (HN) or codon optimized HPIV3-HN 
(CO), or doubly transfected with wild-type HPIV3-F and wild-type HPIV3-HN (HN+F) or 
codon-optimized HPIV3-HN (CO+F), or infected with wild-type (WT) HPIV3 virus at an 
MOI of 1.  (B)  Hela cells (20,000) were singly transfected (0.2 μg each) with an 
expression plasmid for wild-type HPIV3-F (F) or doubly transfected with wild-type 
HPIV3-F and wild-type HPIV3-HN (F+HN) or codon-optimized HPIV3-HN (F+CO), or 
infected with wild-type (WT) HPIV3 virus at an MOI of 1.  Two days later, the cells were 
washed, fixed (2% paraformaldehyde), blocked (PBS/sera), and sequentially 
immunostained with a mouse monoclonal antibody against (A) HPIV3-HN (66/4) or (B) 
HPIV3-F (215), and an HRP-conjugated anti-mouse secondary antibody.  The stained 
cells were developed with a solution of OPD, the optical density at 490 nm was 
measured using an absorbance plate reader, and the nonspecific background at 650nm 
was subtracted.  Values for each point are the mean of at least triplicate wells.  
Statistically significant differences (p<0.05) from cells singly transfected with an 
expression plasmid for wild-type HN or F are denoted with an asterisk. 
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that had been previously concentrated 10-fold, separated the immunoprecipitated 
proteins by gel electrophoresis, dried the gel, and visualized the labeled proteins by 
autoradiography (Figure 3.6A).  We found that codon optimization increased the amount 
of HN incorporated into lentiviral particles, as well as increased expression in producer 
cells.  To quantify the amount of HN in each sample, we excised the bands that 
contained HN from the gel and measured their radioactivity with a scintillation counter.  
We found that lentivirus particles produced using codon optimized HN contained 2.2-fold 
more HN than particles produced with the original expression plasmid, and virus 
producer cells transfected with codon optimized HN expressed 1.7-fold more HN than 
cells transfected with the original expression plasmid. 
We next determined whether codon optimization of HPIV3-HN increased titers of 
pseudotyped lentiviruses.  Titers of the viruses made with the codon optimized HN were 
1.2 to 6.4-fold higher than those made with the original HN, but were still more than 100-
fold lower than lentiviruses pseudotyped with the amphotropic envelope protein (Table 
3.2).  These findings prompted us to determine if the HPIV3-pseudotyped lentiviruses 
contained fewer envelope proteins per virus particle than the amphotropic-pseudotyped 
viruses.  We transfected 293T/17 cells with plasmids encoding β-galactosidase, Gag-
Pol, and the amphotropic envelope protein only, HPIV3-F only, codon optimized HPIV3-
HN only, HPIV3-F and codon optimized HPIV3-HN, or no envelope protein.  Next, we 
metabolically labeled the cells for 16 hours, concentrated the supernatant by 
ultracentrifugation through a 20% sucrose cushion, separated the proteins by size using 
SDS-PAGE, and then visualized the gel by autoradiography.  Using image analysis 
software (ImageJ), we found that amphotropic-pseudotyped lentiviruses contained 14- 
fold more envelope proteins (Figure 3.6B, lane 3) than lentiviruses pseudotyped with 
HPIV3 F and codon-optimized HN (Figure 3.6B, lane 6) even though ample amounts of  
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Table 3.2.  Lentivirus titers. 
     
Target 
Cells 
HN+F LV 
 (cfu/mL)a 
CO-HN+F LV 
 (cfu/mL)a 
Ampho LV  
(cfu/mL)a 
WT HPIV3 
(pfu/mL)b 
     
293T 3.5 (± 0.43) x 102 2.3 (± 0.12) x 103 2.4 (± 0.29) x 105 2.9 (± 0.21) x 105 
Hela 1.1 (± 0.14) x 102 2.0 (± 0.10) x 102 8.2 (± 0.87) x 103 3.5 (± 0.29) x 105 
MDCK 9.3 (± 0.15) x 101 4.3 (± 1.2) x 102 5.4 (± 1.0) x 104 2.6 (± .05) x 104 
Vero 5.2 (± 0.03) x 101 3.3 (± 0.87) x 102 6.5 (± 1.1) x 102 1.2 (± 0.10) x 106 
A549 2.0 (± 0.15) x 102 1.9 (± 0.50) x 103 7.0 (± 1.7) x 103 4.8 (± 0.35) x 105 
3T3 4.6 (± 1.1) x 100 5.3 (± 1.2) x 100 2.5 (± 0.09) x 105 8.5 (± 0.29) x 102 
     
Lentiviruses pseudotyped with wild-type HN and F (HN+F LV), codon optimized HN and 
wild-type F (CO-HN+F LV), or amphotropic Env (Ampho LV), and wild-type HPIV3 (WT 
HPIV3) were used to transduce target cells.  Titer of alentiviral pseudotypes (cfu/mL) and 
bwild-type HPIV3 (pfu/mL) represent the mean of experimental values +/- one standard 
deviation.   
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Figure 3.6.  The number of envelope proteins incorporated by HPIV3/LV is higher when 
they are generated by virus producer cells transfected with codon-optimized HN than 
when they are generated by virus producer cells transfected with non codon-optimized 
HN, but several-fold lower than in amphotropic lentiviruses.  293T/17 cells (1x107) were 
transfected with expression plasmids (6 μg each) for β-galactosidase, HIV-1 Gag-Pol, 
and (A) HPIV3-F, and either HPIV3-HN (lanes 1 and 3) or codon-optimized HPIV3-HN 
(lanes 2 and 4), or (B) the amphotropic envelope protein only (lanes 3 and 8), HPIV3-F 
only (lane 4), codon-optimized HPIV3-HN only (lane 5), or both HPIV3-F and codon-
optimized HPIV3-HN (lanes 6, 9, 10), or no envelope protein as a negative control (lanes 
2 and 7).  The next day, the cells were serum-starved for 15 minutes, metabolically-
labeled with 450 μCi [35S] methionine and cysteine for 12-16 hours, after which the cells 
were lysed and the culture medium supernatants collected, ultracentrifuged through a 
20% sucrose cushion, and then resuspended in PBS to (A) 10-fold or (B) 100-fold their 
original concentration.  (A) The cell culture supernatants (lanes 1 and 2) and cell lysates 
(lanes 3 and 4) were immunoprecipitated with a guinea pig polyclonal antibody against 
HPIV3-HN.  (B) The cell lysates were immunoprecipitated with anti-gp70 (83A25; lane 
8), anti-HPIV3-F (c110; lane 9), or anti-HPIV3-HN (66/4; lane 10) monoclonal antibodies.  
The amount of virus in the cell culture supernatants (lanes 2-6) was quantified by an 
ELISA for p24 and used to ensure equal loading of the samples.  All of the samples were 
resuspended in lysis buffer, separated by size by SDS-PAGE, and then the gel dried and 
visualized by autoradiography. 
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HN and F were expressed (Figure 3.6B, lanes 9 and 10).  These results suggest that 
lentiviruses inefficiently incorporate HN and F envelope proteins. 
 Finally, we wanted to determine if lentiviruses produced using the expression 
plasmid for codon optimized HN infected polarized epithelial cells more efficiently than 
lentiviruses produced using the expression plasmid for wild-type HN.  MDCK cells were 
plated in tissue culture-treated Transwell polyester supports and transduced them from 
the apical or basolateral surface with lentiviruses that were pseudotyped with HPIV3-F 
and HPIV3-HN or HPIV3-CO-HN, or with the amphotropic envelope protein as a control.  
Two days later we used flow cytometry for GFP expression to quantify the number of 
transduced cells (Figure 3.7).  We found that lentiviruses produced by cells transfected 
with codon optimized HN transduced 1.4-fold more polarized MDCK cells than 
lentiviruses produced by cells transfected with wild-type HN.  Codon optimized HN-
containing pseudotyped lentivirus also transduced 1.9-fold more cells than amphotropic 
pseudotyped lentivirus, even though their titer on dividing non-polarized MDCK cells was 
100-fold lower.  This is consistent with previous observations that amphotropic 
pseudotyped lentiviruses preferentially transduce polarized cells via their basolateral 
surface [29], whereas HPIV3 preferentially transduces polarized cells via their apical 
surfaces [30].  We also examined the effect of depolarization of the cells on transduction 
by incubating the cells with medium that contained EDTA.  Consistent with other studies, 
we found that amphotropic lentivirus transduction increased 3-fold when the cells were 
depolarized [29, 31].    
Interestingly, depolarization of the cells reduced HPIV3-lentivirus transduction by 
1.3-fold.  Perhaps this is because the cellular receptors for HPIV3, which are 
predominantly expressed in the apical membrane of polarized MDCK cells [32], 
redistribute throughout the entire plasma membrane when the cells are depolarized,  
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Figure 3.7.  HPIV3 pseudotyped lentiviruses produced by cells transfected with codon-
optimized HN transduce polarized MDCK cells more efficiently than amphotropic 
lentiviruses or HPIV3 pseudotyped lentiviruses produced by cells transfected with non 
codon-optimized HN.  eGFP encoding lentiviruses (100 μL) pseudotyped with the 
amphotropic Env, HPIV3 F + codon-optimized HPIV3 HN, or HPIV3 F + non-codon-
optimized HPIV3 HN were brought to 8 μg/mL Polybrene and applied to the apical (white 
bars) or basolateral (black bars) surfaces of polarized MDCK cells.  As a control, cells 
were depolarized with 6 mM EDTA in HEPES (10 mM) for 30 min prior to and during 
apical transduction (grey bars).  Two hours later, the cells were washed with medium to 
remove any unbound viruses, and cultured for 2 days at 370C, after which flow cytometry 
was used to determine the number of cells that expressed eGFP.  Values are from three 
different experiments.  Statistically significant differences (p<0.05) in transduction 
efficiencies when the cells were transduced 1) via their apical and basolateral surfaces, 
2) with viruses pseudotyped with non codon-optimized or codon-optimized HN, and 3) 
with viruses pseudotyped with the amphotropic Env or with codon optimized HN are 
denoted with *, Δ, and † respectively.   
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Table 3.3.  Number of polarized HBE cells transduced by virus. 
    
Virus Apical Basolateral Apical + EDTA 
    
None 117 1121 107 
Ampho/LV 142 3847 1055 
CO-HPIV3/LV 161 4393 174 
HPIV3/LV 107 1753 174 
    
Flow cytometric analysis was used to determine the number of polarized HBE cells that 
were transduced with pseudotyped lentiviruses.  eGFP encoding lentiviruses (100 μL) 
pseudotyped with the amphotropic Env, HPIV3 F + codon-optimized HPIV3 HN, or 
HPIV3 F + non-codon-optimized HPIV3 HN were brought to 8 μg/mL Polybrene and 
applied to the apical or basolateral surfaces of polarized HBE cells.  As a control, cells 
were depolarized with 6 mM EDTA in HEPES (10 mM) for 30 min prior to and during 
apical transduction.  Four hours later, the cells were washed with medium to remove any 
unbound viruses, and cultured for 2 days at 370C, after which flow cytometry was used 
to determine the number of cells that expressed eGFP.  Values are a representative of 
three different experiments.       
 
 
 
reducing the concentration of receptors that are available for HPIV3-lentivirus 
transduction. 
 We also wanted to determine if lentiviruses produced using the expression 
plasmid for codon optimized HN infected polarized lung cells more efficiently than 
lentiviruses produced using the expression plasmid for wild-type HN.  HBE cells were 
plated in tissue culture-treated Transwell polyester supports and transduced from the 
apical or basolateral surface with lentiviruses that were pseudotyped with HPIV3-F and 
HPIV3-HN or HPIV3-CO-HN, or with the amphotropic envelope protein as a control.  
Two days later we used flow cytometry for GFP expression to quantify the number of 
transduced cells (Table 3.3).  We found that lentiviruses produced by cells transfected 
with codon optimized HN transduced 1.5-fold more polarized HBE cells from the apical 
surface than lentiviruses produced by cells transfected with wild-type HN.  Codon 
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optimized HN-containing pseudotyped lentivirus also transduced 1.1-fold more cells 
apically than amphotropic pseudotyped lentivirus. 
 
3.5  Discussion 
We have previously shown that it is possible to pseudotype lentiviruses with 
HPIV3 envelope proteins and that these viruses are able to transduce polarized cells via 
their apical surfaces, but the titers of these viruses are too low to be useful for clinical 
gene transfer.  We hypothesized that titers were low because the virus producer cells 
released too few particles, cellular expression of the HPIV3 envelope proteins (HN and 
F) was low, or too few HPIV3 envelope proteins were incorporated by the lentiviruses.  
To test this hypothesis, we compared the amount of virus capsid protein in stocks of 
HPIV3 pseudotyped viruses and high titer amphotropic lentiviruses.  We also examined 
the expression levels of HN and F mRNA in the nucleus and cytoplasm of transfected 
virus producer cells, and compared them to expression levels in cells infected with 
replication competent wild-type HPIV3.  Finally, we metabolically labeled cells that were 
producing HPIV3 and amphotropic pseudotyped lentiviruses, and compared the 
numbers of envelope proteins that were incorporated into the two types of viruses. We 
found that stocks of HPIV3 pseudotyped viruses contained similar numbers of viruses as 
stocks of high titer amphotropic lentiviruses.  We also found that transfected virus 
producer cells expressed similar levels of HN and F mRNA as cells infected with wild-
type HPIV3, but fewer cell-surface HN and F proteins (3.8 and 1.3-fold less, 
respectively).  Fortunately, codon-optimization of HPIV3 HN increased expression more 
than 2-fold in cells co-transfected with HPIV3 F and HN.  Most significant, we found that 
even when virus producer cells were transfected with codon-optimized HPIV3 HN, 
HPIV3 pseudotyped lentiviruses incorporated nearly 14-fold fewer envelope proteins 
than amphotropic pseudotyped lentiviruses.  Lysates of the two sets of producer cells 
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contained similar amounts of HPIV3 and amphotropic envelope proteins, which, coupled 
with our mRNA expression data, suggest that the number of envelope proteins in HPIV3-
pseudotyped viruses is low not because these proteins are poorly expressed, but 
because they are not efficiently incorporated by lentivirus particles.   
Our observation that titers increased more than 6-fold when the number of HPIV3 
HN per particle increased about 2-fold is consistent with our conclusion that these 
viruses contain a low number of envelope proteins (Env).  This is because previous work 
has shown that increasing the number of Env per retrovirus raises titers, but only when 
the number of Env per particle is below a relatively small threshold number, above which 
further increases do not improve titers [33-37].  This suggests that the number of Env 
per HPIV3 pseudotyped virus is below the threshold number, and that titers can be 
significantly improved with further increases in the number of HPIV3 Env per particle. 
One straightforward strategy to increase the number of Env per particle is to 
enhance their expression in virus producer cells.  In this study, we increased HPIV3 HN 
expression by codon-optimizing its sequence.  Interestingly, codon-optimization 
increased HPIV3 HN expression only in cells that also expressed HPIV3 F.  Also, the 
cell-surface expression of HPIV3 F was higher in cells that co-expressed codon-
optimized HPIV3 HN than in cells that co-expressed wild-type HPIV3 HN.  These 
observations suggest that HPIV3 F and HN may interact within the cell such that an 
increase in the expression level of one may promote higher levels of cell-surface 
expression of the other.  Previous work supports the possibility that HPIV F and HN 
interact intracellularly.  For example, Hu et al showed that the HPIV type 2 and 3 F 
proteins do not cause fusion unless they are co-expressed with HN from the same type 
of human parainfluenza virus [38].  Furthermore, Tong et al found that mutant forms of 
HPIV F proteins, engineered to contain a C-terminal signal for retention in the 
endoplasmic reticulum, inhibited cell fusion by blocking the transport of HPIV2 HN to the 
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cell surface (when HPIV2 F-KDEL was used) or by reducing its steady-state intracellular 
expression (when HPIV3 F-KDEL was used) [39].   
These studies suggest that HPIV3 F and HN interact intracellularly, but we can 
only speculate how, in virus producer cells, an increase in the expression of one of these 
proteins would result in an increase in the cell-surface expression of the other.  Perhaps 
F and HN influence each other’s intracellular trafficking dynamics such that, when the 
expression of either protein is increased, a higher proportion of the proteins are part of a 
heterodimer of the two proteins, which may increase the likelihood that they will localize 
to, or be retained at, the cell surface.  Previous work with other proteins has shown that 
protein-protein interactions and heterodimerization can significantly affect their 
subcellular trafficking and localization.  For example, the feline herpesvirus glycoprotein 
E must form a heterodimer with glycoprotein I to be efficiently transported out of the 
endoplasmic reticulum (ER) [40].  Similarly, the alphavirus E1 protein must form a 
complex with p62, the precursor of the E2 protein, to efficiently translocate from the ER 
[41].  Sandrin et al showed murine leukemia virus core proteins interact with envelope 
glycoproteins, causing them to relocalize to late endosomes [42].  Protein-protein 
interactions appear to significantly alter the trafficking and subcellular localization of non-
viral proteins as well.  For example, certain G-protein coupled receptors (GPCR) require 
heterodimerization for proper surface expression, and their trafficking and internalization 
is sometimes dramatically altered when they associate with other GPCR subtypes [43, 
44].  We do not know if processes similar to these affect HPIV3 F and HN trafficking.  
Additional work is needed to characterize the intracellular trafficking itineraries of HPIV3 
F and HN in virus producer cells, and to determine to what extent they interact with each 
other, and how these interactions affect their subcellular localization and incorporation 
into virus particles.   
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We found that codon-optimized HPIV3 HN is expressed in virus producer cells to 
similar levels as wild-type HPIV3 HN is expressed in cells infected by replication 
competent HPIV3.  Nevertheless, HPIV3 pseudotyped viruses contain about 14-fold 
fewer Env than high-titer amphotropic pseudotyped viruses.  This suggests that the 
major factor limiting the titer of HPIV3 pseudotyped viruses is not the expression levels 
of the HPIV3 Env, but the low efficiency with which they are incorporated by lentiviruses.  
Recent work has shown that whether or not a protein is incorporated into a lentivirus 
particle is primarily dictated by whether or not the protein is colocalized with the virus 
when it buds from the cell [42, 45, 46].  Most proteins that are incorporated by 
lentiviruses are incorporated through a passive process in which they fortuitously 
localize to the same site within the cell that lentiviruses bud from [47-49].  We do not 
know if HPIV3 Env colocalize with budding lentiviruses, but previous work suggests that 
HPIV3 Env and lentiviruses do not share a common intracellular trafficking pathway.  For 
example, in polarized cells HN and F are preferentially trafficked towards the apical 
surface from which HPIV3 buds [50], whereas lentivirus capsid proteins (i.e., Gag) are 
preferentially directed to the basolateral surface from which lentiviruses bud [51].  In 
nonpolarized cells, recent work suggests that lentiviruses bud from intracellular 
compartments such as multivesicular bodies and recycling endosomes [52-55] while the 
same has not been shown for HPIV3 and other paramyxoviruses.   
Alternatively, some proteins are incorporated into lentiviruses by an active 
process that involves specific interactions between the lentivirus protein capsid proteins 
and the cytoplasmic tails of envelope glycoproteins [45, 56-58].  For example, the HIV-1 
glycoprotein gp41 contains an alpha helical motif that appears to interact with and 
stabilize lattice-like holes in the lipid bilayer that are formed by the oligomerization of 
HIV-1 matrix proteins during virus assembly and budding [59-61].  Interestingly, even 
some viral envelope proteins that are not derived from HIV-1, such as MuLV and RD114, 
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appear to be actively recruited to the sites of lentivirus assembly [45].  These retroviral 
envelope proteins are normally distributed primarily within the ER, but were found to 
relocate to the late endosomes in cells that expressed the lentiviral accessory protein 
Nef.  Given that HPIV3 is a different family of virus than HIV-1, and given that HPIV3 HN 
is a type II protein whereas HIV-1 Env is a type I protein, it is unlikely that HPIV3 Env, 
and HPIV3 HN in particular, contain amino acid motifs that actively interact with lentivirus 
proteins.   
One strategy to significantly increase the titers of HPIV3 pseudotyped viruses 
may be to modify their Env to passively or actively colocalize with budding lentiviruses.  
Some approaches have already been employed to promote the active or passive 
colocalization of other glycoproteins with lentiviral proteins.  For example, Kowolik et al 
showed that appending the cytoplasmic tail of HIV-1 Env to the Sendai virus F protein 
increases it incorporation into lentivirus particles, presumably by inducing the F protein 
to actively interact with lentivirus proteins [62].  Similarly, Kobayashi et al. [17] 
successfully pseudotyped SIV particles with Sendai virus HN and F envelope proteins by 
truncating the cytoplasmic tail of F and by appending the cytoplasmic tail of SIV Env to 
HN.  Unfortunately, the mechanism by which these alterations led to improved 
pseudotype formation was not investigated, although presumably these modifications 
increased the passive incorporation of F and the active incorporation of HN. 
These studies suggest that it may be possible to significantly improve the titers of 
HPIV3 pseudotyed viruses by modifying their cytoplasmic tails to include amino acid 
motifs that cause them to colocalize to sites of lentivirus budding.  It is important to note 
that colocalization is necessary, but not always sufficient, for proteins to be incorporated 
by lentiviruses.  In some cases, proteins appear to be actively excluded from lentivirus 
particles, even though they colocalize with them [47, 48, 63, 64].  Steric hindrance 
between the cytoplasmic tail of these proteins and the capsids of the budding virus 
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particles is one likely mechanism by which proteins are actively excluded from 
lentiviruses [65].  Although we can not rule out the possibility that HPIV3 Env are actively 
excluded from lentiviruses, it seems unlikely that steric hindrance plays a role since both 
HPIV3 HN and F have short cytoplasmic domains (31 and 23 amino acids, respectively 
[66, 67]), and envelope proteins with naturally short cytoplasmic tails such as MuLV Env, 
and envelope proteins from HIV-2 and SIV with long cytoplasmic tails that have been 
truncated, have been shown to be efficiently incorporated into lentiviral particles [68, 69]. 
In conclusion, our results suggest that the titers of HPIV3 pseudotyped 
lentiviruses are low because HPIV3 envelope proteins are not efficiently incorporated by 
lentivirus particles.  Future work should focus on characterizing the intracellular 
trafficking itineraries of HN and F, determining to what extent HN and F interact within 
the cells and thereby influence each others subcellular localization and expression, and 
engineering HN and F to be more efficiently incorporated by lentiviruses by promoting 
their passive or active colocalization at intracellular sites of lentivirus budding.  
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CHAPTER 4 
 
PROTEIN COLOCALIZATION WITH LENTIVIRUS-ASSOCIATED RAFTS ENABLE 
INCORPORATION INTO LENTIVIRAL PARTICLES 
 
  
 
4.1  Abstract 
Lipid rafts have been shown to be important for proper lentivirus assembly and 
budding.  We hypothesized that lipid rafts compartmentalize host cell raft proteins, and 
protein incorporation into the lentiviral lipid bilayer is dependent upon colocalization with 
lentivirus-associated rafts.  To test this hypothesis, we studied the ability of two 
glycosylphosphatidylinositol (GPI) anchored proteins, folate receptor (FR-WT) and Tac-
CD16 (the interleukin-2 receptor alpha chain fused with the cytoplasmic domain of the 
GPI-anchored CD16 protein) to associate with viral proteins, Gag and amphotropic Env, 
in lipid rafts and lentivirus particles.  We examined the distribution of the GPI anchored 
proteins and virus proteins in whole cells, lipid rafts, and viral supernatant.  We found 
that Tac-CD16 and FR-WT exhibited the classic GPI anchored protein property of 
associating with lipid rafts, however Tac-CD16 colocalized with Gag and incorporated 
into lentiviral particles, while FR-WT did not colocalize with Gag and was not 
incorporated into virus particles.  In raft fractions separated by a linear sucrose gradient, 
FR-WT generally colocalized to less dense rafts while Gag and Env were localized to 
more dense rafts.  Tac-CD16 was also located to less dense rafts, but had a wider 
distribution in the linear gradient than FR-WT.  Most significantly, we found that when we 
treated producer cells with fumonisin B1 (FB1) or methyl-beta-cyclodextrin (MβCD), the 
amount of colocalization between FR-WT and Gag increased, FR-WT had a wider 
distribution in the linear raft gradient, and FR-WT was incorporated 2.9 to 11.6-fold more 
into lentiviral particles, respectively.  In contrast, the raft distribution of Tac-CD16 in a 
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linear gradient decreased and the amount of Tac-CD16 in virus particles decreased 2.4-
fold with MβCD treatment.  Taken together, these results demonstrated lipid rafts 
segregate raft proteins, and for a protein to be incorporated into virus particles, it must 
be colocalized with lentivirus-associated rafts. 
 
4.2  Introduction 
Lipid rafts are structured cell membrane subdomains enriched in cholesterol, 
sphingolipids, and glycosphingolipids [1].  Also known as detergent resistant membranes 
or detergent insoluble glycolipid enriched membrane domains, rafts are defined 
biochemically as membrane regions that are insoluble in cold nonionic detergent and are 
often isolated by flotation through a sucrose gradient [2, 3].  Lipid rafts are dynamic and 
enriched with glycosylphosphatidylinositol (GPI) anchored proteins [4], doubly acylated 
proteins [5], and palmitoylated transmembrane proteins [6].  Though the existence of 
lipid rafts is somewhat controversial in literature [7, 8], their association with particular 
membrane proteins strongly suggests that lipid rafts have physiological functions such 
as serving as exclusive platforms for protein and lipid signaling and sorting [9, 10].  
Signaling examples include IgE [11], T-cell receptor [12], and integrin signaling [13], and 
sorting examples include trafficking of proteins through the endoplasmic reticulum [10], 
Golgi complex [14], vesicles [15], and cell membrane [16].  Rafts have also been 
implicated as assembly and budding sites for enveloped viruses [17] and proteins from 
viruses such as human immunodeficiency virus type 1 (HIV-1) [18], influenza [19], Ebola 
[20], and measles [21] have been shown to associate with rafts.   
Much evidence for rafts as sites of HIV assembly exists.  The lipid composition of 
HIV, distinct from that of the host cell, is enriched in cholesterol and sphingolipids [22].  
Gag proteins are localized to punctate regions in the plasma membrane instead of being 
evenly distributed [23].  The matrix protein from Gag, and gp41, the transmembrane 
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portion of the envelope protein, are both targeted to lipid rafts in the membrane [24, 25].  
Assembly and budding is driven by the oligomerization of Gag [26], and depletion of 
cholesterol from the cell membrane not only causes raft deformities, HIV budding and 
infectivity is reduced [27-29].   
Generally, when HIV buds from the host cell, it incorporates host cell raft 
molecules such as GM1, and GPI anchored proteins such as Thy-1 and CD59, and does 
not incorporate host cell proteins excluded from rafts such as CD45 [30, 31].  The ability 
of HIV to incorporate non-HIV proteins into its lipid bilayer is often exploited for the 
generation of pseudotyped viruses for targeted gene therapy [32], the generation of 
decorated viruses in order to enhance virus transduction [33, 34], or the generation of 
viruses to stimulate the immune system for vaccines [35, 36].  For example, lentiviruses 
have been pseudotyped with envelope proteins from VSV-G and amphotropic murine 
leukemia virus [37, 38] and have incorporated proteins such as cell adhesion molecules 
[34, 39, 40] and cytokines [41, 42].  However it is often challenging to modify the virus 
surface with a specific protein.  In the case of targeting lentiviruses to polarized lung 
epithelial cells, envelope proteins from influenza, respiratory syncytial virus, baculovirus, 
and Sendai virus have failed to form pseudotypes with lentiviruses [43].  A clear 
understanding of how proteins are incorporated into lentiviruses would not only enable a 
better understanding of lentiviral assembly, it would facilitate the surface modification of 
lentiviral particles. 
There is increasing evidence pointing to distinct and separate populations of lipid 
rafts [44, 45].  In this study, we tested the hypothesis that lipid rafts compartmentalize 
host cell raft proteins, and protein incorporation into the lentiviral lipid bilayer is 
dependent upon colocalization with lentivirus-associated rafts.  The implications of our 
findings for understanding the assembly of lentivirus particles and the generation of 
surface-modified lentiviruses useful for therapeutic purposes are discussed. 
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4.3  Materials and Methods 
Chemicals and antibodies.  Poly-L-lysine, o-phenylenediamine dihydrochloride 
(OPD), saponin, Brij 98, methyl-β-cyclodextrin, gluteraldehyde, paraformaldehyde, and 
5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) were purchased from Sigma 
Chemical (St. Louis, MO).  Hydrogen peroxide 30%, Triton X-100, and polyoxyethylene 
20-sorbitan monolaurate (Tween 20) were purchased from Fisher Scientific (Fair Lawn, 
NJ).  Complete mini protease inhibitor cocktail tablets were purchased from Roche 
Diagnostics (Indianapolis, IN).  Coomassie Plus-200 protein assay reagent was 
purchased from Pierce (Rockford, IL).  Nonfat dry milk (blotting grade) was purchased 
from Bio-Rad Laboratories (Hercules, CA).  Fumonisin B1 was purchased from Biomol 
International, LP (Plymouth Meeting, PA).   
HIV-1 p24 gag mouse ascites monoclonal antibody #24-3 (from Dr. Michael H. 
Malim), HIV-1 p24 mouse monoclonal antibody 183-H12-5C (from Dr. Bruce Chesebro 
and Kathy Wehrly), and sheep antiserum to HIV-1 p24 (from Dr. Michael Phelan) were 
obtained through the AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH.  Goat polyclonal antibody to HIV-1 p24 was purchased from 
Advanced Biotechnologies Incorporated (Columbia, MD).  Rabbit polyclonal antibody 
against IL-2Rα was purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA).  
Rabbit anti-folate receptor antisera was a kind gift from V.L. Stevens (Emory University 
School of Medicine, Atlanta, GA) [46].  Goat polyclonal anti-gp70 (79S834) was 
purchased from Quality Biotech (Camden, NJ).  Mouse anti-gp70 antibodies were 
purified from the supernatant of the 83A25 hybridoma cell line [47] and mouse anti-Tac 
antibodies were purified from the supernatant of the 7G7 hybridoma cell line [48] 
following standard procedures [49].  Cy2-conjugated, Cy-3 conjugated, and horseradish 
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peroxidase (HRP)-conjugated antibodies, and normal donkey serum were purchased 
from Jackson Immunoresearch Laboratories, Inc. (West Grove, PA). 
Cell culture.  293T/17 cells were maintained in Dulbecco’s modified essential 
medium (DMEM) supplemented with 10% heat inactivated fetal bovine serum (FBS), 
100 U/mL of penicillin, and 100 μg/mL streptomycin (HyClone Laboratories; Logan, UT).  
Plates coated with poly-L-lysine were incubated for 5 min in the 0.01% solution (150-300 
kDa), washed once with deionized water, and dried. 
Virus production.  Lentiviruses pseudotyped with the amphotropic Env alone or 
with either FR-WT or Tac-CD16 were produced by transfecting 293T/17 cells, seeded 
(1x107 per well) the previous day on poly-L-lysine coated plates with Lipofectamine 2000 
(Invitrogen; Carlsbad, CA) and 6 μg of the packaging construct pCMVΔR8.91 [50], 6 μg 
of the lentivirus vector pTYEFnlacZ (AIDS Research and Reference Reagent Program; 
Bethesda, MD), and 6 μg of the amphotropic envelope protein expression plasmid 
pFB4070ASALF [51] alone or with either 6 μg of the Tac-CD16 expression plasmid (kind 
gift of Harish Radhakrishna (School of Biology, Georgia Institute of Technology, Atlanta, 
GA [52]) or the folate receptor-α (FR-WT) expression plasmid (kind gift of V.L. Stevens 
[46]).  The following day, producer cells may have been treated with 0.5 mM MβCD or 50 
μM FB1.  Viral supernatants were collected every 12 h from 48 to 60 h after transfection, 
filter sterilized (0.45 μm), and frozen (-80°C) for later use.  Viruses were clarified and 
concentrated by ultracentrifugation through a 20% sucrose cushion at 35,000 rpm for 2 
hours at 40C in a SW41 rotor.   
Indirect immunofluorescence.  To detect the presence of Gag and surface 
proteins, cells were seeded (1x105 per well) the previous day on poly-L-lysine coated 12-
well plates containing coverslips (no. 1.5, 12 mm, Fisher Scientific; Suwanee, GA).  Cells 
were then transfected with Polyfect (Qiagen, Valencia, CA) according to manufacturer’s 
instructions.  The next day cells were incubated with 4% paraformaldehyde (0.5 mL/well) 
 81
for 15 min and then blocked with PBS/sera (0.5 mL/well) (5% donkey sera in PBS) for 10 
min.  Cells were then incubated with primary antibody for 1 hour at room temperature in 
PBS/sera/0.2% saponin (1:500), washed 3 times with PBS, incubated with the 
secondary antibody for 1 hour at room temperature in PBS/sera/0.2% saponin (1:500), 
and then washed three times with PBS and once with distilled water.  Cells may or may 
not have been labeled with 5 μg/mL A594-conjugated cholera toxin B subunit in PBS for 
1 hour (Invitrogen) and washed three times.  Coverslips were mounted on glass slides 
with gelvatol [53] at 40C.  The next day cells were visualized by confocal microscopy at 
63X.  For each condition, eight cells were chosen at random and extent of colocalization 
was quantified by calculating the Pearson’s overlap coefficient with ImageJ [54] and the 
Colocalisation Threshold plugin (Tony Collins, Wayne Rasband, and Kevin Baler).  This 
calculation is based on the overlap of red and green pixels, with a high degree of overlap 
corresponding to a value of 1 and a low degree of overlap corresponding to a value of 0 
[55].  Coefficients for eight separate cells were averaged and statistical significance was 
determined. 
Immunoblotting.  To detect p24, Tac-CD16, FR-WT, or amphotropic Env in 
virus samples and rafts, equal amounts of protein from each sample were combined 1:2 
(v/v) with sample buffer containing 5% β-mercaptoethanol (both from Bio-Rad; Hercules, 
CA), vortexed, boiled for 5 min, separated by size by SDS-PAGE (4-20% Tris-HCl gel, 
Bio-Rad), and transferred to a PVDF membrane (0.2 μm, Bio-Rad).  To probe for p24 in 
the membrane, mouse anti-p24 (24-3) was diluted 1:5000 in blocking buffer (5% nonfat 
milk in PBS with 0.1% Tween 20) and followed by incubation with HRP-conjugated 
donkey anti-mouse (diluted 1:400,000 in blocking buffer).  Similarly, to probe for Tac-
CD16, rabbit anti-IL-2Rα was diluted 1:1000 in blocking buffer followed by HRP-
conjugated donkey anti-rabbit (1:400,000 in blocking buffer).  To probe for FR-WT, rabbit 
anti-folate receptor antisera was diluted 1:2500 in blocking buffer followed by HRP-
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conjugated donkey anti-rabbit (1:400,000 in blocking buffer).  To probe for amphotropic 
Env, goat anti-gp70 antibody 79S834 was diluted 1:1000 in blocking buffer followed by 
HRP-conjugated donkey anti-goat (1:400,000 in blocking buffer).  A chemiluminescent 
detection system was used for detection (Super Signal West Femto kit; Pierce).  To 
quantitatively compare the amount of protein that was visualized as bands on the film, 
we used ImageJ to measure the band area and intensity and compared the product of 
the two values. 
Lipid raft isolation.  To detect for proteins in lipid rafts, 293T/17 cells, seeded 
(1x107 per well) the previous day on poly-L-lysine coated plates with Lipofectamine 2000 
and 6 μg of pCMVΔR8.91, 6 μg of the lentivirus vector pTYEFnlacZ, and 6 μg of  
pFB4070ASALF alone or with either 6 μg of the Tac-CD16 expression plasmid or the 
FR-WT expression plasmid.  Cells were then pelleted with versene (PBS and 5 mM 
EDTA pH 7.5) and resuspended in 1 mL of ice-cold 0.5% Brij 98 in TNE buffer (25 mM 
Tris-base, 0.15 M sodium chloride, 5 M EDTA, pH 7.5).  Lysates were dounce 
homogenized, adjusted to 40% sucrose by adding an equal volume of 80% sucrose in 
TNE buffer and placed in ultracentrifuge tubes.  For whole raft isolation, samples were 
overlaid with 5 mL of ice-cold 30% sucrose in TNE followed by 4 mL of ice-cold 5% 
sucrose in TNE.  For linear gradient raft isolation, samples were overlaid with 9 mL of a 
5-30% continuous sucrose density gradient prepared with a SG series gradient maker 
(Hoefer Scientfici Instruments; San Francisco, CA).  The samples were centrifuged at 
30,000 rpm for 15 hours at 40C in an SW41 rotor (Beckman Coulter, Palo Alto, CA).  For 
whole raft isolation, the proteins at the interface of the 5% and 38% sucrose solutions 
was isolated, mixed with ice-cold TNE buffer, and then centrifuged at 30,000 rpm for 1 
hour at 40C in a SW41.  The pelleted lipid raft fraction was resuspended in 100 µL of 
TNE buffer.  For the linear gradient isolation, fractions of 1 mL were collected, and the 
density of each fraction was determined as mass/volume and reported as g/mL. 
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p24 ELISA.  We used p24 ELISA to quantitatively compare the amount p24 viral 
supernatant and lipid rafts.  ELISA plates (Nunc immuno Maxisorp 96-well plates, 
Nalgene Nunc International, Rochester, NY) were coated overnight at 370C with 1:800 
dilution of mouse anti-p24 antibody 183-H12-5C (100 μL/well) in PBS.  The next day, the 
antibody solution was removed and wells were washed twice (PBS, 0.05% Tween-20).  
Blocking buffer (PBS, 0.05% Tween-20, 5% non-fat milk) was added at 200 μL/well for 1 
hour at 370C and removed.  Samples were lysed in 2% Triton X-100 1:1 and added to 
the ELISA plate (100 μL/well), and incubated for 2 hours at 370C.  Bound p24 was 
sandwiched by the addition of the sheep polyclonal anti-p24 antisera diluted 1:250 in 
blocking buffer, and incubated for 2 hours at 370C.  The HRP-conjugated anti-sheep 
secondary antibody was diluted 1:1000 in blocking buffer and added to the ELISA plate 
(100 μL/well) for 1 hour at 370C.  Plates were then developed for 20 min using a solution 
(100 μL/well) of 3 mg of OPD, 3 μL hydrogen peroxide, 7.5 mL substrate buffer (24 mM 
citric acid-monohydrate, 51 mM Na2HPO4*7H2O, pH 5.0).  8N sulfuric acid (50 μL/well) 
was used to stop the reaction and the optical density at 490 nm was measured using an 
absorbance plate reader (non-specific background at 650 nm was subtracted).  Values 
for each point are the average of at least triplicate wells. 
Transduction.  293T cells were seeded in poly-L-lysine coated 12-well plates 
(1x105 cells per well) and incubated at 37°C. The next day, viral supernatant dilutions 
were incubated with cells for 48 h, after which the cells were fixed with gluteraldehyde 
and stained for β-galactosidase activity with X-Gal, and the number of lacZ+ colony-
forming units (CFU) per milliliter was counted.   
Statistics.  Data are summarized as the mean ± the standard deviation for at 
least triplicate samples.  Statistical analysis was performed using one-way analysis of 
variance for repeated measurements of the same variable.  The Tukey multiple 
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comparison test was used to conduct pairwise comparisons between means.  
Differences at p < 0.05 were considered statistically significant. 
 
4.4  Results 
In order to determine whether lipid rafts compartmentalize host cell raft proteins, 
and whether protein incorporation into the lentiviral lipid bilayer is dependent upon 
colocalization with lentivirus-associated rafts, we studied the ability of two 
glycosylphosphatidylinositol (GPI) anchored proteins, folate receptor (FR-WT) and Tac-
CD16 (i.e., the interleukin-2 receptor alpha chain fused with the cytoplasmic domain of 
the GPI-anchored CD16 protein [52]) to incorporate into lentivirus particles.  GPI 
anchored proteins have been shown to associate with lipid rafts and lentivirus particles 
[56, 57], however not all GPI anchored proteins are incorporated into the lentiviral lipid 
bilayer [22, 58, 59].  As a first step, we examined whether Tac-CD16 and FR-WT 
displayed typical GPI anchored protein properties.  We analyzed the amount of 
colocalization between the proteins and lipid rafts by transfecting 1x105 293T cells on 
glass coverslips with plasmids encoding for Tac-CD16 and FR-WT.  Cells were also 
transfected with a plasmid encoding for HIV-1 Gag-Pol as an example of a protein that 
colocalizes with rafts [24].  The next day cells were fixed, permeabilized, and 
immunostained with a monoclonal antibody against Tac-CD16 or FR-WT followed by a 
Cy2-conjguated secondary antibody, and then stained for lipid rafts with A549-
conjugated cholera toxin B subunit which binds to GM1 found in rafts (Figure 4.1A).  
Cells were visualized by confocal microscopy and the extent of colocalization between 
the GPI anchored protein and rafts was quantified by calculating the Pearson’s overlap 
coefficient.  We found a high degree of colocalization between lipid rafts and Tac-CD16, 
FR-WT, and Gag as shown by the overlapping of corresponding red (raft) and green  
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Figure 4.1.  FR-WT and Tac-CD16 display typical GPI anchored protein properties 
however FR-WT is not incorporated into lentiviral particles.  293T cells were transiently 
transfected to express HIV-1 Gag-Pol (Gag), Tac-CD16, or FR-WT.  Cells were fixed, 
permeabilized, and immunostained with a monoclonal antibody against Gag, Tac-CD16, 
or FR-WT followed by Cy2 conjugated secondary antibody.  Cells were also stained for 
lipid rafts with A549-conjugated cholera toxin B subunit (CTB).  Cells were visualized 
with confocal microscopy at 63X and overlays of CTB (red) with proteins (green) are 
shown.  Eight cells were chosen at random and extent of colocalization was quantified 
with ImageJ (A).  FR-WT and Tac-CD16 are in lipid rafts (B) but FR-WT is not in virus 
particles (C).  293T cells (1x107) were transfected with expression plasmids (8 µg each) 
for β-galactosidase, HIV-1 Gag-Pol, and either FR-WT or Tac-CD16.  Detergent 
resistant domains were isolated by lysing cells with ice-cold Brij 98 (0.5% in TNE) and 
flotation through a discontinuous sucrose gradient.  The lipid raft fraction was pelleted by 
centrifugation and the pellet was analyzed by Western blot for the presence of Tac-
CD16 (B, Lane 2) or FR-WT (B, Lane 3).  The virus supernatant was harvested and 
ultracentrifuged through a 20% sucrose cushion, and then resuspended in PBS to 100-
fold their original concentration.  Samples were resuspended in lysis buffer and analyzed 
by Western blot for the presence of Tac-CD16 (C, Lane 2), FR-WT (C, Lane 3), and p24 
(C, Lanes 2-3). 
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(proteins) pixels producing a yellow color, and also shown by the high Pearson’s 
coefficient number (> 0.80).   
To confirm biochemically that Tac-CD16 and FR-WT resided in lipid rafts, and 
determine if they are incorporated into lentiviral particles, we transfected cells with 
expression plasmids for β-galactosidase, HIV-1 Gag-Pol, and either FR-WT or Tac-
CD16.  Detergent resistant domains were isolated by lysing cells with ice-cold Brij 98 
(0.5% in TNE) and flotation through a discontinuous sucrose gradient.  The lipid raft 
fraction was pelleted by centrifugation and the pellet was analyzed by Western blot for 
the presence of Tac-CD16 or FR-WT (Figure 4.1B).  As expected, FR-WT and Tac-
CD16 were both detected in the detergent resistant fraction.  The virus supernatant of 
the transfected cells was then analyzed for protein content after it was harvested, 
ultracentrifuged through a 20% sucrose cushion, and then resuspended in PBS to 100-
fold the original concentration.  Samples were resuspended in lysis buffer and analyzed 
by Western blot for the presence of Tac-CD16, FR-WT, and the lentiviral Gag protein 
p24 (Figure 4.1C).  Surprisingly, even though both are GPI anchored proteins, Tac-
CD16 was incorporated into lentiviral particles while FR-WT was not. 
To see whether FR-WT was not incorporated into lentiviruses because FR-WT 
was not colocalized virus proteins, we analyzed the amount of colocalization between 
FR-WT and lentiviral proteins, Gag and amphotropic Env, and compared it to Tac-CD16.  
293T cells (1x105) on coverslips were transiently transfected to express HIV-1 Gag-Pol 
or amphotropic Env, and either Tac-CD16 or FR-WT.  To determine whether Tac-CD16 
and FR-WT were colocalized with each other, cells were also transfected with both Tac-
CD16 and FR-WT.  Cells were fixed, permeabilized, and immunostained with a mouse 
monoclonal antibody against Gag or Env, followed by a Cy2 conjugated secondary 
antibody.  Corresponding cells were also stained with a monoclonal antibody against 
FR-WT or Tac-CD16 followed by a Cy3-conjugated secondary antibody.  Cells were 
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visualized by confocal microscopy and the extent of colocalization was quantified by 
calculating the Pearson’s overlap coefficient with ImageJ (Figure 4.2).  As expected, 
Tac-CD16 and Gag were strongly colocalized (0.82 ± 0.046).  Interestingly, even though 
FR-WT, Tac-CD16, and Gag were all found in lipid rafts, FR-WT was not highly 
colocalized with Gag (0.55 ± 0.070, p<0.05) or even Tac-CD16 (0.72 ± 0.20).  Tac-CD16 
was slightly more colocalized with the amphotropic Env than FR-WT (0.780 ± 0.079 and 
0.72 ± 0.047), although the difference was not statistically significant.  These results 
suggested that FR-WT may be localized to a different set of rafts than Tac-CD16, Gag, 
and Env. 
In a typical raft isolation procedure, proteins are collected at the interface of the 
5% and 30% sucrose solutions.  To further characterize the location of GPI anchored 
proteins compared to virus proteins in lipid rafts, we analyzed the distribution of FR-WT, 
Tac-CD16, Gag, and amphotropic Env in a linear gradient of 5-30% sucrose.  293T cells 
(1x107) were transfected with expression plasmids for HIV-1 Gag-Pol or Env, and either 
FR-WT or Tac-CD16.  Detergent resistant domains were isolated by flotation through a 
linear sucrose gradient after lysing cells with ice-cold Brij 98 (0.5% in TNE).  Fractions 
were collected and analyzed by Western blot for the presence of Tac-CD16 and FR-WT 
(Figure 4.3A) and Env (Figure 4.3C).  When co-expressed with Gag, Tac-CD16 was 
distributed as very strong bands in fractions 3-6, a strong band in fraction 2, and a weak 
band in fraction 7.  However when co-expressed with Gag, the bands for FR-WT were 
present as average bands in fractions 4-5, and as weak bands in fraction 3 and 6.  To 
characterize the distribution of Gag in the linear sucrose gradient, a p24 ELISA was 
performed on the fractions (Figure 4.3B).  Generally as the fraction density increased, 
the concentration of p24 increased.  Significant amounts of p24 was detected when Gag 
was co-expressed with Tac-CD16, however the amount detected when co-expressed 
with FR-WT was on average 5-fold less.  Similar to Gag, the amphotropic Env bands  
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Figure 4.2.  FR-WT is not colocalized with Gag or Env while Tac-CD16 is.  293T cells 
were transiently transfected to express HIV-1 Gag-Pol or amphotropic Env and either 
Tac-CD16 or FR-WT.  Cells were also co-transfected with both Tac-CD16 and FR-WT.  
Cells were fixed, permeabilized, and immunostained with a monoclonal antibody against 
Gag (A) or Env (B), followed by Cy2 conjugated secondary antibody, and a monoclonal 
antibody against Tac-CD16 or FR-WT followed by Cy3 conjugated secondary antibody.  
Cells were visualized with confocal microscopy at 63X and overlays of red with green 
are shown.  Eight cells were chosen at random and extent of colocalization was 
quantified with ImageJ.  Statistically significant differences (p<0.05) in colocalization 
values between Tac-CD16 colocalized with Gag and FR-WT colocalized Gag are 
denoted with *.   
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Figure 4.3.  Tac-CD16 distribution in rafts overlap Gag while FR-WT does not, and Tac-
CD16 reduces amount of Env in rafts while FR-WT does not.  293T cells (1x107) were 
transfected with expression plasmids for HIV-1 Gag-Pol, and either FR-WT or Tac-CD16 
(A and B) or amphotropic Env alone or with either FR-WT or Tac-CD16 (C).  Detergent 
resistant domains were isolated by lysing cells with ice-cold Brij 98 (0.5% in TNE) and 
flotation through a linear sucrose gradient.  Fractions were collected and analyzed by 
Western blot for the presence of Tac-CD16 (A, top), FR-WT (A, bottom), or Env (C).  
Amount of p24 in the fractions from A was also quantified with p24 ELISA (B).  The 
density of fractions 2-10 were 1.073, 1.076, 1.083, 1.091, 1.091, 1.097, 1.104, 1.130, 
1.115 g/mL. 
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were intense in the denser fractions of 6-10, and were most intense in fractions 9 and 
10.  Interestingly, FR-WT had no effect on the distribution of amphotropic Env in 
fractions 6 and 7 compared to Env alone, whereas Tac-CD16 seemed to decrease the 
amount of amphotropic Env in raft fractions 6-8 compared to Env alone.   
 Since our data suggested FR-WT inhibited Gag localization to the less dense, 
FR-WT-containing rafts, we determined whether FR-WT would affect the budding, 
envelope incorporation, and titer of amphotropic pseudotyped lentivirus particles.  293T 
cells were transfected with expression plasmids for β-galactosidase, HIV-1 Gag-Pol, 
amphotropic Env alone or with either FR-WT or Tac-CD16.  Whole cell lysates were 
isolated by lysing cells with ice-cold Brij 98 (0.5% in TNE), and whole raft fractions were 
isolated by flotation through a discontinuous sucrose gradient.  The virus supernatant 
was harvested and ultracentrifuged through a 20% sucrose cushion, and then 
resuspended in PBS to 100-fold their original concentration.  Whole cell lysates, whole 
raft fractions, and amount of virus produced was analyzed for p24 concentrations with a 
p24 ELISA (Figure 4.4, A, B, C, respectively).  In the presence of Tac-CD16, the amount 
of p24 in whole cell lysates and whole raft isolates dropped 2.7-fold (p<0.05) and 2.5-
fold (p>0.05), respectively, while the amount of virus produced increased 1.2-fold 
(p>0.05).  In the presence of FR-WT, the amount of p24 in whole cell lysates increased 
1.4-fold (p<0.05) while the amount of virus produced decreased 1.2-fold (p>0.05).  
Consistent with the previous data, the amount of p24 in rafts decreased 3.8-fold 
(p<0.05).  Since the amount of FR-WT in whole cell lysates increased and rafts 
decreased while the amount of virus released into the supernatant decreased, these 
results suggested that not only did FR-WT reduce localization of Gag to rafts, it also 
reduced viral budding. 
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Figure 4.4.  FR-WT inhibits Gag localization to rafts and lentiviral budding while Tac-
CD16 does not.  293T cells (1x107) were transfected with expression plasmids (6 µg 
each) for β-galactosidase, HIV-1 Gag-Pol, amphotropic Env alone or with either FR-WT 
or Tac-CD16.  Whole cell lysates were isolated by lysing cells with ice-cold Brij 98 (0.5% 
in TNE) and detergent resistant domains were isolated by flotation through a 
discontinuous sucrose gradient.  The virus supernatant was harvested and 
ultracentrifuged through a 20% sucrose cushion, and then resuspended in PBS to 100-
fold their original concentration.  Whole cell lysates (A), whole raft fractions (B), or virus 
supernatant (C) were analyzed for p24 amounts with a p24 ELISA.  * denotes 
statistically significant difference (p<0.05) in p24 amounts between whole cell lysates or 
rafts containing Ampho only or Ampho + GPI anchored protein. 
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The whole raft fractions and virus supernatants were then analyzed by Western 
blot for amount of Tac-CD16, FR-WT, and amphotropic Env (Figure 4.5, A, B, C, 
respectively).  Densitometry analysis on the bands showed the amount of Tac-CD16 in 
virus and in lipid rafts decreased 7.9-fold and 1.3-fold, respectively, in the presence of 
the amphotropic envelope protein.  Consistent with previous data, FR-WT was not 
detected in virus particles.  However, the amount of FR-WT in lipid rafts decreased 1.2-
fold when the amphotropic Env was co-transfected.  There did not seem to be detectable 
differences in the amount of amphotropic Env in virus particles when co-transfected with 
either GPI anchored proteins, however the amount of Env in lipid rafts decreased 1.2-
fold and 1.6-fold when Tac-CD16 and FR-WT were co-transfected, respectively.  When 
the viral supernatant was used to transduce cells in the diluted titer assay (Figure 4.5D), 
the normalized titer of amphotropic Env + Tac-CD16 pseudotyped viruses decreased 
1.9-fold while the normalized titer of amphotropic Env + FR-WT pseudotyped viruses 
was not statistically different from amphotropic Env pseudotyped viruses.   
 Our data suggested there are dense, lentivirus-associated rafts and less dense, 
non-lentivirus-associated rafts, and that residing in separate rafts may prevent raft 
proteins from interacting with each other.  Lipid rafts are enriched in cholesterol, 
glycolipids, and sphingolipids, and cholesterol levels have been shown to affect the 
integrity of lipid rafts and also the trafficking of membrane proteins [9, 60].  We 
investigated whether a cholesterol extracting compound such as methyl-beta-
cycodextrin (MβCD) or a cholesterol sequestering and sphingolipids synthesis inhibiting 
compound such as fumonisin B1 (FB1) would have an effect on raft integrity such that 
colocalization of proteins residing in different rafts can occur.  We first determined 
whether MβCD or FB1 treatment would affect the colocalization GPI anchored proteins  
 
 93
 
A.   B.   
C 
 
 
D 
 
Figure 4.5.  FR-WT is not present in virus particles, does not alter amount of 
amphotropic Env in rafts or virus particles, and does not affect virus titer while Tac-CD16 
does.  293T cells (1x107) were transfected with expression plasmids (6 µg each) for β-
galactosidase, HIV-1 Gag-Pol, amphotropic Env alone (Ampho), Tac-CD16 alone, FR-
WT alone, or amphotropic Env with either FR-WT (F) or Tac-CD16 (T).  The virus 
supernatant (v) was harvested, ultracentrifuged through a 20% sucrose cushion, 
resuspended in PBS to 100-fold their original concentration, and analyzed by Western 
blot after normalization for p24 (A and B Lanes 2-3, C Lanes 2-4).  Detergent resistant 
domains (r) were isolated by lysing cells with ice-cold Brij 98 (0.5% in TNE) and flotation 
through a discontinuous sucrose gradient.  The lipid raft fraction was pelleted by 
centrifugation and the pellet was analyzed by Western blot after normalization for protein 
content (A and B Lanes 4-5, C Lanes 5-7).  Blots were for the presence of Tac-CD16 
(A), FR-WT (B), or Ampho (C).  In Part A, samples are as follows:  Tac-CD16 alone 
(Lanes 2 and 4) or Tac-CD16 + Ampho (Lanes 3 and 5).  In Part B, samples are as 
follows:  FR-WT alone (Lanes 2 and 4) or FR-WT + Ampho (Lanes 3 and 5).  In Part C, 
samples are as follows:  Ampho alone (Lanes 2 and 5), Ampho + FR-WT (Lanes 3 and 
6), Ampho + Tac-CD16 (Lanes 4 and 7).  Titer of viruses was analyzed with diluted titer 
assay (D).  Viruses were used to transduce target cells and transduced cells were 
incubated for 2 days at 370C until confluent, fixed, and stained for lacZ activity with X-
Gal, colonies of lacZ+ cells were counted, and the titer normalized to p24 amounts.  * 
denotes statistically significant differences (p<0.05) in normalized titer of viruses 
containing amphotropic Env only or amphotropic Env + Tac-CD16.  
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with virus proteins.  293T cells were transiently transfected to express HIV-1 Gag-Pol, β-
galactosidase, amphotropic Env, and either Tac-CD16 or FR-WT.  Cells were then 
cultured in the presence of 50 µM FB1 or 0.5 mM MβCD.  Cells were fixed, 
permeabilized, and immunostained with a monoclonal antibody against amphotropic Env 
or Gag followed by Cy2 conjugated secondary antibody, and then a monoclonal antibody 
against Tac-CD16 or FR-WT followed by a Cy3 conjugated secondary antibody.  Cells 
were then visualized by confocal microscopy and the extent of colocalization was 
quantified by calculating the Pearson’s overlap coefficient with ImageJ (Figure 4.6).  
Treatment of cells with MβCD or FB1 did not statistically alter the amount of 
colocalization of Tac-CD16 with amphotropic Env or Gag.  Treatment of cells with MβCD 
and FB1 had no statistical effect on amount of colocalization between amphotropic Env 
and FR-WT, however the amount of colocalization between FR-WT and Gag increased 
significantly (p<0.05). 
 To further determine the effects of MβCD and FB1 on raft integrity, we analyzed 
the distribution of GPI anchored protein and virus protein in rafts.  293T cells were 
transiently transfected to express HIV-1 Gag-Pol and either Tac-CD16 or FR-WT.  Cells 
were then cultured in the presence of 50 µM FB1 or 0.5 mM MβCD.  Detergent resistant 
domains were isolated by flotation through a linear sucrose gradient after lysing cells 
with ice-cold Brij 98 (0.5% in TNE).  Fractions were collected and analyzed with Western 
blot for the presence of Tac-CD16 or FR-WT (Figure 4.7A).  Treatment of cells with FB1 
or MβCD shifted the Tac-CD16 distribution in lipid rafts slightly to less dense fractions 
(fractions 2-5 and 2-6, respectively) compared to untreated cells in Figure 4.3A.  The 
treatment of cells with FB1 or MβCD greatly enhanced the amount of FR-WT in lipid raft 
fractions in both cases, as well as increased the distribution of FR-WT to more dense 
fractions (lanes 3-5, with weak bands in lanes 6 and 7) compared to untreated cells in 
Figure 4.3A.  The amount of Gag in the fractions was also quantified with p24 ELISA  
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Figure 4.6.  Treatment of cells with FB1 and MβCD increases colocalization of FR-WT 
with amphotropic Env and Gag.  293T cells were transiently transfected to express HIV-
1 Gag-Pol (Gag), β-galactosidase, amphotropic Env (Ampho), and either Tac-CD16 or 
FR-WT.  Cells were then cultured in the presence of 50 µM fumonisin B1 (FB1) or 0.5 
mM (MβCD).  Cells were fixed, permeabilized, and immunostained with a monoclonal 
antibody against Ampho or Gag followed by Cy2 conjugated secondary antibody, and 
then a monoclonal antibody against Tac-CD16 or FR-WT followed by a Cy3 conjugated 
secondary antibody.  Cells were visualized with confocal microscopy at 63X and 
overlays of red with green are shown.  Eight cells were chosen at random and extent of 
colocalization was quantified with ImageJ.  * denotes statistically significant differences 
(p<0.05) in colocalization between FR-TW and Gag in untreated cells (Figure 4.2) and 
cells treated with FB1 or MβCD.  
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Figure 4.7.  Treatment of cells with FB1 and MβCD disturbs lipid rafts and increases 
lentiviral budding and FR-WT incorporation into lentiviral particles.  293T cells were 
transiently transfected to express HIV-1 Gag-Pol (Gag) and either Tac-CD16 or FR-WT.  
Cells were then cultured in the presence of 50 µM fumonisin B1 (FB1) or 0.5 mM methyl-
beta-cyclodextrin (MβCD).  Detergent resistant domains were isolated by lysing cells 
with ice-cold Brij 98 (0.5% in TNE) and flotation through a discontinuous sucrose 
gradient (A).  Fractions were collected and analyzed by Western blot for the presence of 
Tac-CD16 (A top) or FR-WT (A bottom).  Amount of p24 was also quantified with p24 
ELISA on the fractions (B).  The density of fractions 2-10 were 1.060, 1.068, 1.076, 
1.081, 1.086, 1.098, 1.110, 1.113, 1.118 g/mL.  The virus supernatant was harvested 
and ultracentrifuged through a 20% sucrose cushion, and then resuspended in PBS to 
100-fold their original concentration and analyzed by Western blot for FR-WT after 
normalization for p24 (C).  Lanes are as follows  1) FR-WT LV untreated, 2) FR-WT LV 
with 50 µM FB1, 3) FR-WT LV with 0.5 mM MβCD, and 4) FR-WT in lipid raft as positive 
control.  Virus supernatant was also analyzed for amount of p24 by p24 ELISA (D).  
Statistically significant differences (p<0.05) in p24 amounts between (1) untreated FR-
WT LV with treated FR-WT LV or (2) untreated Tac-CD16 LV with treated Tac-CD16 LV 
are denoted with * and ∆, respectively. 
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(Figure 4.7B).  Similar to previous results, the overall amount of p24 was higher when 
co-transfected with Tac-CD16 than FR-WT, and amount of p24 increased as fraction 
density increased.  However in MβCD and FB1 treated cells, the presence of Gag when 
co-transfected with FR-WT was detectable in less dense fractions (beginning in fractions 
5 and 6) compared untreated cells in Figure 4.2C (where presence of Gag was 
detectable beginning in fraction 7).  Also the amount of Gag in FR-WT co-transfected 
cells was only 2.6-fold and 3.5-fold less, respectively, with FB1 and MβCD treatment 
than cells co-transfected with Tac-CD16 (compared to 5-fold less in untreated cells from 
Figure 4.2C).   
 Since FB1 and MβCD treatment increased colocalization of FR-WT with Gag, we 
then examined whether FB1 or MβCD treatment would increase the amount of folate 
receptor incorporated into lentiviral particles.  The virus supernatant from the above 
treated cells were harvested and ultracentrifuged through a 20% sucrose cushion, and 
then resuspended in PBS to 100-fold their original concentration and analyzed by 
Western blot for FR-WT after normalization for p24 (Figure 4.7C).  FB1 and MβCD 
treatment of producer cells increased the amount of FR-WT in virus particles 2.9-fold 
and 11.6-fold, respectively, however the amount incorporated was still significantly less 
than Tac-CD16 or amphotropic Env.  Virus supernatant was also analyzed for amount of 
virus produced by p24 ELISA (Figure 4.7D).  FB1 and MβCD treatment decreased the 
amount of virus produced from Tac-CD16 cells 1.1-fold (p>0.05) and 1.2-fold (p<0.05), 
respectively.  Interestingly, FB1 and MβCD increased the amount of virus produced from 
FR-WT transfected cells 2.4-fold (p<0.05) and 1.5-fold (p<0.05), respectively. 
 We then determined whether MβCD treatment would have an effect on Tac-
CD16 and amphotropic Env incorporation into rafts and virus particles.  293T cells were 
transiently transfected to express HIV-1 Gag-Pol, β-galactosidase, amphotropic Env or 
Tac-CD16.  Cells were then cultured in the presence or absence of 0.5 mM MβCD.  
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Detergent resistant domains were isolated by lysing cells with ice-cold Brij 98 (0.5% in 
TNE), flotation through a discontinuous sucrose gradient, and pelleting the raft fraction.  
The virus supernatant was harvested and ultracentrifuged through a 20% sucrose 
cushion, and resuspended in PBS to 100-fold their original concentration.  The lipid raft 
fractions and virus supernatants were then analyzed by Western blotting for amount of 
Tac-CD16 (Figure 4.8A) and amphotropic Env (Figure 4.8B).  In Tac-CD16 transfected 
cells, MβCD treatment decreased the amount of Tac-CD16 in virus particles 2.4-fold and 
also decreased the amount in lipid rafts 1.1-fold.  Interestingly, MβCD treatment also 
decreased the amount of amphotropic Env in virus particles 1.3-fold and the amount in 
rafts 1.9-fold.   
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Figure 4.8.  Treatment of cells with MβCD decreases amount of Tac-CD16 and 
amphotropic Env in raft and virus.  293T cells were transiently transfected to express 
HIV-1 Gag-Pol, β-galactosidase, and either amphotropic Env (Ampho) or Tac-CD16.  
Cells were then cultured in the presence or absence of 0.5 mM MβCD.  Detergent 
resistant domains were isolated by lysing cells with ice-cold Brij 98 (0.5% in TNE) and 
flotation through a discontinuous sucrose gradient.  The raft fraction (r) was pelleted and 
analyzed by Western blot after being normalized for protein content (A and Lanes 3-4).  
The virus supernatant (v) was harvested and ultracentrifuged through a 20% sucrose 
cushion, and then resuspended in PBS to 100-fold their original concentration and 
analyzed by Western blot after normalization for p24 (A and B, Lanes 1-2).  Gels were 
immunoblotted for Tac-CD16 (A), or amphotropic Env (B). 
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Discussion 
Lipid rafts have been shown to be important for proper lentivirus assembly and 
budding.  We hypothesized that lipid rafts compartmentalize host cell raft proteins, and 
protein incorporation into the lentiviral lipid bilayer is dependent upon colocalization with 
lentivirus-associated rafts.  To test this hypothesis, we studied the ability of two 
glycosylphosphatidylinositol (GPI) anchored proteins, folate receptor (FR-WT) and Tac-
CD16 (the interleukin-2 receptor alpha chain fused with the cytoplasmic domain of the 
GPI-anchored CD16 protein) to associate with viral proteins, Gag and amphotropic Env, 
in lipid rafts and lentivirus particles.  We examined the distribution of the GPI anchored 
proteins and virus proteins in whole cells, lipid rafts, and viral supernatant.  We found 
that Tac-CD16 and FR-WT exhibited the classic GPI anchored protein property of 
associating with lipid rafts, however Tac-CD16 colocalized with Gag and incorporated 
into lentiviral particles, while FR-WT did not colocalize with Gag and was not 
incorporated into virus particles.  In raft fractions separated by a linear sucrose gradient, 
FR-WT generally colocalized to less dense rafts while Gag and Env were localized to 
more dense rafts.  Tac-CD16 was also located to less dense rafts, but had a wider 
distribution in the linear gradient than FR-WT.  Most significantly, we found that when we 
treated producer cells with fumonisin B1 (FB1) or methyl-beta-cyclodextrin (MβCD), the 
amount of colocalization between FR-WT and Gag increased, FR-WT had a wider 
distribution in the linear raft gradient, and FR-WT was incorporated 2.9 to 11.6-fold more 
into lentiviral particles, respectively.  In contrast, the raft distribution of Tac-CD16 in the 
linear raft gradient decreased and the amount of Tac-CD16 in virus particles decreased 
2.4-fold with MβCD treatment.  Taken together, these results demonstrated lipid rafts 
segregate proteins, and for a protein to be incorporated into virus particles, it must be 
colocalized with lentivirus-associated rafts. 
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We also found folate receptor inhibited p24 localization to less dense rafts and 
proteins may compete with each other for space in lipid rafts.  The amount of p24 
detected in rafts when co-expressed with FR-WT was 5-fold less in linear gradients than 
when co-expressed with Tac-CD16. The presence of FR-WT inhibited Gag localization 
to rafts 3.8-fold (p<0.05) and virus release 1.2-fold (p>0.05), while the presence of Tac-
CD16 decreased Gag localization to rafts 2.5-fold (p>0.05) and increased virus release 
1.2-fold (p<0.05).  However, amphotropic Env raft distribution in a linear gradient and 
titers of Env pseudotyped lentiviruses were not affected when producer cells were co-
transfected with FR-WT, while Env raft distribution decreased and titers dropped 1.9-fold 
(p<0.05) when cells were co-transfected with Tac-CD16.  In general, FB1 or MβCD 
treatment of producer cells disrupted rafts but did not abolish rafts such that previously 
sequestered raft proteins were localized to lentivirus-associated rafts.  When cells were 
treated with FB1 or MβCD, the amount of p24 detected in rafts when co-expressed with 
FR-WT was only 2.6 to 3.5-fold less in linear gradients than when co-expressed with 
Tac-CD16.  In addition, FB1 or MβCD treatment increased virus production in FR-WT 
transfected cells 2.4 and 3.5-fold (both p<0.05), respectively, while virus production from 
Tac-CD16 transfected cells decreased about 1.2-fold.  Interestingly, MβCD treatment of 
producer cells decreased the amount of Tac-CD16 in rafts 1.1-fold and the amount in 
virus particles 2.4-fold, and also decreased the amount of Env in rafts 1.9-fold and the 
amount in virus particles 1.3-fold. 
Our results demonstrating lipid rafts compartmentalize raft proteins on the cell 
surface is consistent with literature on the heterogeneity of lipid rafts.  Previous work has 
shown the existence of distinct raft populations such as less dense and more dense rafts 
[61], Brij 98 or Triton X-100 isolated rafts [62], apical and basolateral rafts [63], and 
caveolae-positive and caveolae-negative rafts [64].  Indeed, raft markers such as Thy-1, 
Yes, and Lyn [62], Thy-1 and GM1 [65], and even GPI anchored proteins such as Thy-1 
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and prion protein [66], and folate receptor and PLAP [67], are located in different raft 
domains.  Raft-raft separation by detergent solubility and density, perhaps because of 
differences in content and ordered structure of proteins and lipids [2, 68], presumably 
allows for further separation of raft proteins based on functional diversity.  In this study, 
we chose to use the nonionic detergent Brij 98 at a concentration of 0.5%, since it has 
been shown to inhibit inter-mixing of raft proteins with each other and nonraft proteins 
[66], and populations of assembling, membrane-bound Gag (termed ‘barges’) was 
isolated using Brij 98, and not with Triton X-100 [68].   
The localization of Gag and GPI anchored proteins on linear raft gradients 
showed rafts may separate raft proteins based on their ability to localize to low or high 
density rafts, and that lentivirus-associated rafts were localized to high density rafts.  
This is consistent with literature that indicates lentiviruses assemble and bud from 
specific locations in the cell, even though the precise location still remains controversial.  
In 293T, a common producer cell type that was also used in this study, Gag either is 
targeted directly to the plasma membrane [69, 70], or first to multivesicular bodies and 
then transported to the plasma membrane [71].  Besides lipid rafts in general [25, 30, 72, 
73], tetraspanin-containing regions have also been implicated as assembly and budding 
sites [74-76], although rafts and tetraspanin-enriched domains have not yet been shown 
to be exclusive.  One apparent reason for lentivirus assembly and budding to occur in 
rafts is to further concentrate lentiviral proteins for proper assembly.  For proteins to be 
incorporated into lentivirus particles, they have to be localized to sites of assembly [77-
79].  These assembly sites must be specific to specific rafts since raft markers such as 
flotillin [22] and the GPI anchored protein CD14 [58, 59] are not incorporated into virus 
particles.  Indeed we and others have shown Gag is located in the more dense fractions 
[25], and in this study, we have shown proteins that were not in the dense fractions, like 
FR-WT, were not incorporated into virus particles.   
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Tac-CD16 and FR-WT may be used as probes to determine what affects virus 
assembly and incorporation into lentiviral particles.  Our data showed FR-WT had no 
effect on the distribution of amphotropic Env in linear raft fractions compared to Env 
alone, whereas Tac-CD16 seemed to decrease the amount of amphotropic Env in raft 
fractions compared to Env alone.  Env also decreased the amount of Tac-CD16 in rafts 
1.3-fold while the amount of FR-WT in rafts decreased 1.2-fold compared to Tac-CD16 
or FR-WT transfected alone.  While the amount of Env did not decrease in virus particles 
with the presence of GPI anchored proteins, the amount of Tac-CD16 decreased in virus 
particles 7.9-fold.  However titer of Env pseudotyped lentiviruses decreased 1.9-fold 
(p<0.05) when Tac-CD16 was expressed and was not significantly affected when FR-
WT was expressed.  Since amphotropic Env and Tac-CD16 overlapped in linear raft 
gradients while Env and FR-WT did not, these results suggested the composition of 
lentivirus-associated rafts may be altered by proteins and that Tac-CD16 and Env may 
compete with each other for space in lentivirus-associated rafts.  Since the degree of 
packing in lipid rafts depends on types and amounts of proteins and lipids [80], there is 
presumably limited space in rafts.  FR-WT probably had no effect on Env raft 
localization, virus incorporation, and titer since it was not localized with Env in lentivirus-
associated rafts and not incorporated in virus particles.  The reason the amount of 
amphotropic Env incorporated in virus particles was not affected by GPI anchored 
proteins may have been because Env was highly colocalized with Gag in the denser raft 
fractions.  However since Tac-CD16 was slightly colocalized with the denser raft 
fractions, the presence of amphotropic Env may have had a greater detrimental effect on 
Tac-CD16 incorporation.  Our data also showed that even though virus levels of 
amphotropic Env was not greatly decreased by the incorporation of Tac-CD16, titers 
were still significantly affected.  The small decrease in Env incorporated may have 
resulted in lower transduction efficiency [81-83], although this seemed unlikely since the 
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amount of Env detected was so high. It is also possible Tac-CD16 may be interfering 
with Env binding or fusion, or increasing the amount of uncleaved Env incorporated in 
virus particles [84]. 
Interestingly, our results also indicated FR-WT may inhibit Gag localization to 
less dense rafts and inhibit, but not abolish, budding.  We found the amount of p24 
detected in rafts when co-expressed with FR-WT was about 5-fold less on a linear raft 
gradient than when co-expressed with Tac-CD16.  Budding seemed to have decreased 
since the presence of FR-WT in producer cell inhibited release 1.2-fold (p>0.05) while 
the amount of Gag in whole cell lysates increased 1.4-fold (p<0.05).  Since viruses still 
continued to be released, this suggested FR-WT may have caused Gag to be 
redistributed and bud from non-lipid rafts, yet still retain infectivity.  However this may be 
unlikely since Gag oligomerization is dependent on rafts [85], and lentivirus and Env 
fusion depends on cholesterol levels [29, 86].  Alternatively, FR-WT may have 
strengthened compartmentalization of lentivirus-associated rafts, further restricting virus 
proteins to more dense raft fractions, and enabling viruses to still bud from the denser 
raft fractions while not affecting titer.  It was also interesting that FB1 and MβCD 
treatment increased the amount of virus that budded from FR-WT transfected cells 2.4 
and 1.5-fold, respectively.  In Tac-CD16 transfected and MβCD treated cells, the amount 
of virus budding decreased 1.2-fold, similar to MβCD-treated HIV and MLV producer 
cells [24, 86].  However an increase in particle production after MβCD-treatment was 
also seen in Newcastle disease virus [87], influenza [88], Sendai virus [89], and VSV M 
protein transfected cells [24]. 
Our data showed we were disturbing and not abolishing raft integrity with 0.5 mM 
MBCD or 50 µM FB1 since Tac-CD16, FR-WT, amphotropic Env, and even Gag were 
still present in raft extractions.  Previous studies that demonstrated MβCD permeabilized 
virus and disrupted rafts used 10 mM MβCD or higher concentrations [27, 29, 85].  In 
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addition, FB1 treatment may be affecting lipid raft integrity by reducing the amount of 
sphingolipids in the cell [90].  When MβCD or FB1 was added to producer cells, raft 
disturbance decreased the amount of proteins concentrated in the dense, lentivirus-
associated rafts since total raft amounts of Tac-CD16 decreased 1.1-fold and 
amphotropic Env decreased 1.9-fold, and Tac-CD16 was present in fewer high density 
fractions.  However, raft disruption increased the amount of colocalization and 
association of proteins sequestered to low density rafts, like FR-WT, with the more 
dense lentivirus-associated rafts such that a measurable amount of FR-WT was 
incorporated.  Others have shown cholesterol depletion with MβCD does not disrupt Gag 
association with rafts [91] or Gag targeting to the cell membrane [85], however it does 
reduce the efficiency of Gag oligomerization [85].  Taken together, our data suggested 
raft disruptions allowed previously sequestered raft protein to inter-mix and may have 
caused previously concentrated raft proteins to decrease in concentration.  Therefore, 
FB1 or MβCD treatment has more of a detrimental effect on virus incorporation of 
proteins already localized to lentivirus-associated rafts, and a positive effect on proteins 
that are not localized lentivirus-associated rafts. 
In addition to affecting lipid rafts, cholesterol sequestration or depletion may be 
affecting the trafficking of FR-WT, the only known transport protein anchored to GPI 
moiety [92].  We do not know how Tac-CD16 trafficking is affected since the Tac protein 
is a cell surface protein not normally GPI anchored, and as such, has its own trafficking 
signals.  MβCD and FB1 treatment noticeably increased the amount of FR-WT found in 
lipid rafts.  Lipid rafts are often involved in the internalization of cell signaling molecules 
[9], and others have demonstrated cholesterol depletion resulted in increased protein 
concentrations at the plasma membrane because of either reduced endocytosis and 
degradation [60, 93], or increased trafficking to the cell surface [94].  FB1 treatment can 
also alter the distribution of proteins in the cells since it inhibits sphingolipids synthesis 
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and sphingolipids can affect vesicular trafficking of proteins to the apical surface [90, 95, 
96].  Depletion of sphingolipids has been shown to enhance the rate of GPI anchored 
proteins trafficking to the plasma membrane from the recycling endosomes [97]. 
In conclusion, our results demonstrated lipid rafts segregate raft proteins, and for 
a protein to be incorporated into virus particles, it must be colocalized with lentivirus-
associated rafts.  Our data has demonstrated rafts may control the protein content of 
virus particles.  Future studies should focus on manipulating rafts to alter protein 
incorporation into viruses and virus function, and also investigating the effects of 
cholesterol depletion on protein trafficking, and perturbing the lipid rafts on other types of 
viruses for the incorporation of other difficult-to-incorporate proteins.   
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CHAPTER 5 
 
IMPROVING INTERACTIONS WITH GAG INCREASES INCORPORATION OF 
HUMAN PARAINFLUENZA TYPE 3 ENVELOPE PROTEINS 
 
  
 
5.1  Abstract 
We have previously shown HPIV3 pseudotyped lentiviruses had titers too low to 
be useful for clinical gene transfer since the envelope proteins, HN and F, were not 
efficiently incorporated into lentivirus particles.  We reasoned that incorporation was low 
because interactions between HN and F, or HN and F with lentiviral Gag were low.  We 
found that HN and F were colocalized with each other, however HN and F were not as 
colocalized with Gag or lipid rafts as amphotropic Env.  We then hypothesized that 
increasing interactions of HN and F with Gag would enhance their incorporation into 
lentiviral particles.  To test this hypothesis, we used two main approaches: 1) we created 
HN and HIV Env fusion proteins that would actively interact with Gag, and 2) we 
disrupted the barriers that prevented HN and F from passively interacting with Gag.  We 
found that when HN fusion proteins were created with portions of HIV gp41’s 
cytoplasmic domain, HN-mpr and HN-LLP2, colocalization of the HN chimeras with Gag 
increased slightly from unmodified HN.  The level of incorporation also increased 1.6-fold 
and 2.2-fold, respectively, however titers significantly decreased at least 25-fold.  We 
then determined whether increased colocalization with Gag was sufficient for envelope 
protein incorporation.  Previously we found small concentrations of methyl-beta-
cyclodextrin (MβCD) disturbed lipid rafts such that raft proteins segregated by lipid rafts 
could inter-mix with lentivirus-associated rafts and become incorporated into virus 
particles.  When lentiviruses pseudotyped with HPIV3 (HPIV3 LV) or amphotropic Env 
(Ampho LV) producer cells were treated with 0.5 mM MβCD for 54 hours after 
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transfection,  titers of HPIV3 LV increased 6.4-fold while titers of Ampho LV decreased 
3.6-fold.  When we analyzed the amount of envelope incorporation from MβCD treated 
producer cells, we found the amount of amphotropic Env in virus particles decreased 
3.0-fold while the amount of HN increased 1.4-fold.  This data suggested that increasing 
interactions of HPIV3 envelope proteins with Gag through active and passive 
interactions enhanced HN and F incorporation into lentiviral particles. 
 
5.2 Introduction 
Lentivirus vectors have the potential to be useful tools for tissue engineering, 
prevention of disease, and for treatment of inherited diseases, infectious diseases, and 
cancer [1-4].  They offer attractive properties such as permanent integration, ability to 
transduce non-dividing cells, and ability to alter their tropism and target specific cells 
through replacement of the wild-type envelope protein [5].  However, pseudotyping 
lentiviruses can be very challenging.  In the case of generating lentiviral vectors for 
respiratory diseases, many lung-tropic viruses including influenza, respiratory syncytial 
virus, Ross River virus, and Jaagsiekte sheep retrovirus [6-8], either do not pseudotype 
well, do not transduce polarized airway cells via their apical surfaces, or do not do so 
efficiently. 
In addition to viral proteins, lentiviruses incorporate many host cell proteins 
during the lentivirus assembly process [9-11].  However, not all proteins are included as 
some are specifically excluded such as CD45, flotillin, and CD14 [12-16].  Generally, 
proteins are incorporated into virus particles if there are direct interactions between the 
cytoplasmic domain of the protein with Gag, the lentivirus core protein, or passive 
interactions with Gag [12, 16-18].  The only requirements for passive incorporation are to 
be present at the site of lentiviral budding and to have a cytoplasmic domain that is not 
sterically incompatible with virus assembly [19].   
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The assembly and budding of lentiviruses is driven by the oligomerization of Gag 
[20].  In cell lines such as 293T, Gag either is targeted directly to the plasma membrane 
[21, 22], or first to multivesicular bodies and then transported to the plasma membrane 
[23].  Gag has been shown to use lipid rafts, plasma membrane subdomains enriched in 
cholesterol, sphingolipids, and glycosphingolipids, as sites of assembly and budding 
[24].  Besides lipid rafts in general [15, 25-27], tetraspanin-containing regions have also 
been implicated as assembly and budding sites [28-30] although rafts and tetraspanin-
enriched domains have not yet been shown to be exclusive.  
Previously, we have shown envelope proteins F and HN from human 
parainfluenza virus type 3 (HPIV3), a lung-tropic virus, can pseudotype lentiviruses and 
that these viruses can infect polarized cells via their apical surfaces [31].  However titers 
of HPIV3 pseudotyped lentiviruses are low mainly because too few envelope proteins 
are incorporated [32].  In this study, we tested the hypothesis that increasing interactions 
with Gag will enhance HN and F incorporation into lentiviral particles.  The implications 
of our findings for the generation of pseudotyped lentiviruses useful for clinical gene 
transfer are discussed. 
 
5.3 Materials and Methods 
Chemicals and antibodies.  Poly-L-lysine, 1,5-Dimethyl-1,5-
diazaundecamethylene polymethobromide (Polybrene), saponin, o-phenylenediamine 
dihydrochloride (OPD), methyl-β-cyclodextrin, gluteraldehyde, paraformaldehyde, and 5-
Bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) were purchased from Sigma 
Chemical (St. Louis, MO).  Complete mini protease inhibitor cocktail tablets were 
purchased from Roche Diagnostics (Indianapolis, IN).  Hydrogen peroxide 30%, Triton 
X-100, and polyoxyethylene 20-sorbitan monolaurate (Tween 20) were purchased from 
Fisher Scientific (Fair Lawn, NJ).  Coomassie Plus-200 protein assay reagent was 
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purchased from Pierce (Rockford, IL).  Nonfat dry milk (blotting grade) was purchased 
from Bio-Rad Laboratories (Hercules, CA).   
Goat polyclonal antibody to HIV-1 p24 was purchased from Advanced 
Biotechnologies Incorporated (Columbia, MD).  Mouse ascites monoclonal antibody 66/4 
and 170 against HPIV3-HN were generously provided by Judy Beeler (WHO Programme 
for Vaccine Development Reagent Bank for Respiratory Syncytial Virus and 
Parainfluenza Type 3).  Mouse monoclonal antibody against HPIV3 HN was purchased 
from Fitzgerald Industries International, Inc. (Concord, MA).  Mouse ascites monoclonal 
antibody c110 against HPIV3-F was generously provided by B.R. Murphy, Respiratory 
Viruses Section, NIAID, NIH (Bethesda, MD).  Goat polyclonal anti-gp70 (79S834) was 
purchased from Quality Biotech (Camden, NJ).  Mouse anti-gp70 antibodies were 
purified from the supernatant of the 83A25 hybridoma cell line [33] following standard 
procedures [34].  Cy2-conjugated, Cy-3 conjugated, and horseradish peroxidase (HRP)-
conjugated antibodies, and normal donkey serum were purchased from Jackson 
Immunoresearch Laboratories, Inc. (West Grove, PA). 
Cell culture.  293T/17 cells were maintained in Dulbecco’s modified essential 
medium (DMEM) supplemented with 10% heat inactivated fetal bovine serum (FBS), 
100 U/mL of penicillin, and 100 μg/mL streptomycin (HyClone Laboratories; Logan, UT).  
Vero cells were maintained in Minimum essential medium (Eagle) supplemented with 
10% fetal bovine serum, 100 U/mL of penicillin, and 100 μg/mL streptomycin.  Plates 
coated with poly-L-lysine were incubated for 5 min in the 0.01% solution (150-300 kDa), 
washed once with deionized water, and dried. 
HN Chimeras.  A pCAGGS derived expression plasmid (pCAGGS-HPIV3-HN-
mpr) encoding for the 43 amino acid gp41 cytoplasmic domain appended to HPIV3-HN 
with the structure 5’- ClaI site - reversed gp41 cytoplasmic domain – HN envelope 
protein – NheI site – 3’ was constructed as follows: (1) oligos encoding for  the reversed 
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sequence of the 43 amino acids after the gp41 transmembrane domain and restriction 
sites NheI and XbaI were mixed in equal amounts in STE buffer, heated to 940C in a 
PCR machine for 5 min, and the temperature lowered by 15 degrees every 5 min until 
40C.  The oligo sequences are as follows:  Gp41-mpr-top:  
CTAGCGTGTTACGAATTTCCAGAGACAGAGACAGAGAGGGAGGTGAAGAAGAAATA
GGAGAACCCAGGGACCCCGGAAGGCCGATCCCACTCCACACCCAGTTTTCGTTAC
CATCATATGGACAGAGGGTTAGAT, and gp41-mpr-bottom:    
CTAGATCTAACCCTCTGTCCATATGATGGTAACGAAAACTGGGTGTGGAGTGGGAT
CGGCCTTCCGGGGTCCCTGGGTTCTCCTATTTCTTCTTCACCTCCCTCTCTGTCTCT
GTCTCTGGAAATTCGTAACACG.  Samples were run on a 2% agarose gel, extracted, 
digested, and ligated into the NheI and XbaI sites in pcDNA3.1+/Neo vector (Invitrogen).  
(2) The pcDNA3.1 gp41-mpr sequences were then PCR amplified with primers 
gp41mprHN-gFOR: TAGGCGATCGATATGGTGTTACGAATTTCCAGAGAC and 
gp41mprHN-hREVsewg: TGGTATGCTTCCAGTATTCCATTCTAACCCTCTGTCCATA.  
(3)  The HN sequence from pCAGGS-HPIV3-HN was PCR amplified with primers 
gp41mprHN-gFORsewh: TATGGACAGAGGGTTAGAATGGAATACTGGAAGCATACCA 
and HN-REV: CATGGACGTCTCCAGCTCATTGCCAGC.  (4)  The PCR products of (2) 
and (3) were separated by agarose gel, extracted, and PCR amplified (75 ng each PCR 
product) with primers gp41mprHN-gFOR and HN-REV.  The final PCR product was 
digested with ClaI and NheI and ligated back into the pCAGGS backbone.  The 
sequence of pCAGGS-HPIV3-HN-mpr was verified by DNA sequencing. 
 Similarly, a pCAGGS derived expression plasmid (pCAGGS-HPIV3-HN-LLP2) 
encoding for the 31 amino acid alpha helix 2 of the gp41 cytoplasmic domain appended 
to HPIV3-HN with the structure 5’- ClaI site - reversed gp41 LLP2 cytoplasmic domain – 
HN envelope protein – NheI site – 3’ was constructed as follows: (1) oligos encoding for  
the reversed sequence of the 31 amino acids of the alpha helix 2 domain from the 
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cytoplasmic tail and restriction sites NheI and XbaI were mixed in equal amounts in STE 
buffer, heated to 940C in a PCR machine for 5 min, and the temperature lowered by 15 
degrees every 5 min until 40C.  The oligo sequences are as follows:  Gp41LLP2Rtop: 
CTAGCATCGATATGCTCGCCGAATGGGGGAGGCGCGGACTGCTTGAAGTGATTAG
GACGGTAATTTTGCTCTTAGACAGATTGCGCCACTACAGCTTCCTCTGCCTGT and  
GP41LLP2Rbot: 
CTAGACAGGCAGAGGAAGCTGTAGTGGCGCAATCTGTCTAAGAGCAAAATTACCGT
CCTAATCACTTCAAGCAGTCCGCGCCTCCCCCATTCGGCGAGCATATCGATG.  
Samples were run on a 2% agarose gel, extracted, digested, and ligated into the NheI 
and XbaI sites in pcDNA3.1+/Neo vector (Invitrogen).  (2) The pcDNA3.1 gp41-mpr 
sequences were then PCR amplified with primers gp41LLP2R-gFOR: 
ATATAATCGATATGCTCGCCGAATGGGGGAG and gp41LLP2R-hREVsewg: 
TATGCTTCCAGTATTCCATCAGGCAGAGGAAGCTGTA.  (3)  The HN sequence from 
pCAGGS-HPIV3-HN was PCR amplified with primers gp41LLP2R-gFORsewh: 
CTACAGCTTCCTCTGCCTGATGGAATACTGGAAGCATAC and HN-REV: 
CATGGACGTCTCCAGCTCATTGCCAGC.  (4)  The PCR products of (2) and (3) were 
separated by agarose gel, extracted, and PCR amplified (75 ng each PCR product) with 
primers gp41LLP2R-gFOR and HN-REV.  The final PCR product was digested with ClaI 
and NheI and ligated back into the pCAGGS backbone.  The sequence of pCAGGS-
HPIV3-HN-mpr was verified by DNA sequencing. 
Virus production.   Human parainfluenza virus type 3 (strain Wash/57/47885), 
obtained from the National Institute of Allergy and Infectious Disease (Bethesda, MD), 
was propagated on monolayers of Vero cells.  Lentiviruses pseudotyped with the 
amphotropic or human parainfluenza virus type 3 envelope proteins were produced by 
transfecting 293T/17 cells, seeded (1x107 per well) the previous day on poly-L-lysine 
coated plates with Lipofectamine 2000 (Invitrogen; Carlsbad, CA) and 6 μg of the 
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packaging construct pCMVΔR8.91 [35], 6 μg of the lentivirus vector pTYEFnlacZ or 
pTYEFeGFP (AIDS Research and Reference Reagent Program; Bethesda, MD), and 6 
μg of the amphotropic envelope protein expression plasmid pFB4070ASALF [36] or 6 μg 
each of the HPIV3 F and codon optimized HN envelope expression plasmids (i.e., 
pCAGGS-hPIV3-F and co-pCAGGS-hPIV3-HN, respectively).  The following day, 
producer cells may have been treated with 0.5 mM MβCD.  Viral supernatants were 
collected every 12 h from 48 to 60 h after transfection, filter sterilized (0.45 μm), and 
frozen (-80°C) for later use.  Viruses were concentrated by incubation with 320 μg/mL 
polybrene for 30 min at 370C and centrifuging at 10,000 g for 30 min at room 
temperature [37].  For cholesterol measurement, the Amplex red cholesterol assay kit 
(Invitrogen) was used according to manufacturer’s instructions.  Codon-optimization of 
HPIV3-HN was performed by GENEART, Inc (Toronto, Canada).  The cDNA was 
subcloned into the Cla I and Sph I sites of the pCAGGS.MCS expression vector [38] and 
the structure of the ligation sites was verified by DNA sequencing.  
Metabolic labeling.  To detect proteins in virus stocks and producer cells, cells 
were transfected as above with 6 μg  each of pCMVΔR8.91, pTYEFnlacZ, pCAGGS-
hPIV3-F, and either co-pCAGGS-hPIV3-HN, pCAGGS-hPIV3-HN-LLP2, or pCAGGS-
hPIV3-HN-mpr for twenty-four hours.  Cells were then incubated with methionine and 
cysteine-free DMEM for 15 min at 37°C and radiolabeled for 16 h at 37°C with 500 μCi of 
[35S]methionine-cysteine protein labeling mix (GE Healthcare; Piscataway, NJ).  Virus 
samples were obtained by ultracentrifugation of the viral supernatants in a SW41Ti 
Beckman rotor (150,000 x g, 2 h, 4°C) through a 20% sucrose cushion after which the 
pellets were resuspended in RIPA buffer (50 mM Tris- HCl [pH 7.6], 150 mM NaCl, 0.5% 
Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, and protease inhibitors) for 30 min 
at 25°C.  The proteins were separated by size by SDS-PAGE (4-15%), and then the gel 
dried (72°C for 45 min) and visualized by autoradiography (Bio-Max MR film; Amersham; 
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Piscataway, NJ).  To quantitatively compare the amount of protein that was visualized as 
bands on the film, we used ImageJ to measure the band area and intensity and 
compared the product of the two values.  We also compared the amount of radioactivity 
that was in the bands.  We cut out the bands from the gels as slices, brought their 
volume to 3 mL with Ecoscint A scintillation cocktail (National Diagnostics, Atlanta, GA), 
and used a scintillation counter (Tricarb 2900TR; Perkin Elmer) to quantify the amount of 
35S in the samples. 
Indirect immunofluorescence.  To detect the presence of Gag and surface 
proteins, cells were seeded (1x105 per well) the previous day on poly-L-lysine coated 12-
well plates containing coverslips (no. 1.5, 12 mm, Fisher Scientific; Suwanee, GA).  Cells 
were then transfected with Polyfect (Qiagen, Valencia, CA) according to manufacturer’s 
instructions.  The next day cells were incubated with 4% paraformaldehyde (0.5 mL/well) 
for 15 min and then blocked with PBS/sera (0.5 mL/well) (5% donkey sera in PBS) for 10 
min.  Cells were then incubated with primary antibody for 1 hour at room temperature in 
PBS/sera/0.2% saponin (1:500), washed 3 times with PBS, incubated with the 
secondary antibody for 1 hour at room temperature in PBS/sera/0.2% saponin (1:500), 
and then washed three times with PBS and once with distilled water.  Some cells were 
immunostained (1:250 in PBS/sera/0.2% saponin) with 488-conjugated anti-F (c110) or 
anti-HN (170) antibodies labeled with DyLight antibody labeling kit according to 
manufacturer’s instructions (Rockford, IL).  Cells also may or may not have been labeled 
with 5 μg/mL A594-conjugated cholera toxin B subunit in PBS for 1 hour (Invitrogen) and 
washed three times.  Coverslips were mounted on glass slides with gelvatol [39] at 40C.  
The next day cells were visualized by confocal microscopy at 63X.  For each condition, 
eight cells were chosen at random and extent of colocalization was quantified by 
calculating the Pearson’s overlap coefficient with ImageJ [40]and the Colocalisation 
Threshold plugin (Tony Collins, Wayne Rasband, and Kevin Baler).  This calculation is 
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based on the overlap of red and green pixels, with a high degree of overlap 
corresponding to a value of 1 and a low degree of overlap corresponding to a value of 0 
[41].  Coefficients for eight separate cells were averaged and statistical significance was 
determined. 
Immunoblotting and lipid raft isolation.  To detect wild-type HN in raft 
samples, 293T/17 cells, seeded (1x107 per well) the previous day on poly-L-lysine 
coated plates, were infected with wild-type HPIV3 at an MOI of 1.  Cells were then 
pelleted with versene (PBS and 5 mM EDTA pH 7.5) and resuspended in 1 mL of ice-
cold 1% Triton X-10 in TNE buffer (25 mM Tris-base, 0.15 M sodium chloride, 5 M 
EDTA, pH 7.5).  Lysates were dounce homogenized, adjusted to 40% sucrose by adding 
an equal volume of 80% sucrose in TNE buffer and placed in ultracentrifuge tubes.  
Samples were then overlaid with 5 mL of ice-cold 38% sucrose in TNE followed by 4 mL 
of ice-cold 5% sucrose in TNE and centrifuged at 30,000 rpm for 15 hours at 40C in an 
SW41 rotor (Beckman Coulter, Palo Alto, CA).  The proteins at the interface of the 5% 
and 30% sucrose solutions was isolated, mixed with ice-cold TNE buffer, and then 
centrifuged at 30,000 rpm for 1 hour at 40C in a SW41.  The pelleted lipid raft fraction 
was resuspended in 100 µL of TNE buffer.  Equal amounts of protein from each sample 
were combined 1:2 (v/v) with sample buffer containing 5% β-mercaptoethanol (both from 
Bio-Rad; Hercules, CA), vortexed, boiled for 5 min, separated by size by SDS-PAGE (4-
20% Tris-HCl gel, Bio-Rad), and transferred to a PVDF membrane (0.2 μm, Bio-Rad).  
To probe for HN in the membrane, mouse monoclonal antibody against HN was diluted 
1:1000 in blocking buffer (5% nonfat milk in PBS with 0.1% Tween 20) and bound IgG 
was detected by incubation with HRP-conjugated donkey anti-mouse (diluted 1:400,000 
in blocking buffer), and detected with a chemiluminescent detection system (Super 
Signal West Femto kit; Pierce).  To probe for amphotropic Env, amphotropic Env 
pseudotyped lentivirus was generated as before.  Virus samples were obtained by 
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ultracentrifugation of the viral supernatants in a SW41Ti Beckman rotor (150,000 x g, 2 
h, 4°C) through a 20% sucrose cushion after which the pellets were resuspended in 
RIPA buffer.  The proteins were separated by size by SDS-PAGE (4-15%), transferred to 
a PVDF membrane, and blotted as described previously.  For detection, goat anti-gp70 
antibody 79S834 was diluted 1:1000 in blocking buffer followed by HRP-conjugated 
donkey anti-goat (1:400,000 in blocking buffer).  To quantitatively compare the amount 
of protein that was visualized as bands on the film, we used ImageJ to measure the 
band area and intensity and compared the product of the two values. 
p24 ELISA.  We used p24 ELISA to quantitatively compare the amount p24 viral 
supernatant.  ELISA plates (Nunc immuno Maxisorp 96-well plates, Nalgene Nunc 
International, Rochester, NY) were coated overnight at 370C with 1:800 dilution of mouse 
anti-p24 antibody 183-H12-5C (100 μL/well) in PBS.  The next day, the antibody solution 
was removed and wells were washed twice (PBS, 0.05% Tween-20).  Blocking buffer 
(PBS, 0.05% Tween-20, 5% non-fat milk) was added at 200 μL/well for 1 hour at 370C 
and removed.  Samples were lysed in 2% Triton X-100 1:1 and added to the ELISA plate 
(100 μL/well), and incubated for 2 hours at 370C.  Bound p24 was sandwiched by the 
addition of the sheep polyclonal anti-p24 antisera diluted 1:250 in blocking buffer, and 
incubated for 2 hours at 370C.  The HRP-conjugated anti-sheep secondary antibody was 
diluted 1:1000 in blocking buffer and added to the ELISA plate (100 μL/well) for 1 hour at 
370C.  Plates were then developed for 20 min using a solution (100 μL/well) of 3 mg of 
OPD, 3 μL hydrogen peroxide, 7.5 mL substrate buffer (24 mM citric acid-monohydrate, 
51 mM Na2HPO4*7H2O, pH 5.0).  8N sulfuric acid (50 μL/well) was used to stop the 
reaction and the optical density at 490 nm was measured using an absorbance plate 
reader (non-specific background at 650 nm was subtracted).  Values for each point are 
the average of at least triplicate wells. 
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Transduction.  293T cells were seeded in poly-L-lysine coated 12-well plates 
(1x105 cells per well) and incubated at 37°C. The next day, viral supernatant dilutions 
were incubated with cells for 48 h, after which the cells were fixed with gluteraldehyde 
and stained for β-galactosidase activity with X-Gal, and the number of lacZ+ colony-
forming units (CFU) per milliliter was counted.   
Statistics.  Data are summarized as the mean ± the standard deviation for at 
least triplicate samples.  Statistical analysis was performed using one-way analysis of 
variance for repeated measurements of the same variable.  The Tukey multiple 
comparison test was used to conduct pairwise comparisons between means.  
Differences at p < 0.05 were considered statistically significant. 
 
5.4 Results 
We have previously shown that lentiviruses incorporated too few HPIV3 envelope 
proteins (HN and F) for high transduction efficiency [32].  We reasoned that 
incorporation was low because interactions between HN and F, or HN and F with 
lentiviral Gag were low.  To determine whether HN and F could interact in producer 293T 
cells, we analyzed the amount of colocalization between the envelope proteins.  We 
transfected 1x105 293T cells on glass coverslips with plasmids encoding for HPIV3-F 
and HPIV3-HN.  The next day cells were fixed, permeabilized, and immunostained with 
a mouse monoclonal antibody against F (c110) followed by a Cy3-conjguated secondary 
antibody, and a mouse monoclonal antibody against HN (170) conjugated to A488 
(Figure 5.1).  Cells were visualized by confocal microscopy and the extent of 
colocalization between F and HN was quantified by calculating the Pearson’s overlap 
coefficient.  We found a high degree of colocalization between F and HN as shown by 
the overlapping of corresponding red and green pixels producing a yellow color, and also 
shown by the high Pearson’s coefficient number (0.88 ± 0.031).  This indicated HN and  
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B. 
 
0.88 ± 0.031  
Figure 5.1.  HPIV3-F and HPIV3-HN colocalize with each other.  293T cells were 
transiently transfected to express HPIV3-F and HPIV3-HN (A).  As a control, cells were 
not transfected (B).  Cells were fixed, permeabilized, and immunostained with a mouse 
monoclonal antibody (c110) against F followed by donkey anti-mouse Cy3 conjugated 
secondary antibody, and then a mouse monoclonal antibody (170) against HN 
conjugated to A488.  Cells were visualized with confocal microscopy at 63X and 
overlays of F (red) and HN (green) are shown.  Eight cells were chosen at random and 
extent of colocalization between F and HN was quantified with ImageJ.     
 
 
 
 
Figure 5.2.  HPIV3-F and HPIV3-HN are not highly colocalized with Gag. 293T cells 
were transiently transfected to express HIV-1 Gag-Pol (Gag) and either amphotropic Env 
(Ampho) or HPIV3-F (F) and HPIV3-HN (HN).  Cells were fixed, permeabilized, and 
immunostained with a mouse monoclonal antibody against Gag, followed by donkey 
anti-mouse Cy3 conjugated secondary antibody.  Corresponding cells were also stained 
with a rat antibody against amphotropic Env (83A25) followed by donkey anti-rat Cy2 
conjugated secondary antibody, or a mouse monoclonal antibody against HN (170) or F 
(b108) conjugated to A488.  Cells were visualized with confocal microscopy at 63X and 
overlays of Gag (red) with Ampho, F, or HN (green) are shown.  Eight cells were chosen 
at random and extent of colocalization was quantified with ImageJ.  Statistically 
significant differences (P<0.05) in colocalization values between Ampho and F or HN 
colocalized with Gag are denoted with *.   
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F can interact with each other and can together be incorporated into a budding lentiviral 
particle since they are located in the same area. 
To determine whether HN and F could interact with Gag in HPIV3-lentivirus 
producer cells, we analyzed the amount of colocalization between the proteins.  293T 
cells (1x105) on coverslips were transiently transfected to express HIV-1 Gag-Pol (Gag), 
HPIV3-F (F), and HPIV3-HN (HN).  Cells were fixed, permeabilized, and immunostained 
with a mouse monoclonal antibody against Gag, followed by a Cy3 conjugated 
secondary antibody.  Corresponding cells were also stained with a rat antibody against 
amphotropic Env followed by an anti-rat Cy2-conjugated secondary antibody, or a 
mouse monoclonal antibody against HN or F conjugated to A488.  Cells were visualized 
by confocal microscopy and the extent of colocalization was quantified by calculating the 
Pearson’s overlap coefficient with ImageJ (Figure 5.2).  As a positive control, cells were 
also transfected and stained for Gag and the amphotropic Env, which is highly 
incorporated into lentiviral particles [42].  As expected, amphotropic Env was strongly 
colocalized with Gag (0.87 ± 0.042).  Interestingly, F and HN were less colocalized with 
Gag (0.78 ± 0.13 (p>0.05) and 0.67 ± 0.083 (p<0.05), respectively) than amphotropic 
Env was, particularly HN.  This strongly suggested the reason for low incorporation of 
HN and F was the lack of available interaction with Gag. 
Since HN was the least colocalized with Gag, we constructed two chimeric HN 
proteins modified with sequences from the cytoplasmic domain of the HIV-1 glycoprotein 
gp41 to examine the effects of increasing interactions with Gag (Figure 5.3).  The N-
terminal cytoplasmic domain of HN was attached to the inverted 31 amino acid 
sequence of the gp41 helix2 (HN-LLP2) or the inverted sequence of the first 43 amino 
acids of the gp41 cytoplasmic tail (HN-mpr), which have both been shown to interact 
with HIV-1 matrix and the plasma membrane [43] [44-46].  To see if the chimeric HN 
proteins interacted more with Gag, 293T cells were transfected with plasmids expressing  
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Figure 5.3.  Schematic diagram of HN chimeras.  Schematic diagrams of the structure of 
wild-type HIV gp160 envelope protein, wild-type HPIV3-HN envelope protein, and 
chimeras HN-mpr and HN-LLP2 are shown.  The positions of some of the functional 
regions are indicated: CD, cytoplasmic domain;  TMD, transmembrane domain; Ecto, 
ectodomain; mpr, transmembrane proximal region; LLP2, LLP2 region;  N, N-terminus;  
C, C-terminus. 
 
 
 
 
 
 
Figure 5.4.  HN chimeras demonstrate increased colocalization with Gag.  293T cells 
were transiently transfected to express HIV-1 Gag-pol (Gag), HPIV3-F, and either HN-
mpr or HN-LLP2.  Cells were fixed, permeabilized, and immunostained with a mouse 
monoclonal antibody against Gag, followed by donkey anti-mouse Cy3 conjugated 
secondary antibody.  Cells were also stained with a mouse monoclonal antibody against 
HN (170) conjugated to A488.  Cells were visualized with confocal microscopy at 63X 
and overlays of Gag (red) with HN chimeras(green) are shown.  Eight cells were chosen 
at random and extent of colocalization was quantified with ImageJ.   
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Gag-Pol and either HN-LLP2 or HN-mpr.  The next day cells were fixed, permeabilized, 
and stained with a mouse monoclonal antibody against Gag, followed by an anti-mouse 
Cy3-conjugated secondary antibody, and also a monoclonal antibody against HN 
conjugated to A488.  Cells were visualized by confocal microscopy and the extent of 
colocalization was quantified by calculating the Pearson’s overlap coefficient with 
ImageJ (Figure 5.4).  The amount of colocalization between the HN chimeras and Gag 
increased slightly (HN-LLP2 with Gag was 0.81 ± 0.071, p=0.06, and HN-mpr with Gag 
was 0.71 ± 0.09, p=0.21). 
We next measured the amount of HN-LLP2 or HN-mpr incorporated into lentiviral 
particles.  293T cells (1x107) were transfected with expression plasmids for β-
galactosidase, HIV-1 Gag-Pol, HPIV3-F, and either HPIV3-HN, HN-LLP2, or HN-mpr.  
The next day, cells were metabolically-labeled with 500 µCi [35S] methionine and 
cysteine for 18 h, after which culture supernatant were harvested, ultracentrifuged 
through a 20% sucrose cushion, and then resuspended in PBS to 100-fold their original 
concentration.  Samples were then separated by size by SDS-PAGE, and then the gel 
dried and visualized by autoradiography (Figure 5.5).  We found that incorporating 
sequences from the gp41 cytoplasmic tail increased the amount of the HN incorporated 
into lentiviral particles.  To quantify the amount of HN in each sample, we excised the 
bands that contained HN from the gel, measured their radioactivity with a scintillation 
counter, and normalized the amount to radioactive p24.  We found that HN-mpr was 
incorporated into lentiviral particles 1.6-fold more, and HN-LLP2 was incorporated 2.2-
fold more than unmodified HN. 
To determine whether the HN chimeras were functional in lentiviral particles, we 
generated viruses as before and used them to transduce target cells in a diluted titer 
assay.  We also measured the amount of particles produced (Table 5.1).  We found that 
producer cells transfected with the HN chimeras produced less virus particles, and those  
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Figure 5.5.  The number of envelope proteins incorporated by lentiviruses are higher 
with HN chimeras than normal HN.  293T cells (1x107) were transfected with expression 
plasmids (6 µg each) for β-galactosidase, HIV-1 Gag-Pol, HPIV3-F, and either HPIV3-
HN (Lane 2), HN-LLP2 (Lane 3), or HN-mpr (Lane 4).  The next day, cells were serum-
starved for 15 min, metabolically-labeled with 500 µCi [35S] methionine and cysteine for 
18 h, after which culture supernatant were harvested, ultracentrifuged through a 20% 
sucrose cushion, and then resuspended in PBS to 100-fold their original concentration.  
Samples were resuspended in lysis buffer, separated by size by SDS-PAGE, and then 
the gel dried and visualized by autoradiography. 
   
 
 
 
 
 
 
 
Table 5.1.  Lentivirus titers of HN chimeras and F.   
    
Pseudotype Titer (CFU/mL)a p24 Amount 
(OD490-650)b 
Normalized Titer 
    
    
HN+F LV 2.7 (± 0.52) x 103 0.30 ± 0.028 9.2 (± 2.0) x 103 
HN-mpr + F LV 8.3 (± 2.8) x 101 0.19 ± 0.005 4.4 (± 1.5) x 102 
HN-LLP2 + F LV 5.0 (± 1.0) x 100 0.17 ± 0.012 3.0 (± 0.63) x 101 
    
Lentiviruses pseudotyped with HN and F (HN+F LV), HN-mpr and F (HN-mpr +F LV), or 
HN-LLP2 and F (HN-LLP2 + F LV) were used to transduce 293T cells.  Titer of alentiviral 
pseudotypes (CFU/mL) and bp24 levels (OD490-650) represent the mean of experimental 
values +/- standard deviation.  Normalized titer was obtained by normalizing titer to 
corresponding p24 amount. 
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virus particles were very inefficient at transducing cells.  When titer was normalized by 
the amount of p24 produced, viruses containing HN-mpr was 20-fold less efficient than 
viruses containing normal HN, and viruses containing HN-LLP2 was 300-fold less 
efficient. 
Because appending gp41 sequences to the HN chimeras may have altered the 
structure and subsequent binding and/or fusion activation function of HN, we 
investigated other less disruptive methods of increasing associations of Gag with HPIV3 
envelope proteins.  Since the above data suggested HN and F did not localize with Gag, 
we wanted to further characterize the location of HN in the cell.  Gag has been shown to 
be localized to and bud out of lipid rafts in the cell [47].  To determine whether HN was 
localized to lipid rafts or merely present, we infected 293T cells with wild-type HPIV3 at 
an MOI of 1.  Cells were then lysed with ice-cold Triton X-100 and subject to equilibrium 
flotation centrifugation.  Detergent resistant membranes were isolated, pelleted, and 
analyzed by Western blot for the presence of HN (Figure 5.6).  Wild-type infected HN did 
not appear to be enriched in lipid rafts although it was present in rafts. 
In our previous chapter, Chapter 4, we showed lipid rafts segregated raft 
proteins, and for a protein to be incorporated into virus particles, it must be colocalized 
with lentivirus-associated rafts.  We also showed we were able to disturb the integrity of 
lipid rafts with the cholesterol extracting compound, methyl-beta-cycodextrin (MβCD), 
such that raft proteins segregated away from lentivirus-associated rafts were associated 
with lentivirus proteins and incorporated into lentiviral particles.  We investigated whether 
MβCD would increase the presence of HN or F with lipid rafts.  293T cells were plated 
on coverslips and transiently transfected to express HIV-1 Gag-Pol, HPIV3-F, and 
HPIV3-HN.  As a control, some cells were transfected with Gag-Pol and amphotropic 
Env.  Cells were then exposed to the presence or absence of 0.5 mM MβCD, and 24 
hours later, fixed, permeabilized, and stained for lipid rafts with A549-conjugated cholera  
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Figure 5.6.  Wild-type HN are present but not concentrated in lipid rafts.  Lipid rafts were 
isolated from 293T cells infected with wild-type HPIV3 at an MOI of 1.  Cells were lysed 
with ice-cold Triton X-100 (1% in TNE) and subjected to equilibrium flotation 
centrifugation.  The lipid raft fraction (Lane 2) was isolated and pelleted by 
ultracentrifugation and then analyzed by Western blot for the presence of HN.  As a 
control, the whole cell lysate of the cells (Lane 3) was also analyzed for HN. 
 
 
 
 
Figure 5.7.  Lipid raft disruption with MβCD increases colocalization of F and HN with 
lipid raft marker.  293T cells were transiently transfected to express HIV-1 Gag-Pol 
(Gag), amphotropic Env (Ampho), or HPIV3-F (F) and HPIV3-HN (HN) in the presence 
(bottom row) or absence (top row) of 0.5 mM MβCD.  Cells were fixed, permeabilized, 
and immunostained with a mouse monoclonal antibody against Gag followed by a 
donkey anti-mouse Cy2 conjugated secondary antibody, a rat antibody against 
amphotropic Env (83A25) followed by a donkey anti-rat Cy2 conjugated secondary 
antibody, or a mouse monoclonal antibody against HN (170) or F (b108) conjugated to 
A488.  Cells were then incubated with 5 µg/mL A549 conjugated cholera toxin B subunit 
(CTB).  Cells were visualized with confocal microscopy at 63X and overlays of CTB (red) 
with Gag, Ampho, F, or HN (green) are shown.  Eight cells were chosen at random and 
extent of colocalization was quantified with ImageJ.  Statistically significant differences 
(P<0.05) in colocalization values between Gag with CTB and Gag with CTB in the 
presence of MβCD are denoted with *. 
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toxin B subunit.  Cells were also immunostained with a corresponding antibody against 
Gag followed by Cy2 secondary antibody, amphotropic Env followed by a Cy2 
secondary antibody, or A488-conjugated F antibody, or A488-conjugated HN antibody.  
Cells were visualized by confocal microscopy and the extent of colocalization was 
quantified by calculating the Pearson’s overlap coefficient with ImageJ (Figure 5.7).  As 
expected, Amphotropic Env and Gag was highly colocalized with the lipid raft marker 
(0.92 ± 0.021 and 0.90 ± 0.065, respectively) while F and HN were significantly not as 
colocalized with lipid raft marker (0.75 ± 0.071 and 0.64 ± 0.13, respectively, p<0.05 for 
both).  Treatment with MβCD significantly decreased the amount of Gag associated with 
the lipid raft marker (0.72 ± 0.065), while it increased the amount of F and HN 
associated with the raft marker, although not significantly (0.87 ± 0.050 and 0.75 ± 
0.058, respectively). 
We next determined whether MβCD treatment affected the production of virus 
particles from producer cells and whether it had an impact on the amount of cholesterol 
in virus particles.  293T cells were transfected with expression plasmids for β-
galactosidase, HIV-1 Gag-Pol, and either amphotropic Env or HPIV3-F and HPIV3-HN.  
Producer cells were then incubated in the presence or absence of 0.5 mM MβCD for 30 
and 54 hours before viral supernatant was harvested, pelleted and resuspended in PBS, 
and analyzed for p24 content and cholesterol levels (Figure 5.8).  In the presence of 
MβCD, the production of amphotropic pseudotyped lentiviruses increased 1.6-fold 
(p<0.05) however the amount of HPIV3 pseudotyped lentiviruses produced did not 
significantly change.  When analyzing cholesterol content however, the amount of 
cholesterol in amphotropic pseudotyped lentiviruses decreased 1.4-fold (p>0.05) while 
the amount in HPIV3 pseudotyped lentiviruses increased 1.5-fold (p>0.05). 
Since 0.5 mM MβCD treatment did not appear to drastically alter the production 
or cholesterol content of viruses, we next determined the transduction efficiency of  
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Figure 5.8.  Virus production of pseudotyped lentiviruses increase with MβCD while 
cholesterol content in Ampho/LV decreases and HPIV3/LV increases.  293T cells 
(1x107) were transfected with expression plasmids (6 µg each) for β-galactosidase, HIV-
1 Gag-Pol, and either amphotropic Env (white bars) or HPIV3-F and HPIV3-HN (black 
bars).  The next day, cells were incubated in the presence or absence of 0.5 mM MβCD.  
Viral laden supernatant were harvested 30 and 54 hours after addition of MβCD, pelleted 
with 320 µg/mL polybrene and resuspended in PBS to the original volume.  The 
concentration of 54-hour virus was determined with the p24 ELISA and the cholesterol 
content was determined with a cholesterol kit.  * denotes statistically significant 
difference (P<0.05) in amphotropic lentivirus production in the presence or absence of 
MβCD treatment. 
 
 
 
viruses produced from MβCD-treated cells (Figure 5.9).  In the first 30 hours of MβCD 
treatment, the titer of amphotropic pseudotyped lentiviruses decreased 2.3-fold (p<0.05).  
After an additional 24 hours of treatment, the titer decreased 3.6-fold (p<0.05) compared 
to untreated producer cells.  Interestingly, the first 30 hours of MβCD treatment did not 
alter the titer of HPIV3 pseudotyped lentiviruses, however 24 additional hours of MβCD 
treatment increased titer 6.4-fold (p<0.05) compared to untreated producer cells. 
Finally we wanted to determine whether or not this effect on titers was due to the 
amount of envelope protein incorporated into viruses from MβCD-treated producer cells.  
293T cells (1x107) were transfected with expression plasmids (6 µg each) for β-
galactosidase, HIV-1 Gag-Pol, and either amphotropic Env or HPIV3-F and HPIV3-HN.  
The next day cells were incubated in the presence or absence of 0.5 mM MβCD.  HPIV3 
pseudotyped lentiviral producer cells were also serum-starved for 15 min, metabolically-  
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Figure 5.9.  Amphotropic pseudotyped lentiviral titer decreases with MβCD treatment 
and HPIV3 pseudotyped lentiviral titer increases with MβCD treatment.  293T cells 
(1x107) were transfected with expression plasmids (6 µg each) for β-galactosidase, HIV-
1 Gag-Pol, and either amphotropic Env (Part A, Part C white bars) or HPIV3-F and 
HPIV3-HN (Part B, Part C black bars).  The next day, cells were incubated in the 
presence or absence of 0.5 mM MβCD.  Viral laden supernatant were harvested 30 
(Parts A and B, white bars) and 54 (Parts A and B, black bars, and Part C whole graph) 
hours after addition of MβCD, pelleted with 320 µg/mL polybrene and resuspended in 
PBS to the original volume.  Viruses were used to transduce target cells in the diluted 
titer assay.  The transduced cells were incubated for 2 days at 370C until confluent, 
fixed, and stained for lacZ activity with X-Gal, colonies of lacZ+ cells were counted, and 
the titer normalized to p24 amounts.  * and ∆ denote statistically significant differences 
(P<0.05) in normalized titer of viruses produced in the presence or absence of MβCD 
treatment. 
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Figure 5.10.  Amphotropic pseudotyped lentiviruses produced in the presence of MβCD 
contain fewer envelope proteins while HPIV3 pseudotyped lentiviruses incorporate more 
envelope proteins.  293T cells (1x107) were transfected with expression plasmids (6 µg 
each) for β-galactosidase, HIV-1 Gag-Pol, and either amphotropic Env (Ampho) (A), or 
HPIV3-F and HPIV3-HN (B).  The next day, cells were incubated with 0.5 mM MβCD for 
54 hours (Part A and B, Lane 3) and as a control cells were not treated (Part A and B, 
Lane 2).  HPIV3 pseudotyped lentivirus producer cells were also serum-starved for 15 
min, and metabolically-labeled with 500 µCi [35S] methionine and cysteine.  Both 
pseudotyped viruses were harvested and ultracentrifuged through a 20% sucrose 
cushion, and then resuspended in PBS to 100-fold their original concentration.  Samples 
were resuspended in lysis buffer and separated by size by SDS-PAGE.  Amphotropic 
pseudotyped lentiviruses were analyzed by Western blot for the amphotropic envelope 
protein.  The gel for HPIV3 pseudotyped lentiviruses was dried and visualized by 
autoradiography. 
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labeled with 500 µCi [35S] methionine and cysteine.  Tissue culture supernatant were 
harvested for both viruses, ultracentrifuged through a 20% sucrose cushion, and then 
resuspended in PBS to 100-fold their original concentration.  Amphotropic pseudotyped 
lentiviruses were analyzed by Western blot for the amphotropic envelope protein and the 
gel for HPIV3 pseudotyped lentiviruses was dried and visualized by autoradiography 
(Figure 5.10).  When producer cells were treated with 0.5 mM MβCD, less amphotropic 
envelope protein was incorporated into lentiviral particles, however more HN and F 
proteins were incorporated.  Using ImageJ, we found the amount of amphotropic 
envelope protein in lentiviral particles produced from 0.5 mM-treated producer cells was 
3-fold less than amphotropic pseudotyped viruses from untreated producer cells.   To 
quantify the amount of HN from virus particles, we excised the bands that contained HN 
from the gel, measured their radioactivity with a scintillation counter, and normalized the 
amount to radioactive p24.  We found that 1.4-fold more HN was incorporated into 
lentiviral particles produced from cells treated with 0.5 mM MβCD than untreated 
producer cells.  
 
5.5 Discussion 
We have previously shown HPIV3 pseudotyped lentiviruses had titers too low to 
be useful for clinical gene transfer since the envelope proteins, HN and F, were not 
efficiently incorporated into lentivirus particles.  We reasoned that incorporation was low 
because interactions between HN and F, or HN and F with lentiviral Gag were low.  We 
found that HN and F were colocalized with each other, however HN and F were not as 
colocalized with Gag or lipid rafts as amphotropic Env.  We then hypothesized that 
increasing interactions of HN and F with Gag would enhance their incorporation into 
lentiviral particles.  To test this hypothesis, we used two main approaches: 1) we created 
HN and HIV Env fusion proteins that would actively interact with Gag, and 2) we 
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disrupted the barriers that prevented HN and F from passively interacting with Gag.  We 
found that when HN fusion proteins were created with portions of HIV gp41’s 
cytoplasmic domain, HN-mpr and HN-LLP2, colocalization of the HN chimeras with Gag 
increased slightly from unmodified HN.  The level of incorporation also increased 1.6-fold 
and 2.2-fold, respectively, however titers significantly decreased at least 25-fold.  We 
then determined whether increased colocalization with Gag was sufficient for envelope 
protein incorporation.  Previously we found small concentrations of methyl-beta-
cyclodextrin (MβCD) disturbed lipid rafts such that raft proteins segregated by lipid rafts 
could inter-mix with lentivirus-associated rafts and become incorporated into virus 
particles.  When lentiviruses pseudotyped with HPIV3 (HPIV3 LV) or amphotropic Env 
(Ampho LV) producer cells were treated with 0.5 mM MβCD for 54 hours after 
transfection,  titers of HPIV3 LV increased 6.4-fold while titers of Ampho LV decreased 
3.6-fold.  When we analyzed the amount of envelope incorporation from MβCD treated 
producer cells, we found the amount of amphotropic Env in virus particles decreased 
3.0-fold while the amount of HN increased 1.4-fold.  This data suggested that increasing 
interactions of HPIV3 envelope proteins with Gag through active and passive 
interactions enhanced HN and F incorporation into lentiviral particles. 
Our observation that HN and F did not colocalize with Gag, was consistent with 
our previous results that low titer was due to low efficiency of envelope incorporation and 
not poor expression of the envelope proteins [32].  Whether or not a protein is 
incorporated into a lentivirus particle is largely dictated by whether or not a protein is 
colocalized with the virus when it assembles and buds from the cell [17, 18, 48].  
Previous work suggested HPIV3 Env and lentiviruses do not share a common 
intracellular trafficking pathway [49, 50], and HPIV3 has not been shown associated with 
multivesicular bodies and recycling endosomes as Gag has [12, 51, 52].   
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We therefore attempted to increase interactions of F and HN with Gag.  Most 
proteins present on the surface of lentiviruses are incorporated passively when they 
localize to the site of budding [9-11].  Lipid rafts have been implicated as sites of 
lentivirus budding and assembly [15, 25-27].  Previous work has suggested the 
possibility of HPIV3 F and HN interaction with lipid rafts, for example the closely-related 
Sendai virus has been shown to incorporate the lipid raft marker GM1 [48], and measles 
virus H and F glycoproteins associate with lipid rafts (30% and 10%, respectively) [53].  
In addition, the neuraminidase glycoprotein from influenza, a Type II transmembrane 
glycoprotein similar to HPIV3 HN, also localizes to lipid rafts [54].  However our results 
demonstrated HN and F were somewhat colocalized with rafts, and that wild-type HPIV3 
HN was associated but not concentrated in rafts.  Since our previous chapter (Chapter 
4) showed that raft proteins not heavily localized to lentivirus-associated rafts were 
incorporated when lipid rafts were disturbed, we attempted to increase passive 
interactions of HPIV3 HN and F with Gag by disturbing rafts.  We used 0.5 mM MβCD to 
treat producer cells and found that not only did it increase colocalization of F and HN 
with lipid raft markers, production of virus particles increased 1.1-fold (p>0.05).  Other 
papers have reported increases in budding of Newcastle disease virus [55], influenza 
[56], Sendai virus [57], and VSV M protein transfected cells [47] after MβCD treatment. 
We also found MβCD treatment of producer cells increased titers of HPIV3 
pseudotyped lentiviruses 6.4-fold, while titers of amphotropic Env pseudotyped viruses 
dropped 3.6-fold.  The increase in HN incorporation was additional to the 2.0-fold 
increase after codon optimization of HN [32].  When viruses from MβCD treated cells 
were analyzed for envelope protein incorporation, lentiviruses incorporated 1.4-fold more 
HN than normal HN while the amount of amphotropic Env incorporated dropped 3.0-fold.  
These results are consistent with our previous chapter’s results in which MβCD 
treatment decreased incorporation of proteins concentrated in lentivirus-associated rafts 
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like amphotropic Env, and increased incorporation of proteins segregated from lentivirus-
associated rafts.    Besides disturbing lipid rafts, cholesterol depletion may have resulted 
in increased F and HN concentrations at the plasma membrane because of either 
reduced endocytosis and degradation [58, 59] or acceleration in export rates from 
internal endosomes [60].  However this is not likely since others have shown HPIV3 HN 
is predominantly found on the cell surface and is not internalized [61].  This increase in 
titer compared to the amount of HN incorporated still suggests the threshold for more 
HPIV3 envelope proteins incorporation has not yet been reached [62-64].  For 
amphotropic Env, the decrease in Env incorporation correlates to the decrease in titer.  
However in addition to decreasing the amount of Env incorporated, cholesterol depletion 
may be affecting Ampho LV titers by inhibiting Env’s fusion ability [65, 66]. 
In addition to increasing passive interactions of HPIV3 envelope proteins with 
Gag, we determined the effect of increasing active interactions of HN with Gag with our 
HN chimeras.  Our previous results [32] and others [67, 68] have demonstrated the 
efficiency of HN incorporation largely determined functional titer or fusion activity.  In the 
creation of the chimeras, we chose to invert the cytoplasmic domain sequences of gp41 
since gp41 is a type I transmembrane protein and HN is a Type II transmembrane 
protein.  The 31 amino acid sequence of the gp41 alpha helix2 and the first 43 amino 
acids of the gp41 cytoplasmic tail have both been shown to interact with HIV-1 matrix 
and the plasma membrane, and are both critical for gp41 incorporation into lentivirus 
particles [43-46, 67].  Colocalization with Gag increased slightly with the chimeric 
proteins compared to unmodified HN.   However we found that lentiviruses incorporated 
the HN chimeras 1.6 to 2.2-fold more than unmodified HN, while titers dropped more 
than 25-fold.  The significant decrease in titers while envelope incorporation increased 
may be due to impairment of the binding or fusion-initiation properties of HN, which has 
been shown to undergo structural changes for both to occur normally [69-72] .   
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In summary, we have found that increasing interactions of HPIV3 envelope 
proteins with Gag through active and passive interactions enhanced HN and F 
incorporation into lentiviral particles.  Future studies should focus on investigating the 
effects of cholesterol depletion on F and HN trafficking, perturbing the lipid rafts on other 
types of viruses for the incorporation of other difficult-to-incorporate proteins, and 
optimizing the effects of raft perturbations for increased envelope incorporation and high 
titers. 
 
5.6 References 
1. Cronin, J., X.Y. Zhang, and J. Reiser, Altering the tropism of lentiviral vectors 
through pseudotyping. Curr Gene Ther, 2005. 5(4): p. 387-98. 
2. Verhoeyen, E., et al., IL-7 surface-engineered lentiviral vectors promote survival 
and efficient gene transfer in resting primary T lymphocytes. Blood, 2003. 101(6): 
p. 2167-74. 
3. Breckpot, K., J.L. Aerts, and K. Thielemans, Lentiviral vectors for cancer 
immunotherapy: transforming infectious particles into therapeutics. Gene Ther, 
2007. 14(11): p. 847-62. 
4. Clements, M.O., et al., Lentiviral manipulation of gene expression in human adult 
and embryonic stem cells. Tissue Eng, 2006. 12(7): p. 1741-51. 
5. Naldini, L., et al., In vivo gene delivery and stable transduction of nondividing 
cells by a lentiviral vector. Science, 1996. 272(5259): p. 263-7. 
6. Kang, Y., et al., In vivo gene transfer using a nonprimate lentiviral vector 
pseudotyped with Ross River Virus glycoproteins. J Virol, 2002. 76(18): p. 9378-
88. 
7. Kobinger, G.P., et al., Filovirus-pseudotyped lentiviral vector can efficiently and 
stably transduce airway epithelia in vivo. Nat Biotechnol, 2001. 19(3): p. 225-30. 
8. Sinn, P.L., et al., Gene transfer to respiratory epithelia with lentivirus 
pseudotyped with Jaagsiekte sheep retrovirus envelope glycoprotein. Hum Gene 
Ther, 2005. 16(4): p. 479-88. 
9. Hammarstedt, M. and H. Garoff, Passive and active inclusion of host proteins in 
human immunodeficiency virus type 1 gag particles during budding at the plasma 
membrane. J Virol, 2004. 78(11): p. 5686-97. 
 140
10. Cantin, R., S. Methot, and M.J. Tremblay, Plunder and stowaways: incorporation 
of cellular proteins by enveloped viruses. J Virol, 2005. 79(11): p. 6577-87. 
11. Kolegraff, K., P. Bostik, and A.A. Ansari, Characterization and role of lentivirus-
associated host proteins. Exp Biol Med (Maywood), 2006. 231(3): p. 252-63. 
12. Nguyen, D.G., et al., Evidence that HIV budding in primary macrophages occurs 
through the exosome release pathway. J Biol Chem, 2003. 278(52): p. 52347-54. 
13. Orentas, R.J. and J.E. Hildreth, Association of host cell surface adhesion 
receptors and other membrane proteins with HIV and SIV. AIDS Res Hum 
Retroviruses, 1993. 9(11): p. 1157-65. 
14. Brugger, B., et al., The HIV lipidome: a raft with an unusual composition. Proc 
Natl Acad Sci U S A, 2006. 103(8): p. 2641-6. 
15. Nguyen, D.H. and J.E. Hildreth, Evidence for budding of human 
immunodeficiency virus type 1 selectively from glycolipid-enriched membrane 
lipid rafts. J Virol, 2000. 74(7): p. 3264-72. 
16. Pelchen-Matthews, A., B. Kramer, and M. Marsh, Infectious HIV-1 assembles in 
late endosomes in primary macrophages. J Cell Biol, 2003. 162(3): p. 443-55. 
17. Sandrin, V. and F.L. Cosset, Intracellular versus cell surface assembly of 
retroviral pseudotypes is determined by the cellular localization of the viral 
glycoprotein, its capacity to interact with Gag, and the expression of the Nef 
protein. J Biol Chem, 2006. 281(1): p. 528-42. 
18. Sandrin, V., et al., Intracellular trafficking of Gag and Env proteins and their 
interactions modulate pseudotyping of retroviruses. J Virol, 2004. 78(13): p. 
7153-64. 
19. Henriksson, P., et al., Incorporation of wild-type and C-terminally truncated 
human epidermal growth factor receptor into human immunodeficiency virus-like 
particles: insight into the processes governing glycoprotein incorporation into 
retroviral particles. J Virol, 1999. 73(11): p. 9294-302. 
20. Lindwasser, O.W. and M.D. Resh, Multimerization of human immunodeficiency 
virus type 1 Gag promotes its localization to barges, raft-like membrane 
microdomains. J Virol, 2001. 75(17): p. 7913-24. 
21. Finzi, A., et al., Productive human immunodeficiency virus type 1 assembly takes 
place at the plasma membrane. J Virol, 2007. 81(14): p. 7476-90. 
22. Jouvenet, N., et al., Plasma membrane is the site of productive HIV-1 particle 
assembly. PLoS Biol, 2006. 4(12): p. e435. 
23. Sherer, N.M., et al., Visualization of retroviral replication in living cells reveals 
budding into multivesicular bodies. Traffic, 2003. 4(11): p. 785-801. 
 141
24. Yang, C., C.P. Spies, and R.W. Compans, The human and simian 
immunodeficiency virus envelope glycoprotein transmembrane subunits are 
palmitoylated. Proc Natl Acad Sci U S A, 1995. 92(21): p. 9871-5. 
25. Bhattacharya, J., P.J. Peters, and P.R. Clapham, Human immunodeficiency virus 
type 1 envelope glycoproteins that lack cytoplasmic domain cysteines: impact on 
association with membrane lipid rafts and incorporation onto budding virus 
particles. J Virol, 2004. 78(10): p. 5500-6. 
26. Resh, M.D., Intracellular trafficking of HIV-1 Gag: how Gag interacts with cell 
membranes and makes viral particles. AIDS Rev, 2005. 7(2): p. 84-91. 
27. Campbell, S.M., S.M. Crowe, and J. Mak, Lipid rafts and HIV-1: from viral entry 
to assembly of progeny virions. J Clin Virol, 2001. 22(3): p. 217-27. 
28. Nydegger, S., et al., Mapping of tetraspanin-enriched microdomains that can 
function as gateways for HIV-1. J Cell Biol, 2006. 173(5): p. 795-807. 
29. Jolly, C. and Q.J. Sattentau, Human immunodeficiency virus type 1 assembly, 
budding, and cell-cell spread in T cells take place in tetraspanin-enriched plasma 
membrane domains. J Virol, 2007. 81(15): p. 7873-84. 
30. Deneka, M., et al., In macrophages, HIV-1 assembles into an intracellular plasma 
membrane domain containing the tetraspanins CD81, CD9, and CD53. J Cell 
Biol, 2007. 177(2): p. 329-41. 
31. Jung, C., et al., Lentiviral vectors pseudotyped with envelope glycoproteins 
derived from human parainfluenza virus type 3. Biotechnol Prog, 2004. 20(6): p. 
1810-6. 
32. Jung, C. and J.M. Doux, Lentiviruses inefficiently incorporate human 
parainfluenza type 3 envelope proteins. Biotechnol Bioeng, 2007. 
33. Evans, L.H., et al., A neutralizable epitope common to the envelope 
glycoproteins of ecotropic, polytropic, xenotropic, and amphotropic murine 
leukemia viruses. J Virol, 1990. 64(12): p. 6176-83. 
34. Harlow, E. and D. Lane, Storing and Purifying Antibodies, in Antibodies:  A 
Laboratory Manual. 1988, Cold Spring Harbor Laboratory Press: Cold Spring 
Harbor. p. 288-303. 
35. Zufferey, R., et al., Multiply attenuated lentiviral vector achieves efficient gene 
delivery in vivo. Nat Biotechnol, 1997. 15(9): p. 871-5. 
36. Cosset, F.L., et al., High-titer packaging cells producing recombinant retroviruses 
resistant to human serum. J Virol, 1995. 69(12): p. 7430-6. 
37. Landazuri, N., M. Gupta, and J.M. Le Doux, Rapid concentration and purification 
of retrovirus by flocculation with Polybrene. J Biotechnol, 2006. 125(4): p. 529-
39. 
 142
38. Niwa, H., K. Yamamura, and J. Miyazaki, Efficient selection for high-expression 
transfectants with a novel eukaryotic vector. Gene, 1991. 108(2): p. 193-99. 
39. Smith, R.F., Microscopy and Photomicrography. 2nd ed. 1994, Boca Raton: CRC 
Press. 162. 
40. Rasband, W.S. ImageJ.   [cited 2007 10-21]; Available from: 
http://rsb.info.nih.gov/ij/. 
41. Abramoff, M., P. Magelhaes, and S. Ram, Image processing with ImageJ. 
Biophotonics International, 2004. 11(7): p. 36-42. 
42. Spector, D.H., et al., Human immunodeficiency virus pseudotypes with expanded 
cellular and species tropism. J Virol, 1990. 64(5): p. 2298-308. 
43. Hourioux, C., et al., Identification of the glycoprotein 41(TM) cytoplasmic tail 
domains of human immunodeficiency virus type 1 that interact with Pr55Gag 
particles. AIDS Res Hum Retroviruses, 2000. 16(12): p. 1141-7. 
44. Murakami, T. and E.O. Freed, Genetic evidence for an interaction between 
human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 
cytoplasmic tail. J Virol, 2000. 74(8): p. 3548-54. 
45. Piller, S.C., et al., Mutational analysis of conserved domains within the 
cytoplasmic tail of gp41 from human immunodeficiency virus type 1: effects on 
glycoprotein incorporation and infectivity. J Virol, 2000. 74(24): p. 11717-23. 
46. Freed, E.O. and M.A. Martin, Domains of the human immunodeficiency virus type 
1 matrix and gp41 cytoplasmic tail required for envelope incorporation into 
virions. J Virol, 1996. 70(1): p. 341-51. 
47. Ono, A. and E.O. Freed, Plasma membrane rafts play a critical role in HIV-1 
assembly and release. Proc Natl Acad Sci U S A, 2001. 98(24): p. 13925-30. 
48. Pickl, W.F., F.X. Pimentel-Muinos, and B. Seed, Lipid rafts and pseudotyping. J 
Virol, 2001. 75(15): p. 7175-83. 
49. Bose, S., A. Malur, and A.K. Banerjee, Polarity of human parainfluenza virus type 
3 infection in polarized human lung epithelial A549 cells: role of microfilament 
and microtubule. J Virol, 2001. 75(4): p. 1984-9. 
50. Owens, R.J., et al., Human immunodeficiency virus envelope protein determines 
the site of virus release in polarized epithelial cells. Proc Natl Acad Sci U S A, 
1991. 88(9): p. 3987-91. 
51. Nydegger, S., et al., HIV-1 egress is gated through late endosomal membranes. 
Traffic, 2003. 4(12): p. 902-10. 
52. Orenstein, J.M., et al., Cytoplasmic assembly and accumulation of human 
immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating 
 143
factor-1-treated human monocytes: an ultrastructural study. J Virol, 1988. 62(8): 
p. 2578-86. 
53. Manie, S.N., et al., Measles virus structural components are enriched into lipid 
raft microdomains: a potential cellular location for virus assembly. J Virol, 2000. 
74(1): p. 305-11. 
54. Barman, S. and D.P. Nayak, Analysis of the transmembrane domain of influenza 
virus neuraminidase, a type II transmembrane glycoprotein, for apical sorting and 
raft association. J Virol, 2000. 74(14): p. 6538-45. 
55. Laliberte, J.P., et al., Integrity of membrane lipid rafts is necessary for the 
ordered assembly and release of infectious Newcastle disease virus particles. J 
Virol, 2006. 80(21): p. 10652-62. 
56. Barman, S. and D.P. Nayak, Lipid raft disruption by cholesterol depletion 
enhances influenza A virus budding from MDCK cells. J Virol, 2007. 
57. Gosselin-Grenet, A.S., G. Mottet-Osman, and L. Roux, From assembly to virus 
particle budding: pertinence of the detergent resistant membranes. Virology, 
2006. 344(2): p. 296-303. 
58. Kobayashi, T., A. Yamaji-Hasegawa, and E. Kiyokawa, Lipid domains in the 
endocytic pathway. Semin Cell Dev Biol, 2001. 12(2): p. 173-82. 
59. Ikeda, M. and R. Longnecker, Cholesterol is critical for Epstein-Barr virus latent 
membrane protein 2A trafficking and protein stability. Virology, 2007. 360(2): p. 
461-8. 
60. Mayor, S., S. Sabharanjak, and F.R. Maxfield, Cholesterol-dependent retention 
of GPI-anchored proteins in endosomes. Embo J, 1998. 17(16): p. 4626-38. 
61. Leser, G.P., K.J. Ector, and R.A. Lamb, The paramyxovirus simian virus 5 
hemagglutinin-neuraminidase glycoprotein, but not the fusion glycoprotein, is 
internalized via coated pits and enters the endocytic pathway. Mol Biol Cell, 
1996. 7(1): p. 155-72. 
62. Bachrach, E., et al., Effects of virion surface gp120 density on infection by HIV-1 
and viral production by infected cells. Virology, 2005. 332(1): p. 418-29. 
63. Yuste, E., et al., Virion envelope content, infectivity, and neutralization sensitivity 
of simian immunodeficiency virus. J Virol, 2005. 79(19): p. 12455-63. 
64. Yuste, E., et al., Modulation of Env content in virions of simian immunodeficiency 
virus: correlation with cell surface expression and virion infectivity. J Virol, 2004. 
78(13): p. 6775-85. 
65. Guyader, M., et al., Role for human immunodeficiency virus type 1 membrane 
cholesterol in viral internalization. J Virol, 2002. 76(20): p. 10356-64. 
 144
66. Zavorotinskaya, T. and L.M. Albritton, Failure To cleave murine leukemia virus 
envelope protein does not preclude its incorporation in virions and productive 
virus-receptor interaction. J Virol, 1999. 73(7): p. 5621-9. 
67. Kobayashi, M., et al., Pseudotyped lentivirus vectors derived from simian 
immunodeficiency virus SIVagm with envelope glycoproteins from 
paramyxovirus. J Virol, 2003. 77(4): p. 2607-14. 
68. Dutch, R.E., S.B. Joshi, and R.A. Lamb, Membrane fusion promoted by 
increasing surface densities of the paramyxovirus F and HN proteins: 
comparison of fusion reactions mediated by simian virus 5 F, human 
parainfluenza virus type 3 F, and influenza virus HA. J Virol, 1998. 72(10): p. 
7745-53. 
69. Hu, X.L., R. Ray, and R.W. Compans, Functional interactions between the fusion 
protein and hemagglutinin-neuraminidase of human parainfluenza viruses. J 
Virol, 1992. 66(3): p. 1528-34. 
70. Bagai, S. and R.A. Lamb, Quantitative measurement of paramyxovirus fusion: 
differences in requirements of glycoproteins between simian virus 5 and human 
parainfluenza virus 3 or Newcastle disease virus. J Virol, 1995. 69(11): p. 6712-
9. 
71. Moscona, A. and R.W. Peluso, Fusion properties of cells persistently infected 
with human parainfluenza virus type 3: participation of hemagglutinin-
neuraminidase in membrane fusion. J Virol, 1991. 65(6): p. 2773-7. 
72. Tanaka, Y. and M.S. Galinski, Human parainfluenza virus type 3: analysis of the 
cytoplasmic tail and transmembrane anchor of the hemagglutinin-neuraminidase 
protein in promoting cell fusion. Virus Res, 1995. 36(2-3): p. 131-49. 
 
 145
CHAPTER 6 
 
CONCLUSIONS AND FUTURE CONSIDERATIONS 
 
  
 
6.1 Summary of results 
In chapter two we described the generation of lentiviruses pseudotyped with 
human parainfluenza type 3 envelope (HPIV3) glycoproteins.  Lentivirus particles 
incorporated HPIV3 hemagglutinin-neuraminidase (HN) and fusion (F) proteins into their 
lipid bilayers and were able to transduce human kidney epithelial cells and polarized 
MDCK, HBE, and A549 cells via their apical surface.  Neuraminidase, AZT, and anti-
HPIV3 antisera blocked transduction, which is consistent with lentiviral-mediated 
transduction via sialated receptors for HPIV3.   Our findings showed that HPIV3 
pseudotyped lentiviruses can be formed and may have a number of useful properties for 
human gene transfer. 
In chapter three we investigated the cause of low HPIV3 pseudotyped lentivirus 
titers.  Transfected cells contained similar levels of HN and F cytosolic mRNA, but fewer 
cell-surface HN and F proteins (3.8 and 1.3-fold less, respectively), than cells infected 
with wild-type HPIV3.  To increase expression of HN in transfected cells, we codon-
optimized HN and used it to transfect lentivirus producer cells.  Cell surface expression 
of HN, as well as the amount of HN incorporated into virus particles, increased 2 to 3-
fold.  Virus titers increased 1.2 to 6.4-fold, and the transduction efficiency of polarized 
MDCK cells via their apical surfaces increased 1.4-fold.  Interestingly, even though 
codon optimization improved the expression levels of HN and virus titers, we found that 
HPIV3 pseudotyped viruses contained about 14-fold fewer envelope proteins than 
lentiviruses pseudotyped with the amphotropic envelope protein.  Taken together, our 
findings suggested that titers were low, not because virus producer cells expressed 
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levels of HPIV3 envelope proteins that were too low, but because too few of these 
proteins were incorporated by lentiviruses for them to be able to efficiently transduce 
cells. 
In chapter four we investigated the ability of two glycosylphosphatidylinositol 
(GPI) anchored proteins, folate receptor (FR-WT) and Tac-CD16 (CD25 or the 
interleukin-2 receptor alpha chain which has been modified with the GPI anchor motif 
from CD16) to associate with viral proteins, Gag and amphotropic Env, in lipid rafts and 
lentivirus particles.  We found that Tac-CD16 and FR-WT exhibited the classic GPI 
anchored protein property of associating with lipid rafts, however Tac-CD16 colocalized 
with Gag and incorporated into lentiviral particles, while FR-WT did not colocalize with 
Gag and was not incorporated into virus particles.  We found FR-WT generally 
colocalized to less dense rafts while Gag and Env were localized to more dense rafts.  
Tac-CD16 was widely distributed in both less dense and more dense rafts.  Most 
significantly, we found that when we treated producer cells with fumonisin B1 (FB1) or 
methyl-beta-cyclodextrin (MβCD), the amount of colocalization between FR-WT and Gag 
increased, FR-WT was located to more dense rafts, and FR-WT was incorporated 2.9 to 
11.6-fold more into lentiviral particles, respectively.  In contrast, the raft distribution of 
Tac-CD16 decreased and the amount of Tac-CD16 in virus particles decreased 2.4-fold 
with MβCD treatment.  Taken together, these results demonstrated lipid rafts segregate 
raft proteins, and for a protein to be incorporated into virus particles, it must be 
colocalized with lentivirus-associated rafts. 
In chapter five we reasoned that incorporation of HPIV3 envelope proteins, HN 
and F, into lentiviral particles was low because interactions between HN and F, or HN 
and F with lentiviral Gag were low.  We found that HN and F were colocalized with each 
other, however HN and F were not as colocalized with Gag or lipid rafts as amphotropic 
Env.  We used two main approaches to increase interactions of the envelope proteins 
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with Gag: 1) we created HN and HIV Env fusion proteins that would actively interact with 
Gag, and 2) we disrupted the barriers that prevented HN and F from passively 
interacting with Gag.  We found that the HN chimeras had increased colocalization with 
Gag compared to unmodified HN.  The level of incorporation also increased 1.6-fold and 
2.2-fold, respectively, however titers significantly decreased at least 25-fold.  We then 
determined whether increased colocalization with Gag was sufficient for envelope 
protein incorporation.  When lentiviruses pseudotyped with HPIV3 (HPIV3 LV) or 
amphotropic Env (Ampho LV) producer cells were treated with 0.5 mM MβCD for 54 
hours after transfection to disturb lipid rafts,  titers of HPIV3 LV increased 6.4-fold while 
titers of Ampho LV decreased 3.6-fold.  When we analyzed the amount of envelope 
incorporation from MβCD treated producer cells, we found the amount of amphotropic 
Env in virus particles decreased 3.0-fold while the amount of HN increased 1.4-fold.  
This data suggested that increasing interactions of HPIV3 envelope proteins with Gag 
through active and passive interactions enhanced HN and F incorporation into lentiviral 
particles. 
 
6.2 Conclusions 
In conclusion, we determined: 
1. Lentiviruses can be pseudotyped with the envelope proteins from HPIV3.  
The pseudotyped viruses can infect polarized cells via the apical surface. 
2. Titers of HPIV3 pseudotyped lentiviruses are low because of low 
envelope incorporation levels. 
3. Lipid rafts segregate raft proteins, and for a protein to be incorporated into 
virus particles, it must be colocalized with lentivirus-associated rafts. 
 148
4. Titers of HPIV3 pseudotyped lentiviruses can be improved by enhancing 
active and passive interactions of envelope proteins with Gag, leading to 
improved incorporation levels.  
 
6.3 Future Considerations 
The following are suggestions for future research: 
1. Though we have improved incorporation of HPIV3 envelope proteins with 
lentivirus particles, titers are still at least 5 to 10-fold less than that of 
amphotropic Env pseudotyped lentiviruses.  Future work should focus on 
improving HPIV3 pseudotyped lentivirus infection of polarized cells via the 
apical surface by improving envelope incorporation levels.  For example, 
the F protein could also be codon optimized, the number of plasmids 
used to produce pseudotyped viruses could be reduced, and MβCD or 
FB1 treatment of producer cells could be optimized.  Additional work 
should be performed in an attempt to improve the function of the HN 
fusion proteins since the HN fusion proteins had increased corporation 
levels, however titers were low.  Other sequences for increased Gag 
interaction of localization could be used, for example, the alpha helix 1 
region of the gp41 cytoplasmic tail, or sequences from Type II 
transmembrane proteins that colocalize with virus particles.  Work should 
also be performed to determine how much incorporation can be achieved 
when HN fusion proteins are combined with MβCD or FB1 treatment. 
2. MβCD and FB1 treatment improved lentiviral incorporation and titers of 
HPIV3.  Future work should investigate whether or not treatment 
improves titers of other hard-to-pseudotype envelope proteins such as 
influenza and respiratory syncytial virus for the generation of pseudotyped 
 149
viruses for lung gene transfer.  Additionally, the effect of MβCD and FB1 
treatment on envelope incorporation by retroviruses and SIV should also 
be explored. 
3. We have shown lipid rafts can regulate the proteins incorporated into 
virus particles and disruption of rafts can alter the protein composition of 
viruses.  Future work should investigate how to manipulate lipid rafts for 
protein incorporation into and exclusion from virus particles.  For 
example, non-raft and raft-segregated proteins can be altered or rafts can 
be disrupted for colocalization with lentivirus-associated rafts. 
4. We have shown cell proteins, such as the GPI anchored proteins, can 
affect lentivirus assembly, budding, and envelope incorporation.  These 
results have important implications for the addition of accessory 
molecules that can alter the targeting and signaling of virus particles.  The 
addition of accessory molecules may have to be optimized so as not to 
affect virus infection, since we show Tac-CD16 may limit the number of 
envelope proteins in rafts and affect virus infection.  Additionally, work 
should be performed to determine whether other cellular proteins can 
facilitate lentivirus assembly and budding and targeting. 
5. We have also shown FR-WT inhibited lentivirus localization to lipid rafts, 
although budding and transduction efficiency was not affected, and 
variants of folate receptor were not incorporated into virus particles.  
Future work should focus on determining the sequence for inhibition and 
exploiting this inhibition perhaps for anti-viral purposes. 
6. Future work should also investigate the effects of MβCD and FB1 
treatment on protein expression of envelope proteins and GPI anchored 
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proteins.  Specifically, it should be determined whether or not treatment 
increases surface localization or merely redistributes cell surface proteins.   
7. Future work should further analyze the effects of MβCD and FB1 
treatment on cholesterol levels in lipid rafts and in virus particles, and 
whether or not this affects envelope protein function of binding and fusion. 
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APPENDIX A 
 
ADDITIONAL DATA 
 
  
 
A.1  HPIV3-F Characteristics 
F internalization rates.   The cytoplasmic tail of HPIV3-F contains a YXXR 
sequence, which possibly indicates an internalization motif.  We hypothesized 
lentiviruses may not contain much F protein if it is rapidly internalized.  We therefore 
used site-directed mutagenesis to change the tyrosine to an alanine (F-Y518A).  We 
then compared internalization rates between normal F and F-Y518A by transfecting cells 
grown on coverslips and then incubating for 48 hours.  Media was then replaced with 
cold media for 30 min on ice before cells were incubated with a monoclonal antibody 
against F at 40C.  Coverslips were then transferred to pre-warmed media and incubated 
at 370C for 0, 30 min, 1 hr, and 2 hr.  After each timepoint, cells were chilled on ice in 
cold PBS for 30 min.  Cells were then washed, labeled with A549-conjugated 
concanavalin A to stain for the cell surface, washed, fixed, and then incubated with Cy2-
conjugated secondary antibody before being washed and mounted on slides with 
gelvatol.  Cells were visualized by confocal microscopy and extent of colocalization 
between F and cell surface was quantified with ImageJ.  No significant difference in 
internalization level between F and F-Y518A was detected, and F was stably present on 
the cell surface.  This indicates the F YXXR sequence is not an internalization motif and 
F is not rapidly internalized. 
F RNA localization.  In addition to determining whether HPIV3-F RNA was 
spliced in Chapter 3, we analyzed whether F RNA exported from the nucleus of 
transfected cells.  Cytoplasmic and nuclear RNA were isolated from fractionated cells, 
reverse transcribed, and then amplified by real-time PCR (Figure A.1).  High levels of F 
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RNA were detected in the nucleus and cytoplasm of transfected cells, regardless 
whether cells were transfected only with the expression plasmid for F, or multiply 
transfected to express F, Gag-Pol, and the lentiviral transgene β-galactosidase.  A small 
amount of F RNA was detected in the nuclear fraction of wild-type HPIV3 infected cells 
due to limitations with the experimental procedure which did not completely prevent 
contamination of the nuclear fraction with cytoplasmic mRNA.  These results indicate 
that F mRNA was efficiently exported from the nucleus to the cytoplasm in transfected 
cells.   
 
 
 
 
  
 
Figure A.1.  Transfected F RNA is exported to the cytoplasm of cells.  293T/17 cells 
(2x106) were transfected with 1 μg of an expression plasmid for HPIV3-F (F), 1 μg each 
of expression plasmids for HPIV3-F, HPIV3-HN, β-galactosidase, and lentiviral Gag-Pol 
(LV), or infected with wild-type HPIV3 (WT) at an MOI of 1.  Two days later, RNA from 
the cytoplasmic and nuclear fractions were isolated using the RNeasy kit per the 
manufacturer’s instructions.  Portions (1 μg) of the cytoplasmic and nuclear RNA 
fractions were reverse-transcribed using OligodT primers and then quantified by real-
time PCR using F-specific primers.  Bars show the mean level ± standard deviation of 
triplicate wells. 
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A.2  Pseudotyping Other Retroviruses and Attempts in Increasing HPIV3/LV Titers  
Pseudotyping HPIV3 with SIV and RV.  We determined whether other 
retroviruses could pseudotype HPIV3 envelope proteins and produce titers similar to 
retroviruses pseudotyped with amphotropic Env.  The first retrovirus we tried was MLV-
derived.  The stable retrovirus producing cell line TelCeb6 was transfected with either 
the amphotropic Env or F and HN.  Virus was harvested every 12 hours and used to 
transduce 293T in the diluted titer assay.  The titer of amphotropic Env pseudotyped 
retroviruses was (4.2 ± .038) x 106 CFU/mL while the titer of HPIV3 pseudotyped 
retroviruses was 0. 
The next retrovirus we tried was simian immunodeficiency virus (SIV).  293T cells 
were plated and transfected with plasmids encoding SIV Gag, SIV GFP reporter gene, 
SIV helper plasmid, and either the amphotropic Env or HN and F.  Virus was harvested 
every 12 hours and used to transduce 293T in the diluted titer assay.  The titer of 
amphotropic Env pseudotyped SIV was (3.62 ± .053) x 106 CFU/mL while the titer of 
HPIV3 pseudotyped SIV was (4.9 ± .78) x 102 CFU/mL 
Together these results demonstrated HPIV3 envelope proteins are not easily 
pseudotyped by retroviruses or SIV since the titer difference between amphotropic Env 
and HPIV3 envelope proteins is 106-fold for retroviruses, 104-fold for SIV, and 102-fold 
for HIV. 
Varying DNA amounts of HN and F.  Besides optimizing the amount of DNA 
and Lipofectamine 2000 for HPIV3/LV production, we varied the DNA amount of F and 
HN to each other to determine whether titers would improve.  However the 1:1 ratio of F 
and HN resulted in the highest titers. 
Stable cell line.  We attempted to create a stable HPIV3-F or HPIV3-HN or lacZ 
cell line to reduce the amount of plasmid required for creation of the HPIV3/LV 
pseudotype (currently 4 plasmid transfection system).  We transfected 293T with 3.6 µg 
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F or codon optimized HN or Z and 0.4 µg pSV2-his.  Two days later we incubated cells 
in histidine-free MEM + FBS + 10 mM L-histidinol.  Cells were cultured until the cells that 
were not transfected were dead.  We selected 8 colonies of each F, HN, or lacZ-
transfected cells and tested for F and HN expression by performing flow cytometry and 
lacZ expression by performing an ONPG.  We then selected the best-expressing clone 
of each F and HN, however when compared to transiently transfected HPIV3/LV 
producer cells, the amount of F and HN expressed by the clones were half that of the 4-
plasmid transfected cells.  We then transfected the clones with normal amounts of 3 
plasmids and either 0 µg or half the amount of plasmid normally used of the 
corresponding clone, and tested for the amount of virus produced and the transduction 
efficiency (Table A.1.)  We found that the clones produced less virus particles than 
transiently transfected producer cells.  We also found the virus transduction efficiency 
produced from the clones were almost nonexistent compared to virus from transiently 
transfected cells.  However when half the amount of corresponding clone plasmid was 
transfected, the transduction efficiency of the virus from the HN clone was similar to that 
of transiently transfected cells, while the virus from the F clone was 1.6-fold lower.  
These results indicate the stable F and HN clones did not produce enough F and HN 
required for virus assembly and subsequent infection. 
 
A.3  Lentiviral Incorporation of Other FR and Tac Mutants 
We determined whether mutations of FR and Tac would affect the incorporation 
of FR and Tac into lentiviral particles.  First we determined whether FR mutants FR-
S67P and FR-MCP8 were in lipid rafts and whether or not they were incorporated into 
lentiviral particles.  FR-S67P is similar to that of FR-WT except it is more localized to the 
surface of cells while FR-MCP8 has the GPI anchor of FR-WT replaced with the 
transmembrane region of membrane protein cofactor.  To determine biochemically if FR-  
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Table A.1.  p24 production and titer of virus produced from stable cell lines 
   
Treatment Virus production 
(OD490-650)a 
Titer 
(CFU/mL)b 
   
   
lacZ clone + 0 µg lacZ 0.226 ± 0.011  0 
HPIV3-F clone + 0 µg F 0.135 ± 0.034 40 ± 10 
HPIV3-F clone + ½ µg F 0.297 ± 0.013 2000 ± 100 
HPIV3-HN clone + 0 µg HN 0.166 ± 0.027   10 ± 4 
HPIV3-HN clone + ½ µg HN 0.178 ± 0.015 2900 ± 145 
Transiently transfected HPIV3/LV 0.412 ± 0.042 3100 ± 155 
   
Lentiviruses produced from stable lacZ, HN, or F clones were used to transduce 293T 
cells.  aVirus production (OD490-650) and btiter (CFU/mL) represent the mean of 
experimental values +/- standard deviation.   
 
 
 
 
 
 
S67P and FR-MCP8 reside in lipid rafts, and if they are incorporated into lentiviral 
particles, we transfected cells with expression plasmids for β-galactosidase, HIV-1 Gag-
Pol, and either FR-S67P or FR-MCP8.  Detergent resistant domains were isolated by 
lysing cells with ice-cold Brij 98 (0.5% in TNE) and performing equilibrium flotation 
centrifugation.  The lipid raft fraction was pelleted by centrifugation and the pellet was 
analyzed by Western blot for the presence of the folate proteins (Figure A.2).  As 
expected, FR-S67P was detected in lipid rafts while FR-MPC8, lacking the GPI anchor, 
was not.  The virus supernatant of the transfected cells was then analyzed for protein 
content after it was harvested, ultracentrifuged through a 20% sucrose cushion, and then 
resuspended in PBS to 100-fold their original concentration.  Samples were normalized 
by p24, resuspended in lysis buffer, and analyzed by Western blot for the presence of  
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Figure A.2.  FR mutants FR-S67P and FR-MCP8 do not incorporate into lentiviral 
particles.  293T cells (1x107) were transfected with expression plasmids (6 µg each) for 
β-galactosidase, HIV-1 Gag-Pol, and either FR-S67P or FR-MCP8.  The virus 
supernatant (v) was harvested, ultracentrifuged through a 20% sucrose cushion, 
resuspended in PBS to 100-fold their original concentration, and analyzed by Western 
blot after normalization for p24 (Lanes 2-3).  Detergent resistant domains (r) were 
isolated by lysing cells with ice-cold Brij 98 (0.5% in TNE) and performing equilibrium 
flotation centrifugation.  The lipid raft fraction was pelleted by centrifugation and the 
pellet was analyzed by Western blot after normalization for protein content (Lanes 4-5).  
Whole cell lysates for FR-MCP8 were also analyzed by Western Blot (Lane 6).  Blots 
were for the presence of FR mutants and samples are as follows:  FR-S67P (Lanes 2 
and 4) or FR-MCP8 (Lanes 3, 5, 6). 
 
 
 
 
folate receptor (Figure A.2).  Both FR-S67P and FR-MCP8 were not detected in virus 
particles.   
We then analyzed the raft localization and virus incorporation of two Tac-CD16 
related proteins, normal Tac and Tac-DKQTLL, which has the rapid internalization 
sequence DKQTLL appended to the end of Tac.  To determine biochemically if Tac and 
Tac-DKQTLL reside in lipid rafts, and if they are incorporated into lentiviral particles, we 
transfected cells with expression plasmids for β-galactosidase, HIV-1 Gag-Pol, and 
either Tac or Tac-DKQTLL.  Detergent resistant domains were isolated by lysing cells 
with ice-cold Brij 98 (0.5% in TNE) and performing equilibrium flotation centrifugation.  
The lipid raft fraction was pelleted by centrifugation and the pellet was analyzed by 
Western blot for the presence of the Tac proteins (Figure A.3).  As expected, Tac was 
somewhat localized to rafts and very little Tac-DKQTLL was localized to rafts.  The virus 
supernatant of the transfected cells was then analyzed for protein content after it was 
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harvested, ultracentrifuged through a 20% sucrose cushion, and then resuspended in 
PBS to 100-fold their original concentration.  Samples were normalized by p24, 
resuspended in lysis buffer, and analyzed by Western blot for the presence of the Tac 
proteins (Figure A.3).  Both Tac and Tac-DKQTLL were detected in virus particles.   
We next determined whether FR-WT was not incorporated into lentiviral particles 
because of the GPI anchor.  We therefore swapped the GPI signal sequence of FR-WT 
and Tac-CD16 by PCR sewing and verified the sequence, creating FR-CD16 which is 
the folate receptor with the GPI anchor sequence from Tac-CD16, and Tac-FR which is 
Tac with the GPI anchor sequence from FR-WT.  To determine biochemically if FR-
CD16 and Tac-FR reside in lipid rafts, and if they are incorporated into lentiviral 
particles, we transfected cells with expression plasmids for β-galactosidase, HIV-1 Gag-
Pol, and either FR-WT, FR-CD16, Tac-CD16, or Tac-FR.  Detergent resistant domains  
 
 
 
 
 
Figure A.3.  Tac and Tac-DKQTLL incorporate into viral particles.  293T cells (1x107) 
were transfected with expression plasmids (6 µg each) for β-galactosidase, HIV-1 Gag-
Pol, and either Tac or Tac-DKQTLL.  The virus supernatant (v) was harvested, 
ultracentrifuged through a 20% sucrose cushion, resuspended in PBS to 100-fold their 
original concentration, and analyzed by Western blot after normalization for p24 (Lanes 
2-3).  Detergent resistant domains (r) were isolated by lysing cells with ice-cold Brij 98 
(0.5% in TNE) and performing equilibrium flotation centrifugation.  The lipid raft fraction 
was pelleted by centrifugation and the pellet was analyzed by Western blot after 
normalization for protein content (Lanes 4-5).  Blots were for the presence of Tac 
mutants and samples are as follows:  Tac (Lanes 2 and 4) or Tac-DKQTLL (Lanes 3 and 
5). 
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were isolated by lysing cells with ice-cold Brij 98 (0.5% in TNE) and performing 
equilibrium flotation centrifugation.  The lipid raft fraction was pelleted by centrifugation 
and the pellet was analyzed by Western blot for the presence of the folate proteins 
(Figure A.4A) or Tac proteins (Figure A.4B).  As expected, both FR-CD16 and Tac-FR 
were detected in lipid rafts.  The virus supernatant of the transfected cells was then 
analyzed for protein content after it was harvested, ultracentrifuged through a 20% 
sucrose cushion, and then resuspended in PBS to 100-fold their original concentration.  
Samples were normalized by p24, resuspended in lysis buffer, and analyzed by Western 
blot for the presence of folate proteins (Figure A.4A) or Tac proteins (Figure A.4B).  
Surprisingly, FR-CD16 was not found in virus particles and Tac-FR was found in virus 
particles.  Taken together, these results demonstrate folate receptor is inhibitory to virus 
incorporation. 
 
 
A.  FR-WT and FR-CD16 
 
B.  Tac-CD16 and Tac-FR 
Figure A.4.  FR-CD16 is not incorporated into lentiviral particles while Tac-FR is.  293T 
cells (1x107) were transfected with expression plasmids (6 µg each) for β-galactosidase, 
HIV-1 Gag-Pol, and either FR-CD16 or Tac-FR.  The virus supernatant (v) was 
harvested, ultracentrifuged through a 20% sucrose cushion, resuspended in PBS to 100-
fold their original concentration, and analyzed by Western blot after normalization for p24 
(A and B Lanes 2-3).  Detergent resistant domains (r) were isolated by lysing cells with 
ice-cold Brij 98 (0.5% in TNE) and performing equilibrium flotation centrifugation.  The 
lipid raft fraction was pelleted by centrifugation and the pellet was analyzed by Western 
blot after normalization for protein content (A and B Lanes 4-5).  Blots were for the 
presence of FR (A) or Tac (B).  In Part A, samples are as follows:  FR-WT (Lanes 2 and 
4) or FR-CD16 (Lanes 3 and 5).  In Part B, samples are as follows:  Tac-CD16 (Lanes 2 
and 4) or Tac-FR (Lanes 3 and 5). 
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APPENDIX B 
 
EXPERIMENTAL PROTOCOLS 
 
  
 
B.1.  CsCl Purification of Plasmid DNA 
1. Grow a 30 mL culture to an OD600 = 0.6 (late log phase) 
2. Inoculate 500 mL LB with 25 mL of the culture.  Incubate for 14.5-18.5 hours at 370 
with shaking (if growing with 34 mg/ml chloramphenicol in ETOH, add 2.5 ml 2.5 
hours after culture is started). 
3. Harvest by centrifugation at 4000 rpm for 15 min at 40C in Sorvall GS3 rotor.  
Discard and drain away all the supernatant. 
4. Resuspend the pellet in 100 mL of ice-cold STE (0.1 M NaCl, 10 mM Tris-Cl (pH 8), 
1 mM EDTA (pH 8)) to wash the cells 
5. Centrifuge again at 4000 rpm for 15 min at 40C in the GS3 
6. Resuspend the washed pellet in 18 mL of Solution 1 (50 mM glucose/dextrose, 25 
mM Tris-Cl (pH 8), 10 mM EDTA (pH 8), make 100 mL, autoclave for 15 min and 
store at 40C) 
7. Add 2 mL of freshly prepared solution of lysozyme (10 mg/mL in 10 mM Tris-Cl 
(important!  pH=8)).  
8. Carefully add 40 mL of freshly prepared Solution 2 (0.2 N NaOH, 1% SDS).  Mix by 
inversion and store at room temperature for 5-10 minutes.  Add carefully. 
9. Add 20 mL of ice-cold Solution 3 (60 mL 5M potassium acetate, 11.5 mL glacial 
acetic acid, 28.5 mL water).  Mix well by inversion.  Store on ice for 10 minutes 
10. Centrifuge at 4000 rpm for 15 minutes at 40C in Sorvall GS3. (make sure there is 
pellet) 
11. Filter the supernatant through 4 layers of cheesecloth into a 250 mL centrifuge bottle.  
Add 0.6 volume of isopropanol, mix well, and store for 10 minutes at room 
temperature.  
12. Centrifuge at least 6000 rpm for 30 minutes at room temperature in Sorvall GS3  
13. Decant supernatant carefully and drain away supernatant (turn upside down).  Either 
resuspend in 70% ethanol at room temperature, centrifuge, drain, and then 
evaporate off ethanol, or just rinse with 3 mL ethanol and evaporate off.   
14. Dissolve the pellet of nucleic acid in 3 mL of TE (pH 8) (10 mM Tris acid (pH=7.4), 1 
mM EDTA, filter sterilized) 
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15. For every mL of DNA solution, add exactly 1 g CsCl.  All the salt should be dissolved 
(warm to 300C if necessary) 
16. Add 0.08 mL of ethidium bromide solution (10 mg/ml in water) for every 1 mL of 
DNA/CsCl solution.  Mix immediately 
17. Centrifuge the solution at 3300 g for 5 min at room temperature 
18. Use Pasteur pipette to transfer the clear red solution under/over the scum into a tube 
(Beckman quick-seal or equivalent).  Fill remainder of tube with filtered 
TE/CsCl/Ethidium Bromide in correct concentrations.  Make sure tubes weigh the 
same 
19. Use tube sealer to seal tube.  Turn on for 4 min.  Place seal former on each tube 
neck and press down firmly on tube knob, until it has moved about 2/3 of the way to 
the tube shoulder.  Immediately lift one end of the rack slightly and move it one tube 
position to the right and press the heat sink gently until the seal former sits on the 
tube shoulder (do not go into the shoulder).  Keep the heat sink on for a couple of 
seconds.  Remove the seal former from tube.  For centrifugation in the Ti70 rotor, 
remember to use the red hat on top of the tubes. 
20. Centrifuge at 55,000 rpm for 24 hours at 200C. 
21. Bring 18 and 21 gauge needles, UV light (long wavelength), ring stand, diapers,   
waste bottles, syringes, 15 mL centrifuge tubes to dark room.  The 21 gauge needle 
is to make hole at top and the 18 gauge needle is to collect the bands.  Upper band 
is nicked or chromosomal DNA and lower band is closed plasmid DNA.  Stick needle 
at top to allow air to enter.  Insert needle (beveled side up) so needle is under lowest 
band and make sure to sweep.   Repeat steps 18-21. 
22.  Add an equal volume of 1-butanol saturated with water or (top layer) 
23.  Mix the two phases by vortexing 
24.  Centrifuge the mixture at 1500 rpm for 3 min at room temp 
25.  Transfer the lower, aqueous phase to a clean tube with Pasteur pipette 
26.  Repeat steps 21-24 until all the pink color is gone from both phases 
27.  Remove the CsCl from the DNA solution by adding 
a. 3 volumes of water  
b. enough 3M sodium acetate (pH 5.2) to make final solution 0.3 M keeping in 
mind letter c  
c. 2 volumes of A +B with 100% ethanol 
d. 0.3 M (3v + v + NaAc) * 3 = 3M * NaAc 
28.  Put solutions in fridge for 30 min. 
29.  Centrifuge at 15,000 g for 30 min at 40C in clear tubes.   
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30.  Add room-temperature 70% ethanol.  Invert tube several times and spin again. 
31.  Dissolve the precipitated DNA in 1 mL of TE  
32.  Measure OD260 and store DNA at -200C.  Now STERILE 
 
B.2.  Virus Production and Concentration 
1. The day before:  Plate 293T in DMEM+FBS so they will be very confluent at the time 
of transfection.  See Table A1.  Make sure to coat plate with Poly-l-lysine for 5 min, 
rinse with sterile water, and be completely dry before plating.   
 
2. Dilute DNA with DMEM (no antibiotics or serum).  For lentiviruses, equal amounts of 
gag (R8.91), env, and reporter gene work.  Mix gently.  Total volume should be 0.5 
mL.   
 
3. Mix Lipofectamine 2000 (Lipo) gently before use and then dilute the appropriate 
amount in DMEM.  Mix gently and make sure to go to step 4 before 5 minutes is up. 
 
4. Combine diluted DNA with diluted Lipo.  Mix gently and incubate for 20 minutes at 
room temperature. 
 
5. Replace media on cells with enough DMEM to coat the dish/wells. 
 
6. Add DNA-Lipo mixture to a well.  Mix gently by rocking plate back and forth.  But 
remember not to rock too hard since 293T will come off. 
 
7. 4-6 hours later, aspirate and add plating volume of DMEM+FBS+PS.  DNA-Lipo 
complexes become unstable after 4-6 hours. 
 
8. Incubate cells at 370.  Change media 24 hours after transfection and first harvest is 
36 hours.  Harvest every 12 hours, with 48 -60 hour harvests being the best.  
Remember to filter with .45µm filter before storing at -80. 
 
9. Virus can be concentrated by ultracentrifugation: at least 35,000 rpm in sw41 
beckman rotor for 2 hours, 4 0C through a 2 ml 20% sucrose cushion, or overnight by 
low-speed centrifugation:  40C, 6000g, 12-16 hours, or by incubation with 320 µg/mL 
polybrene for 30 minutes and centrifuging at 10000g for 30 min. 
 
Table B1.  Transfection amounts 
Culture vessel 293T cell 
density 
Total amount of DNA 
and dilution in DMEM 
Lipo and dilution 
in DMEM 
96 well 6.3 e4 0.2 µg in 25 µL .6 µL in 25 µL 
12 well 9.4 e5 1.6 µg in 100 µL 4.8 µL in 100 µL 
6 well 2.3 e6 4 µg in 250 µL 12 µL in 250 µL 
60 mm 4.7 e6 8 µg in 0.5 ml 24 µL in 0.5 ml 
10 cm 1.27 e7 24 µg in 1.5 ml 72 µL in 1.5 ml 
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B.3.  Radiolabeling 
1. Transfect 293T in 10cm dish according to above instructions. 
2. 24 hours later, starve cells for 15 min in starved DMEM (17-204-CI) + 10 % HI-FBS 
(or 2.5%) 
3. Bring to the hood:  trash, pipettes, tray and liner, and paper towel under the tray. 
4. Add S35 radiolabel (in tissue culture room 40C clear box) to each 10 cm at 10uCi/mL  
a. Calculate activity and record on the form.  Make sure to include source # 
i. If on 1/1/03 -> 2.5 mCi, 90 days later is 0.49 * 2.5 = 1.225 mCi 
ii. 97 days later is the 7-day factor * the 90 day activity =             0.946 * 
1.225 mCi= 1.16 mCi 
b. Write down waste:  2/3 of activity to solids, 1/3 of activity to liquids.  Do not 
mix solids of different radionucleotides.  Write down volume used (necessary 
when calculating volume to add per amount of activity).  Note there is 175 µL 
of radiolabel solution.  Activity and date is on the packing slip. 
5. Incubate for 16-18 hours on top of tray with liner 
6. Ultracentrifuge virus.  Remember sucrose cushion.  Resuspend in IP buffer (20mM 
sodium phosphate, 500 mM NaCl, 0.1% SDS, 1% NP40). 
7. Run Biorad gel for 150V for 50 min 
a. 10 µL sample buffer + 10 µL 14C (blue bottle in -20) -> heat 100 deg C for 5 
min and load all 
b. 15 µL sample + 30 µL buffer -> heat 100 deg C for 5 min and load 45 µL 
8. Fix gel with 25 mL fixative with glycerol for 30 min with shaker (10% acetic acid, 40% 
methanol, 3% glycerol, 47% water) 
9. Amplify 25 mL amplifier (Amersham) for 30 min on shaker 
10. Incubate for 5 min in water.  Then cut off thick (bottom) edge very carefully 
11. Mount and dry without heat for 15 hrs 
a. Submerge sheet of cellophane and lay on top.  Hang edges over all four 
sides and remove all air bubbles. 
b. Cut piece of biorad filter paper (165-0921) larger than gel and wet it.  Put gel 
on top of filter paper and lay on cellophane.  Remove bubbles and add lots of 
water to surface of filter paper and around edges of gels and fill in wells of 
gels. 
c. Cut saran wrap same as cellophane, wet it in water and drape over gel from 
one side.  No bubbles at all. 
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d. Wet second sheet of cellophane and lay it over plastic wrap, hanging edges 
on all sides.  No bubbles 
e. Place metal square over cellophane and center over bottom frame and clamp 
(latch side up) 
f. Slide into shelves of GelAir dryier and turn it ON (no heat) 
g. Next day, cut peel of cellophane top layer and plastic wrap 
12. Preflash film and expose to gel for 3-5 days in -800C (order should be screen, film, 
then facing gel) 
13. Let cassette warm to room temp before developing 
14. For scintillation counting, cut out bands and put into scintillation tubes.  Make sure 
gel side is facing up and add 3 mL scintillation cocktail.  Wait 15 min and then 
measure activity on the scintillation counter in 1D (protocol 3). 
 
B.4.  Immunoprecipitation 
1. Ultracentrifuge virus to pellet.  
 
2. Resuspend viral pellet in 200 µL IP buffer minus amount using for 5 µg antibody. 
 
3. Preclear virus to agarose-coupled Protein A or G beads by adding virus to 20 µL 
beads.  Rotate 30 min at 40C.  Centrifuge and keep the supernatant (has virus) 
 
4. Add the 5 µg antibody to virus (0.2 mL total).  General rule is 1-2 µL per mL of virus, 
or 50 µg protein for 1-5 µg antibody.  Incubate overnight at 40C with rotation.  Can 
add 0.02% sodium azide as a preservative 
 
5. Add beads to Antibody+virus and incubate for 2 hours at room temp with rotation.   
General rule is 50 µL of beads per 5 µg of antibody. 
 
6. Wash by centrifuging 2-3 min, aspirating supernatant, and adding 0.5 mL wash 
solution (use IP buffer).  Repeat 6X. 
 
7. If ELISA: 
Elute with elution buffer (0.1M glycine-HCl pH 2.5):  50 µL for 5 min and spin 
down.  Repeat, pooling.  Then add 10 µL 1M Tris pH=8 to the 100 µL tube. 
 
Lyse virus with ELISA lysing buffer for 30 min at room temp.  Centrifuge for 2-
3 min and collect supernatant to run in ELISA or WB. 
If WB: 
Wash with 0.5 mL DI water.  Incubate virus-antibody-bead complex for 5 min 
at 950C with 25 µL of WB sample buffer.  Centrifuge the sample and collect 
the supernatant.  Repeat, pooling supernatant for a total of 50 µL. 
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8.  For cell lysates, make sure to wash cells in cold PBS, lyse them with chilled IP buffer 
and protease inhibitors for 30 min on ice, and then centrifuge at 10000g for 10-15 min 
and keep the supernatant. 
 
 
B.5.  Lipid Raft Isolation 
1. Transfect cells.  The next day, detach cells with versene (PBS, 5 mM EDTA), add 
equal volume of media, and pellet cells at 800 rpm. 
2. Aspirate supernatant.  Resuspend cells in 1 mL cold 1% Triton-X (or Brij 98) in TNE 
buffer (10X TNE = 3.03 g Tris base, 8.77g NaCl, 10 mL 0.5 M EDTA) 
3. Dounce homogenize at least 20X 
4. Quickly add 900 µL of homogenate to ultracentrifuge tube containing 900 µL cold 
80% sucrose in TNE and mix solutions 
5. Aliquot the rest of the homogenate to microcentrifuge tube and store in -200C as a 
whole-cell lysate  
6. Carefully layer 5 mL of cold 38% sucrose in TNE 
7. Then carefully layer 4 mL 5% cold sucrose/TNE on top of that and balance 
8. Ultracentrifuge at 30000 rpm in SW41 rotor 40C for at least 12 hours (preferably 15). 
9. There should be a fluffy white band at the 38%-5% interface.  This is your lipid raft 
fraction.  Carefully (using Pasteur pipette), suck up all the white stuff and put it into a 
new ultracentrifuge tube. 
10. Fill the rest of the tube with cold TNE and mix solutions to make sure you cannot see 
2 separate densities.   
11. Ultracentrifuge for 1 hour at 30k, 40C in SW41 rotor. 
12. Aspirate out supernatant.  There should be a faint white pellet at bottom.  Resuspend 
pellet in 100 µL room temp TNE. 
13. For linear sucrose gradient, steps 1-4 are the same.  Create a linear gradient using 4 
mL 38% cold sucrose/TNE and 4 mL 5% cold sucrose/TNE and have it pour directly 
into ultracentrifuge tube.  Ultracentrifuge same as step 8, and then collect 1 mL 
fractions from the bottom. 
 
 
B.6.  p24 ELISA 
1. Coat a Nunc Maxisorp microtiter plate with p24 monoclonal antibody (183-H12-5C) 
by adding 100 µL of 1:800 dilution in PBS.  Incubate at 370C overnight 
 
2. Wash the plate 2X with Washing buffer (PBS, 0.2% Tween-20), 100 µL into each 
well. 
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3. Block non-specific sites by adding 200 µL of Blocking Buffer (PBS, 5% nonfat milk, 
0.05% Tween-20) per well and incubating for 1 hour at 370C. 
 
4. Wash 4X with Washing buffer 
 
5. Lyse virus samples by 1:1 dilution into Lysing Buffer (PBS, 2% Triton X-100).  Leave 
at room temperature for 30 minutes.   
 
6. Add 100 µL of antigen-containing solution per well and incubate for 2 hr at 370C. 
 
7. Wash 4X with Washing Buffer 
 
8. Add 100 µL per well of sheep polyclonal anti-p24 antisera diluted 1:250 in Blocking 
Buffer.  Incubate for 2 hrs at 370C 
 
9. Wash the plate 4X with Washing Buffer 
 
10. Add 100 µL of HRP-conjugated donkey-antisheep polyclonal serum diluted 1:1000 in 
Blocking Buffer to each well and incubate for 1 hr at 370C. 
 
11. Wash the plate 4X with Washing Buffer 
 
12. Add 100 µL of freshly prepared OPD developer solution (7.5 mL substrate buffer [1L 
water, 4.6g citric acid anhydrous, 7.3g Na2HPO2], 3 mg OPD tablet, 3 µL 1% 
hydrogen peroxide) per well and incubate for 20 minutes 
 
13. Stop development reaction by adding 50 µL of 8 N sulfuric acid to each well 
 
14. Read absorbance in plate reader (OD490-650). 
 
 
B.7.  Indirect Immunofluorescence 
1. To make coverslips, buy 12 mm 1.5 circle (fisher 12-545-81).  Put into beaker and 
put enough 0.1M HCl to at least cover.  Boil for 30 min at slow boil.  Quench with 
distlled water (10X the volume of acid).  Pour down sign and take to hood where you 
rinse with sterile water.  Put into jar with 70% isopropanol  
2. Flame coverslips and transfer coverslip to the well of a 12 well dish.  
3. Put 1 mL of cells into each well and rotate to evenly distribute cells (about 30k-50k 
cells/well) 
4. Treat as required for experimental protocol 
5. Remove medium and fix cells with 4% paraformaldehyde (0.5 g powder in 20 mL 
water, heat to 550C and shake, add NaOH until dissolves, cool to room temp, and 
add 2.5 mL 10X PBS and bring it up to 25 mL with water.  pH = 7.0.  store for 10 
days or less) 
6. Incubate for 10 minutes at room temperature  
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7. Remove fix and add 1 mL of 5% serum in PBS for 15 min.  In general, use the serum 
of the secondary antibody.   
8. Dilute primary into PBS/serum.  If you want to permeabilize membrane, add 0.2% 
saponin (20 µL 10% saponin in water to 980 µL PBS/serum) 
9. Place a piece of parafilm in the bottom of a 150 mm Petri dish labeled with numbers 
corresponding to a 12 well dish. 
10. Add 30 µL of appropriate diluted antibody solution to each spot on the parafilm. 
11. Pick up individual coverslips with tweezers and wick excess fluid on paper towel. 
12. Invert coverslip onto antibody drop (cell side down).  Cover dish and incubate in 
bench drawer for 1 hr. 
13. Aspirate 12 well and add 1 mL PBS to wash.  Place coverslip back into well cell side 
up (use 2 tweezers).  Wash 3 times for 5 min each.  Make sure coverslip is sitting in 
the PBS (push down with tweezers). 
14. Dilute fluorescently-labeled secondary antibody in PBS/serum with or without 0.2% 
saponin.  Spin for 10 min in cold centrifuge 
15. Invert coverslip onto 30 µL drops of antibody on new parafilm and incubate in drawer 
for 1 hr 
16. Wash coverslips 3 times for 5 min each on shaker with 1 mL PBS 
17. Aspirate wash with 1 mL DI water. 
18. With glass pipette, drop 1 drop of gelvatol onto glass slide and let dry overnight at 
40C in the dark. 
19. For colocalization, after images are taken, convert images to JPG files.  Open with 
NIH ImageJ.  Highlight the cell and run the Colocalisation Threshold plugin (Tony 
Collins, Wayne Rasband, and Kevin Baler).  Rtotal is the Pearson’s overlap 
coefficient.  Copy and past values into Excel.  Process 8 cells. 
 
 
B.8.  Diluted Titer Assay 
1. Plate cells such that they are nonconfluent 
2. Transduce cells with virus 
3. 2-3 days later (when cells are confluent, aspirate off media 
4. Fix in 0.5% glutaraldehyde in PBS for 10 minutes 
5. Wash dishes 2-3x with 1 mM MgCl2 in PBS for 10 min each time 
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6. Add Xgal solution (0.5 mL 20X KC [25 mL PBS, 0.82g K3Fe9(CN)6, 1.05g 
K4FE(CN)6*3H2O], 10 µL 1M MgCl2, 0.25 mL Xgal [40 mg/mL in DMSO], brought to 
10 mL in PBS) to dishes 
7. Incubate at 370C overnight 
8. Wash dishes with water 
9. Let air dry then count 
 
 
B.9.  Cell-based ELISA 
1. Plate 20,000 HeLa cells per well in a 96 well and transfect with Polyfect according to 
instructions.  
2. The next day wash cells once with PBS  
3. Fixed cells for 10 min with 4% paraformaldehye and block for 15 min with PBS/sera  
4. Incubate cells with 1:800 antibody in PBS/sera for 1 hour at room temperature. 
5. Wash four times with PBS  
6. Incubate with 1:500 HRP-conjugated secondary antibody for 1 h at room 
temperature. 
7. Wash four times with PBS 
8. Add 100 µL of freshly prepared OPD developer solution and watch incubation 
9. Stop development reaction by adding 50 µL of 8 N sulfuric acid to each well 
 
10. Read absorbance in plate reader (OD490-650). 
 
 
 
B.10. Western Blotting 
1. Perform a protein assay according to manufacturer’s instructions. 
2. Dilute 1 part sample in 2 parts sample buffer (5% mercaptoethanol and 95% 
Laemmli sample buffer – both on shelf by gel machine).  (ie 15 µL sample and 30 µL 
sample buffer) 
3. Prepare marker by taking 5 µL ECL dualview and adding 5 µL sample buffer with 
10% mercaptoethanol instead of 5%l. 
4. Vortex samples and weight marker, and spin down.  Heat for 5 minutes at 1000C 
5. After setting up the gel, make 350 mL 1X Running buffer (10X in 40C fridge:  15 g 
Tris base, 72 g glycine, 5g SDS into 500 mL).  Fill inner chamber and use the rest for 
the outer chamber 
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6. Put 30-50 µL of sample in each gel lane.  Load all of the weight marker. 
7. Run at 150 volts for 50 minutes 
8. Cold everything is, better the transfer 
9. Have at least 350 mL transfer buffer – stored in cold room (700 mL methanol, 2800 
mL ddh20, 10.68 g Tris, 50.4 g glycine) 
10. Pry gel out of gel caster.  Take the plate it sticks to and invert it into cold transfer 
buffer.  Incubate for 15 min  
11. Take filter paper and use it as a guide to cut PVDF membrane smaller than the filter 
paper.  Also cut a corner in the PVDF membrane 
12. Wet membrane in 100% methanol in green bucket 
13. Soak everything going into sandwich in transfer buffer (2 pieces of filter paper, 2 
sponges, 1 membrane).  Membrane should go on bottom so it will not float up and 
dry. 
14. Put sandwich together and stick into machine.  Note which side of gel faces the edge 
of the PVDF membrane.  Sandwich order is light side: pad: filter paper: membrane: 
gel: filter paper: pad.  When laying membrane on top of gel, take Pasteur pipette and 
roll it over the membrane to get rid of bubbles 
15. Slide sandwich into transfer tank.  The light side faces the red circuit 
16. Add ice block (in -20) and fill transfer tank with cold transfer buffer.  Put in stir bar 
and turn on 
17. Run for 100 volts for 1 hr 
18. Blocking is done overnight at 40C or 1 hour at room temperature (5% milk, 0.05% 
tween in PBS).  5-10 mL.  Remember to close lid and seal with parafilm if leaving on 
shaker overnight 
19. Pour blocking solution out.  Add primary antibody to 5-10 mL blocking solution.   
Incubate overnight at 40C or 1 hr at room temperature 
20. Wash 6x with PBS/0.05% tween.  5 minutes each wash 
21. Put secondary into blocking solution (about 1:400,000) and add 1:40,000 S protein.  
Incubate 1 hr at room temperature. 
22. Swtich dark room developer on AND HIT RUN. 
23. Wash 6x with PBS/tween 
24. Take saran wrap and put membrane so that the protein side is up.  Prepare Pierce’s 
Super Signal West Femto 1:1.  Make 1 mL for each membrane.  Remember to do 
this quickly since it is light sensitive. 
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25. Drop the mixture onto the membrane and tilt so that it covers whole membrane.  
Develop for 5 min. 
26. Fold saran wrap over membrane and press out bubbles.  Tape down membrane in 
cassette 
27. Go to dark room with film, cassette, membrane, marker, timer.  Place film on top and 
expose about 5 min or longer.   
28. Slide film into developer. 
29. For determining band density, use ImageJ to measure the area of the band and 
intensity (Analyze > Set Measurements> make sure area and mean gray value is 
checked.  Then go to Analyze>Measure.)  Remember unless image colors are 
inverted, darker colors will be a smaller number.  Multiply values together.  Make 
sure to do an initial test by diluting antibody and measuring to ensure values are 
linear. 
 
